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Abstract 
Protein Kinase C iota (PKC!) is a serine/threonine kinase that is involved in epithelial 
polarity and malignancy where polarity is typically abrogated.  The aim of this thesis 
was to characterise the role of PKC! in oncogenic signaling in the context of polarity 
loss.  This work set out to identify activators, binding partners and downstream 
effectors of PKC! with a view to informing rational therapeutic design. 
Madin Darby Canine Kidney (MDCK) cells, grown as polarised cysts containing a 
central lumen in Matrigel, developed a multiple-lumen phenotype on perturbation of 
PKC!, suggesting a threshold requirement for normal lumenogenesis.  When transfected 
with oncogenic Ras, MDCK cells formed large spheres lacking a lumen and polarity.  
Upon PKC! inhibition with siRNA or small molecules, polarity was partially rescued 
indicating that PKC! lies downstream of Ras in this polarity loss pathway.  
Structural studies have enabled two distinct approaches to identify effectors of PKC!.  A 
novel protein-protein interaction motif (RIPR) within PKC! was identified and shown 
here to be responsible for interaction with a subset of target proteins, including LLGL2.  
MDCK cysts expressing a PKC! mutated in this motif developed a multiple-lumen 
phenotype.  In a second approach, use was made of an inhibitor bound complex of 
PKC! to design a drug insensitive mutant.  Expression of the resistant mutant in 
HEK293 cells led to resistance to inhibitor induced dephosphorylation of LLGL2 and 
protected MDCK cells from developing inhibitor induced multiple lumens and loss of 
polarity.  This tool has been used to screen for PKC! substrates. 
In summary, PKC! lies downstream of H-Ras in MDCK polarity signalling.  The site at 
which PKC! binds LLGL2 is defined and shown to contribute to normal lumenogenesis.  
A drug insensitive PKC! mutant is described that can be utilised for substrate and 
biomarker identification.  
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Chapter 1. Introduction 
 
1.1 Overview of Introduction 
In biological systems, cells are continuously exposed to a diverse array of stimuli.  Cells 
must sense their environment and then relay this information into the cells where it is 
interpreted and responded to appropriately.  This biological information flow is known 
as cell signalling.  Failure of cells to correctly sense their environment or interpret the 
information flow can lead to diseases including cancer.  This thesis focuses on the role 
of protein kinase C iota (PKC!), a signalling molecule that has been implicated in 
cancer when it is inappropriately activated.  The first section of the introduction will 
aim to provide an overview of normal signalling, highlighting areas pertinent to this 
thesis.  In particular, I will describe how post-translational modifications of proteins, 
protein-protein interactions and protein dimerisation or oligomerisation can impact on 
signal transduction.  I will discuss how feedback mechanisms help to regulate and 
increase the complexity of signalling and provide a few classical examples of where 
erroneous signalling results in disease.  The second section will formally introduce 
PKC!, describe the current understanding of where it sits in the signalling cascade and 
the functional roles of PKC! in cells.  In addition, evidence for abrogated PKC! 
signalling in human cancer and the current potential therapeutic strategies will be 
addressed. 
 
1.2 Cell Signalling 
1.2.1 Introduction to signalling 
Cells from multicellular organisms must constantly communicate with each other to 
facilitate their multitude of functions.  The life history of cells encompasses birth from 
cell proliferation and differentiation into specific cell types with specific functions such 
as migration and senescence through to cell death.  In particular cells, processes such as 
Chapter 1. Introduction 
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sensory perception, secretion and mounting of an immune response are also performed.  
Cell signalling is the transfer of biological information required to orchestrate these 
processes (Berridge, 2006, see Downward, 2001 for review). 
There has been an explosion in the characterisation of signalling components and 
pathways.  It is evident that different pathways are combined and adapted to control a 
diverse array of cellular processes in varying spatial and temporal contexts.  Despite this 
diversity, there are common mechanisms that have evolved.  Receptors sense the 
environmental cues and transfer information across the membrane using a range of 
transducers and amplifiers.  These then connect the vast repertoire of intracellular 
signalling molecules comprised of messengers, sensors and effectors and this relay of 
information ultimately results in cellular responses (Berridge, 2006). 
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Figure 1.1 Signalling overview 
The scheme is adapted from (Berridge, 2006). 
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1.2.2 Stimuli and Receptors 
The two-way cellular discourse that is necessary in multicellular organisms occurs 
through electrical, physical and chemical signals.  Electrical signals are usually fast and 
require cells to be coupled together through low resistance pathways such as gap 
junctions.  These junctions allow passing electrical charge and are large enough for 
small metabolites and second messengers to diffuse from one cell to another.  Some 
chemical signals, such as steroid hormones, are able to diffuse through the lipophilic 
plasma membrane to gain access to cytoplasmic or nuclear receptors.  However, most 
water-soluble stimuli including growth factors, hormones, nutrients and 
neurotransmitters, require a means to relay the extracellular information into the cell 
without physically traversing the plasma membrane.  Soluble signals can be derived 
locally from the same cell (autocrine) or neighbouring cells (paracrine) or distally and 
carried around the blood stream (endocrine).  Additionally, stimuli can remain tethered 
to the cell membrane (juxtacrine) or be insoluble extracellular matrix components 
(Singh and Harris, 2005, Berridge, 2006). 
Receptors at the plasma membrane function as embedded molecular antennae.  Upon 
complementary binding of a signal (ligand) to the receptor, the receptor undergoes a 
conformational change that alters the intracellular receptor activity.  The largest family 
of receptors is the G-protein coupled receptors that respond to a diverse array of signals.  
The ligand bound conformational change in these 7-transmembrane/heptahelical 
receptors enables their guanine nucleotide exchange factor (GEF) activity, exchanging 
GDP for GTP in their associated G proteins (see (Wettschureck and Offermanns, 
2005)for review).  One of the most common receptor families is the tyrosine kinase 
receptors, that includes the epidermal growth factor and insulin receptors.  The 
epidermal growth factor receptor dimerises in response to its ligand, EGF, and 
undergoes autophosphorylation of several tyrosine residues in the intracellular C-
terminal domain.  This phosphorylated EGFR is capable of binding to signal 
transducers such as the Src homology 2 containing effector and adaptor proteins which 
recognise phosphotyrosine in a sequence specific context (Pawson et al., 2001).  Other 
receptors trigger the opening of gated ion channels in response to ligand binding, for 
example, the nicotinic acetylcholine receptor (McGehee, 1999).  
Chapter 1. Introduction 
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In order to detect and respond to this multitude of signal inputs a wide range of 
receptors have evolved.  One means of increasing specificity of the receptors is by the 
formation of heterodimers and/or co-operative receptor response.  An example of 
receptors that require heterodimerisation for function is the integrin family that is 
comprised of " and # subunits.  In mammals there are 24 ",# heterodimers made up of 
18 " and 8 # integrin subunits.  While multiple receptors can recognise the same 
signals, the integrin-ligand combination elicit specific signals although the precise 
mechanism for this is currently unknown (for review see Byron et al., 2010).  As well as 
responding to environmental stimuli the integrins are also able to propagate inside-out 
signalling where they reveal the status of the cell to the outside (Qin et al., 2004). 
 
1.2.3 Transducers and Amplifiers 
The signal in the form of receptor conformational changes is transduced and amplified 
by second messengers.  This is well exemplified by cyclic AMP signalling where the 
signal from G-protein coupled receptors (GPCR) is transduced by heterotrimeric G 
proteins that can either activate or inhibit the amplifier adenylate cyclase (AC).  In the 
case of activation, the GEF activity of GPCR causes dissociation of the heterotrimeric G 
protein into G#$ and G"s-GTP and this later subunit is capable to activating adenylate 
cyclase by allosteric maturation of its active site.  Adenylate cyclase is a transmembrane 
enzyme that converts ATP into the second messenger cyclic-AMP.  Adenylate cyclase 
can generate multiple molecules of the second messenger for each ligand bound to 
GPCR and in doing so amplifies the signal (Lynch et al., 2006).  Other prevalent second 
messengers include diacyclglycerol (DAG) (Carrasco and Merida, 2007), calcium and 
inositol 1,4,5-triphosphate (IP3) (Berridge, 2009). 
 
1.2.4 Post translational modifications 
Post translational modifications (PTMs) are various processing events that change the 
maturity, activity, and/or turnover of proteins.  More that 200 different forms of PTM 
Chapter 1. Introduction 
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have been identified and more are expected to be found (Zhu et al., 2003).  This section 
will concentrate on phosphorylation, an important modification upon which much of 
thesis is based and glycosylation which is the most abundant protein modification 
(Larkin and Imperiali, 2011).  Examples of other common and functionally important 
PTMs are show in Table 1.1.   
Phosphorylation involves the transfer of a phosphate group from the terminal phosphate 
of nucleoside triphosphates, usually ATP, on to the hydroxyl group of specific protein 
residues, typically a serine, threonine or tyrosine.  This reaction is carried out by protein 
kinases.  A single phosphate group can dramatically alter the protein conformation 
and/or activity.  A single molecule of protein kinase that is catalytically activated can 
process many thousands of substrate molecules.  If the substrate is itself an enzyme, the 
amplification effects can be magnified further.  Dephosphorylation is achieved by 
protein phosphatases and thus the balance between kinases and phosphatases determines 
the steady state of protein phosphorylation.  Through the control of phosphorylation 
therefore, protein kinases act as rapid, sensitive and reversible molecular switches 
(Mann et al., 2002, Li et al., 2009). 
The human genome project identified 518 putative protein kinases that is about 2% of 
the genome (Manning et al., 2002).  In addition there were 100 phosphatases (Venter et 
al., 2001).  The kinases form 3 classes based on their substrate specificity; the 
serine/threonine kinases, the tyrosine kinases and dual specificity kinases.  At any one 
time in the cell it is estimated that the phospho-amino acid content ratio is 1800:200:1 
(pSer:pThr:pTyr) (Mann et al., 2002).  These kinases may be further classified based on 
their distinct catalytic domains, regulatory domains or biological function (Manning et 
al., 2002).   
The covalent attachment of a phosphate group to a target protein can have a variety of 
effects on the function of the protein. Phosphorylated proteins have acquired a bulky 
negative charge that is capable of protein interactions. Typically the phosphoryl group 
mediates hydrogen bonding to main-chain amide groups or salt bridging to arginine 
residues (Johnson and O'Reilly, 1996).  Phosphorylation can affect the target protein in 
several ways.  Firstly it can change the activity of the protein.  For example 
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phosphorylation of glycogen phosphorylase at Ser14 results in a marked allosteric shift 
of the serine side chain by 50Å leading to rearrangement of subunit-subunit contacts 
and active site activation (Barford and Johnson, 1989).  However, phosphorylation of 
Src kinase at Tyr-527 by other tyrosine kinases is inhibitory (Kmiecik and Shalloway, 
1987, Thomas et al., 1991).  Secondly, phosphorylation can provide new recognition 
sites for binding proteins (see section 1.1.5).   
Proteins that are destined to be placed on the cell surface or secreted into the 
extracellular environment commonly undergo covalent modification by the attachment 
of carbohydrate molecules at specific residues.  This modification is termed 
glycosylation and specific enzymes are required to catalyse these reactions.  There are 
three major types of glycosylation in nature; N-linked, O-linked and GPI-anchored.  N-
linked involves the transfer of an oligosaccharide onto the side chain amide nitrogen of 
asparagine residues.  In O-linked glycosylation monosaccharides are sequentially added 
to the hydroxyl oxygen of predominantly serine or threonine residues.  In the third 
major type, a complex glycosylphosphatidylinositol (GPIanchor) moiety is transferred 
to the C-terminus of a target protein, tethering it to the cell membrane.  Glycosylation is 
thought be involved in intracellular targeting, cell signalling, cellular trafficking and the 
immune response (Larkin and Imperiali, 2011). 
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!
Table 1.1 Post translational modifications. 
Selected common and functionally important post-translational modifications.  Adapted from (Mann and 
Jensen, 2003). 
Post Translational Modification 
 
Functional 
Glycosylation 
 
Cell-cell recognition  
Signalling 
Membrane tethering 
Phosphorylation Activation/inactivation 
Modulation of protein interaction 
Signalling 
Acetylation Protein stability 
Protein-DNA interactions 
Acylation  
eg. Myristoyl, Farnesyl, Palmitoyl 
Membrane targeting  
Stability 
Protein-protein interactions 
Methylation 
 
Regulation of gene expression 
Ubiquitination 
 
Degradation 
Protein (in)activation 
Traffic 
Sulphation Modulator of protein-protein and receptor ligand 
interactions 
 
!"#"$ %&'()*+,*+()&-.(*'+,/'0-*+1,
"#$%&''#%$!()*+,#%-!.*//*%'0!.*%+&#%!/*12'&)!#%+,)&.+#*%!1*/&#%-!3&'-*!4%*5%!&-!),.*$%#+#*%!/*12',-6!+7&+!8&.#'#+&+,!/2'+#9()*+,#%!.*/(',:!8*)/&+#*%!3;2)#0&%!&%1!<*5=2)%>!?@@A6B!!C2)#%$!-#$%&'!+)&%-12.+#*%!+7,-,!#%+,)&.+#*%!1*/&#%-!1,+,)/#%,!+7,!-(,.#8#.#+0!*8!-#$%&'!.*/(',:!&--,/='0!&%1!+&)$,+!+7,/!8*)!&!1,8#%,1!-2=.,''2'&)!'*.&'#D&+#*%!+7&+!#%!+2)%!-(,.#8#,-!57#.7!),$2'&+*)-!&%1!+&)$,+-!+7,0!&),!,:(*-,1!+*!3E&5-*%!,+!&'B>!FGG?6B!
H%+,)&.+#*%!1*/&#%-!&),!#%1,(,%1,%+'0!8*'1,1!/*12',->!+0(#.&''0!IJ9?JG!),-#12,-!#%!',%$+7!+7&+!.&%!-+#''!=#%1!+7,#)!+&)$,+!'#$&%1-!#8!,:(),--,1!#%1,(,%1,%+'0!*8!+7,!82''9',%$+7!()*+,#%B!!K7#-!1*/&#%!*)$&%#-&+#*%!7&-!,L*'L,1!-2.7!+7&+!1#88,),%+!1*/&#%-!/&0!=,!-+)2%$!+*$,+7,)!#%!&!.*/=#%&+*)#&'!/&%%,)!5#+7*2+!1#-)2(+#%$!82%.+#*%!3E&5-*%!,+!&'B>!FGGF>!E&5-*%!&%1!M&-7>!FGGI6B!
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Interaction domains are often arranged into distinct groups whose members have 
related, but not identical, sequence binding.  Common protein interaction domain 
families include Src-homology 3 (SH3), WW domains and EVH1 that all bind to 
proline rich sequences.  PDZ domains bind predominantly to the extreme c-termini of 
their target proteins.  In addition there are the common phospholipid interacting 
domains critical for membrane compartment targeting including pleckstrin homology 
(PH) domains, that bind to phosphoinositides such as PI(4,5)P2 and PI(3,4,5)P3, and 
FYVE, phox homology (PX), C1 domains and some WD40 domains (Pawson et al., 
2002, Pawson and Nash, 2003). 
Other interaction domains bind specifically to sequences containing post-translational 
modifications.  These include 14.3.3, Forkhead-associate (FHA), p21-binding domain 
(PBD) and some WD40 repeats which all bind to phospho-theonine/serine motifs.  A 
further group requiring PTMs are Src-homology 2 (SH2) and some Phosphotyrosine-
binding domains (PTB) which require phosphotyrosine sites (Hunter, 2000, Yaffe, 
2002, Yaffe and Elia, 2001).  WD40 and 14.3.3 binding domains are described here in 
further detail as they pertain to this thesis.  WD40 repeats contain conserved tryptophan 
and aspartic acid residues (‘WD’) and are approximately 40 amino acids in length.  
Their functions include adaptor modules in signal transduction, pre-mRNA processing, 
cytoskeletal assembly, gene transcription activation and cell cycle control.  It has 
emerged that multiple WD40 repeats associate and form #-propeller structures, typically 
comprising 7 blades, that act as a platform for binding partners, particularly those with 
post-translational modifications (Xu and Min, 2011) 
14.3.3 is a family of small 30kDa acidic proteins that form cup-shaped homo and 
heterodimers.  Each subunit of the dimer contains a highly conserved phospho-peptide 
binding pocket separated by ~34Å.  14.3.3 isoforms have been reported to have a 
number of effects on the target protein; conformational change, steric hindrance or 
scaffolding.  Two modes of binding have been defined that have distinguishing primary 
sequence recognition motifs: Mode I, R-S-X-pS/T-X-P and Mode II R-X-X-X-pS/T-X-
P.  Several target proteins were found to contain multiple 14.3.3 binding sites, which 
enhances binding affinity.  Furthermore, many target proteins contained one high 
affinity site and one suboptimal site that had low affinity binding by itself but acted 
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synergistically with a high affinity site.  It was hypothesised that the suboptimal site 
(gatekeeper) may facilitate dissociation and therefore reversibility of the interaction 
(Yaffe, 2002, see Bridges and Moorhead, 2005 for review).  Functional studies and the 
crystal structure of PKC%-14.3.3& have subsequently supported the gatekeeper model 
(Saurin et al., 2008, Kostelecky et al., 2009). 
 
1.2.6 Dimerisation/oligomerisation 
Proteins can bind identical proteins through complementary binding surfaces and form 
complexes that range from dimers to filaments.  The formation of protein polymers has 
broad implications for protein function including their role as scaffolds (as described for 
14.3.3 above) and allosteric protein activation.  The latter is well illustrated by the 
epidermal growth factor receptor (EGFR).   
Different inhibitor bound structures of EGFR have demonstrated both a symmetrical 
and asymmetrical dimer and thus provided an insight into the possible mechanism of 
activation.  Unlike the original model, whereby ligand binding induced receptor 
dimerisation, it appears that EGF causes a shift from a symmetrical dimer to an 
asymmetrical dimer (Schlessinger, 2002, Garrett et al., 2002, Zhang et al., 2006b).  In 
activated structures the kinase domains form a head to tail configuration in which the 
"H helix in the C-lobe of one kinase (activator kinase) docks with the "C helix in the 
N-lobe of its partner kinase (receiver).  This interaction causes a conformational change 
in the "C helix and activation loop to facilitate catalytic activity.  However, this 
interaction is weak and also requires a second intermolecular binding event; the juxta-
membrane segment of the receiver kinase loops around to interact with the C-lobe of the 
activator kinase (Zhang et al., 2006b, Jura et al., 2009).  These models developed from 
structural biology studies indicate how intricate and elegant protein interactions can be. 
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1.2.7 Feedback Control 
Feedback loops are processes that connect output signals back to their inputs.  Such 
feedback loops are abundant in and critical for signal transduction pathways.  Negative 
feedback is necessary for maintaining homeostasis within a system (see Brandman and 
Meyer, 2008 for review).  For example, the p53 pathway is critical for the stress 
response in cells and is tightly regulated by multiple homeostatic feedback mechanisms.  
p53 requires serine phosphorylation by p38 MAP kinase for activation.  Upon p53 
activation one of its transcriptional targets, Wip-1 is up regulated.  Wip-1 is a 
phosphatase that reverses the serine phosphorylation and thus decreases the activity of 
p53 (Harris and Levine, 2005). 
Positive feedback mechanisms are necessary to amplify a signal.  A good example is the 
inositol 1,4,5-triphosphate (IP3)-receptor at the endoplasmic reticulum (ER).  This IP3 
receptor is partially activated by binding of IP3 molecules that result in slight Ca2+ 
release from the ER.  The Ca2+ release fully activates the receptor causing further 
calcium release into the cytosol (Finch et al., 1991, Bezprozvanny et al., 1991).  These 
positive feed back mechanisms help to establish molecular “on/off” switches (see 
(Berridge, 2009)for review).  The threshold upon which the switch is activated depends, 
among other things, on the sensitivity of the regulatory step for a specific pathway, the 
stability of the signalling outputs and temporo-spatial parameters. 
Signalling networks involving both positive and negative feedbacks are likely to 
contribute to the complicated array of signalling outputs from a single stimulus that we 
observe in nature.  The possible complexity of multiple feedback loops is further 
enhanced by interaction with other signalling pathways.  Experimental reports on such 
integrated signalling networks with multiple feedbacks is limited and this probably 
reflects our ingrained approach to studying individual pathway components.  There are 
several situations where multi-threshold responses are apparent and it has been 
proposed that this may be regulated by the combination of feedback loops.  These 
combinations of feedback loops includes diverse behaviours such as the response to 
morphogens in Xenopus and the induction of tolerance in T-cells under the control of 
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Lymphocyte-specific protein tyrosine kinase (Lck) (Green et al., 1994, Stefanova et al., 
2003) 
 
1.2.8 Signalling and disease 
There is a vast array of interconnecting signalling pathways.  Despite a high degree of 
plasticity to cope with changing demands, pathway defects still occur.  Given the 
fundamental role of signalling in all physiological processes, such aberrations have a 
great significance for the onset of human disease.  Pathological organisms and viruses 
can interfere with signalling pathways as can inherited or somatic mutations to the 
genes encoding signalling molecules. 
An excellent example of an infective disruption of signalling is the affect of cholera 
toxin on cAMP generation by adenylate cyclase (see section 1.2.3).  Active efflux of 
chloride ions across the intestinal epithelium into the lumen is regulated in part by 
cAMP.  Cholera is a disease characterized by severe watery diarrhoea.  It is caused by 
the gram negative bacterium Vibrio cholerae that secretes cholera toxin.  The cholera 
toxin catalytic subunit couples the adenosine disphosphate (ADP)-ribose moiety of 
intracellular nicotinamide adenine dinucleotide to a critical residue in G"S, the subunit 
of the heterotrimeric G protein.  This ribosylation inhibits the ability of G"S to 
hydrolyse GTP, which means that the G protein is locked in its active configuration. 
This maintains activation of adenylate cyclase and thus cAMP production and intestinal 
secretion (Farfel et al., 1999). 
Retinoblastoma (Rb) is the prototype of an inherited cancer linked to sequential loss or 
inactivation of both alleles of a tumour suppressor gene, the Rb1 gene.  In order to 
explain the pathogenic mechanism Knudson in 1971, based on epidemiological studies, 
proposed the “two-hit theory”.  The theory states retinoblastoma is inherited by two 
sequential mutational events, the first via the germline and the second occurring 
spontaneously in somatic cells.  Inactivation of Rb was shown to have profound effects 
on the control of the cell cycle.  E2F transcription factors associate with a second 
subunit, DP1 or DP2, to form a heteromeric transcription factor capable of binding to 
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DNA promoters of cell cycle (G1/S) target genes.  Phosphorylation of Rb enables an 
inhibitory interaction with E2F.  In cancer cells, loss of the pRb brake leads to E2F-
dependent G1/S gene expression even in the absence of mitogens (Weinberg, 1995, 
Sherr and McCormick, 2002).  Further intensive study of the role of Rb in cancer has 
added huge complexity to this picture and it is now recognised that in addition to 
serving as a G1 checkpoint Rb has many other cellular roles.  Rb is also identified as a 
somatic mutation in a wide range of human cancers.  Contemporary epidemiologists 
have suggested that the Knudson two hit theory was indeed flawed but perhaps this can 
be explained by the multiple non-inherited roles, the influence of other factors and 
incomplete penetrance (Burkhart and Sage, 2008, Mastrangelo et al., 2009). 
While a proportion of malignancies may be attributed to germline mutations the vast 
majority have been shown to be due to an accumulation of 3-7 somatic mutations and 
has been described as the multistep nature of cancer (Vogelstein and Kinzler, 1993).  
Somatic mutations of the Ras gene are the most frequently detected in human cancer.  It 
is now 30 years since it was recognised that fragments of DNA from human cancer 
derived cells could induce malignant transformation in fibroblasts.  It was later 
demonstrated that for the first of these, the active component was the cellular homolog 
of H-Ras, an oncogene found in the Harvey rat sarcoma retrovirus (see Downward, 
2006 for review).  There are four major isoforms of Ras: H-ras, N-Ras, K-RasA and K-
RasB.  The principal isoform differences are their post-translational modifications that 
determine their compartmental localization.  The first defined function of Ras was as a 
transducer of tyrosine kinase receptors.  Upon ligand occupation the tyrosine kinase 
receptors dimerise and autophosphorylate enabling Grb2, an adaptor protein containing 
SH2/SH3 binding domains, to interact with the intracellular receptor domain.  Grb2 
contributes to the localization of Son-of-sevenless (SoS), a Ras guanine nucleotide 
exchange factor (RasGEF).  SoS binds to the SH3 domain of Grb2 where it can 
facilitate the exchange of GDP for GTP generating activated Ras-GTP.  Switching off 
activated Ras requires the hydrolysis of GTP to GDP by Ras.  Ras GTPase-activating 
proteins (RasGAPs) are required to accelerate this “off” reaction.  Activated Ras is now 
known to relay signals to multiple pathways including Raf, PI3-K, phospholipase C% 
and RalGEFs (Buday and Downward, 2008, Ferro et al., 2008).   
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Somatic K-Ras mutations are common in cancer and are particularly high in 
malignancies of the pancreas (59%), colon (32%), lung  (18%) and ovary (15%) (Wang 
et al., 2010).  Common activating mutations of Ras include the G12V mutation that 
renders activated Ras insensitive to GAPs and Q61K that reduces the rate of Ras-GTP 
hydrolysis.  In colon cancer the G12V mutation was predictive for shorter time to 
treatment failure and reduced overall survival (Andreyev et al., 2001).  Knowledge of 
patients K-Ras mutation status also helps to guide treatments.  For example, in patients 
with chemotherapy refractory metastatic colorectal cancer only those patients with wild 
type K-Ras gain a benefit from treatment with Cetuximab, a monoclonal antibody 
against EGFR (Karapetis et al., 2008).  
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1.3 Atypical Protein Kinase C 
1.3.1 aPKC primary structure and organisation  
The Atypical Protein Kinase Cs (aPKC) consist of iota (!) and zeta (&) gene products 
and are members of the Protein Kinase C (PKC) branch of the AGC kinases (protein 
kinases A,G and C).  PKC lambda (') is the murine homolog of human PKC!.  The 
PKCs are serine/theonine protein kinases that share similar catalytic domains and are 
divided into four separate classes based on their more divergent regulatory domains - 
conventional, novel, atypical and PKN (Figure 1.2).  The Conventional PKC (cPKC) 
isotypes, that include PKC", the alternatively spliced #I and #II and $, are activated 
through a combination of DAG and phosphatidylserine binding to two tandem C1 
domains (Hurley et al., 1997) and Ca2+ - dependent phospholipid binding to the C2 
domain.  These phospholipids include phosphatidylinositol-4,5-bis phosphate (PIP2).  
The C1 domain also binds to tumour promoting phorbol esters such as PMA (Ono et al., 
1989).  Novel PKC (nPKC) isotypes that include PKC (, %, ) and * also contain the 
tandem C1 domains and are therefore DAG sensitive but have a ‘novel’ C2 domain that 
does not bind to Ca2+ or participate in membrane association.  The atypical PKCs do not 
have a C2 domain and have an ‘atypical’ C1 domain with a highly basic cleft that 
prevents ligand binding, rendering aPKCs insensitive to both DAG and Ca2+ (Pu et al., 
2006).  The C1 domain is a cysteine rich sequence that co-ordinates zinc ions and the 
atypical C1 domain has been reported to mediate interactions with proteins such as 
PAR-4 (see section 1.3.3.5)(Hommel et al., 1994). 
All PKC isoenzymes have a regulatory domain pseudosubstrate sequence that occupies 
the substrate binding pocket in the absence of lipid binding (or allosteric activators) and 
maintains the kinase in an autoinhibited state.  Upon binding to second messengers or 
allosteric activators, typically at the plasma membrane, the docking of the regulatory 
domain, including the pseudosubstrate region, is released allowing the activation of 
PKC (Pears et al., 1990). 
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Figure 1.2 The domains of PKC 
 
Both PKC and PKN have protein-protein binding domains, the Phox and Bem1p (PB1) 
and homology region 1 (HR1) domains respectively.  PB1 domain interactions 
associated with aPKC are formed when the conserved acidic segment (termed the 
OPCA motif) of one PB1 domain forms a salt bridge with the conserved basic residues 
(typically lysines) on another (Wilson et al., 2003, Hirano et al., 2005).  For examples 
of PB1 proteins see section 1.3.3.5.  The bivalent engagement of HR1 motifs by the 
Rho-family GTPases Rho or Rac disengages the PKN pseudosubstrate and results in 
kinase activation (Shibata et al., 1996, Flynn et al., 1998).   
All AGC kinases require phosphorylation on conserved Ser or Thr residues that for 
PKC are termed priming phosphorylations.  These priming phosphorylations stabilise 
the kinase and achieve a catalytically competent state that can be rapidly activated upon 
second messenger generation.  cPKCs and nPKC have 3 priming phosphorylation sites, 
one at the activation loop and two at the C-terminus referred to as the turn motif and the 
hydrophobic motif.  However, PKC!/& only have the activation loop (Thr403/410) and 
turn motif (Thr555/556) phosphorylation sites with the hydrophobic site S/T substituted 
with an acidic residue (E), that can potentially act as a phosphomimetic; a similar 
situation pertains in PKN where an aspartate sits at the equivalent hydrophobic site (see 
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Parker and Murray-Rust, 2004 for review).  The activation loop phosphorylation is 
catalysed by the upstream kinase phosphoinositide-dependent kinase-1 (PDK-1), which 
docks onto the hydrophobic motif or phosphomimetic site and has its enzymatic activity 
near the entrance to the aPKC active site (Le Good et al., 1998, Balendran et al., 2000).  
This correctly aligns residues within the aPKC active site for catalysis (Toker and 
Newton, 2000, see Mora et al., 2004 for review). 
For atypical PKC the mechanism of priming phosphorylation of the turn motif has not 
been well described, but it may be reasonable to extrapolate from our more extensive 
knowledge of other PKC family members.  Phosphorylation at the C-terminus depends 
on the activity of the mammalian target of rapamycin 2 complex (mTORC2), a 
complex of mTOR, mLST8, rictor, proctor and sin1 (Facchinetti et al., 2008, Ikenoue et 
al., 2008, Cameron et al., 2011).  For aPKC priming a recent study has speculated that 
all the mTORC2 subunits except rictor are dispensable for priming phosphorylation.  
Presumably the adaptor protein rictor would mediate an interaction between aPKC and 
an as yet unknown kinase (Zhang et al., 2010).  In vitro the carboxyl terminal sites are 
efficiently autophosphorylated (Behn-Krappa and Newton, 1999).  The recent finding 
in cells that priming phosphorylations at the C-terminal sites are dependent on 
nucleotide occupation of the kinase rather than catalytic activity would suggest that 
autophosphorylation of PKC is not what determines priming phosphorylations in vivo 
(Cameron et al., 2009).  The steady state levels of the priming phosphorylation is also 
determined by agonist dependent dephosphorylation.  Prolonged activation of PKC, 
that induces an open conformation of the kinase, increases the sensitivity to 
phosphatases such as PP2A and results in down-regulation of PKC (Hansra et al., 1996, 
Parker et al., 1995).   
 
1.3.2 AGC/PKC tertiary structure 
Eukaryotic protein kinases are dynamic molecules with a diverse array of structures, 
modes of regulation and substrate specificity but with strict organisation of the internal 
architecture.  The AGC kinases, of which PKC! is a member, have a conserved catalytic 
structure.  They share a bilobal catalytic domain of about 250 residues.  The smaller N-
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lobe is dominated by a five-stranded #-sheet, which is coupled to a helical sub-domain 
that typically consists of the C-helix.  The large C-lobe contains mostly "-helices plus a 
# sheet.  The helices provide a stable core and substrate tethering sites whereas the # 
sheet contains most of the catalytic machinery.  There are a number of important 
structural elements to a kinase identified from the sequence and main chain geometry 
(see Table 1.2). 
Utilising an analysis technique called Local spatial pattern (LSP) alignment new 
structure modules have been identified that coordinate kinase function.  LSP considers 
residues within the crystal structure as an individual vector arrayed in space.  As such, 
conserved residues may be identified independently of their sequence or main chain 
geometry.  In this way, strands of conserved spatial position residues that span both N- 
and C-lobes of the kinase were seen to align and were termed the regulatory (R) spine 
and the catalytic (C) spine.  The R-spine includes a C-helix Leu, an activation loop Phe 
(from DFG) and Tyr (from the H/YRD motif) in the catalytic loop.  In addition to the 
role of DFG in coordinating the Mg2+ ion, the aligned Phe and Tyr stabilise the active 
conformation.  The C-spine contains an Ala (from AxK), the adenosine ring from ATP 
and a #7 Leu.  The Leu is flanked by two further Leucines that provide a hydrophobic 
contact with a short D helix that in turn contacts the F-helix, a highly hydrophobic 
region that is integral to the organisation of the kinase core.  The D-helix therefore has 
an important function in contributing to the positioning of ATP with respect to the rigid 
hydrophobic core.  This LSP form of analysis has uncovered a previously unrealised 
and critical role of the D-Helix, has highlighted the importance of the activation loop 
Phe and focused attention on the newly defined regulatory and catalytic spines (Taylor 
and Kornev, 2011). 
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Table 1.2 Common conserved features of AGC kinases 
Summarised from reviews by (Taylor and Kornev, 2011) and (Pearce et al., 2010). 
Motif Function Lobe of 
Kinase 
Activation 
loop 
Contains catalytic elements such as DFG.  Upon phosphorylation there 
is a conformational change which then allows coordination of 
hydrogen bonds between Glu and the C-Helix, Lys on the N-lobe and 
phosphates on ATP. 
C-lobe 
C-terminal 
tail 
Wraps around both lobes and contains elements essential for catalysis. 
1) completes the ATP binding pocket, 2) glycine rich loop positioned 
for catalysis and 3) docking of hydrophobic motif into the N-lobe 
stabilizes the C-helix.  4) C-terminal phosphorylation sites are 
embedded in the tail. 
C-lobe 
F-Helix Highly hydrophobic and is a rigid core around which the kinase 
domain is organised. 
C-lobe 
GHI domain Segment that includes the G, H and I helices. Substrate, regulator and 
allosteric binding, stabilises kinase  
C-lobe 
DFG Aspartic acid residue in the activation segment that binds the Mg2+ 
ions that coordinate the # and $ phosphates of ATP in the binding cleft 
C-lobe 
H/YRD Aspartic acid functions as a base acceptor to achieve proton transfer.  
The Tyr aligns with the Phe from the DFG and Leu in the C-Helix to 
coordinate the N & C lobes poised for catalysis. 
C-lobe 
P+1 loop This provides a docking site for the P+1 residue of the peptide 
substrate. 
C-lobe 
APE Site of anchorage for the GHI domain to the activation loop. 
Demarcates the end of the activation loop. 
C-lobe 
AxK Lysine residue interacts with " and # phosphates of ATP to anchor to 
the C-Helix and orientates ATP. 
N-lobe 
Glycine rich 
loop  
GxGxxG/A.  The loop folds over the nucleotide and positions the $-
phosphate of ATP for catalysis. Makes a hydrophobic contact to the 
base (purine moiety) of ATP. 
N-lobe 
P-Loop GxxxxGKT/S. Anchors nucleotide bound phosphates and binds to the 
$-phosphate. 
N-lobe 
C-Helix Dynamic regulatory element.  Important position between the 2 lobes.  
N-terminus interfaces with the activation loop and its positioning is 
critical for catalysis. 
N-lobe 
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Two groups have published the coordinates of PKC! in the Apo form, ATP bound and 
BIM1 bound determined to 2.1 Å, 2.0Å and 3.0Å respectively (Takimura et al., 2010, 
Messerschmidt et al., 2005).  Overall the ATP bound form was almost identical to the 
BIM1 complex in these structures. PKC! displays most of the characteristics of the 
AGC kinases but there are a number of notable features elicited in these PKC! 
structures.  The glycine rich loop (GXGXXA) is unusual in that it has an alanine in the 
last position rather than the typical glycine of other AGC family members.  It forms a 
fixed and intermediate open conformation that could be because of the ‘fixed’ alanine 
or due to the presence of a tyrosine in the loop.  The catalytically important residues are 
all conserved as is the geometry of the priming phosphorylations at Thr403 and Thr555.  
The substitution of the glutamate residue at the hydrophobic motif does not impact on 
its spatial positioning compared to other AGC kinases.  Interestingly, the side chain of 
Phe543 protrudes into the ATP binding pocket and interacts with the adenine moiety of 
ATP.  Finally the B-helix in the N-lobe, unlike the well-formed B-helices in other AGC 
kinase structures, is partially unfolded and not helical in the PKC! structures 
(Messerschmidt et al., 2005, Takimura et al., 2010). 
 
1.3.3 Regulators and Effectors of aPKC 
1.3.3.1 Introduction 
aPKC is influenced by and regulates a vast array of intracellular signalling pathways 
and these differ depending on cellular context.  Regulation has been reported following 
aPKC manipulation at multiple levels of the signalling cascade that can be broadly 
grouped as stimuli and receptors, transducers, amplifiers and metabolites (see section 
1.2.1).  A schematic overview of oncogenic aPKC signalling is depicted in Figure 1.3.
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Figure 1.3 Schematic overview of oncogenic aPKC signalling 
Atypical PKCs are involved in several major signalling pathways implicated in cancer.  The dotted lines represent weaker level of evidence (see section 1.3.3 for 
details) 
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1.3.3.2 Stimuli and Receptors 
The first growth factors recognised to modulate aPKC in cells were EGF and PDGF.  
Phosphorylation and re-localisation of aPKC in Cos cells occurred in response to this 
growth factor stimulation in a phosphoinositol-3-kinase (PI3K) dependent manner 
(Akimoto et al., 1996).  Subsequently, aPKC was demonstrated to be involved in the 
signalling downstream of at least two members of the Epidermal growth factor receptor 
family – EGFR (ErbB1) and Her2 (ErbB2).  The four members of this family, that also 
includes ErbB3 and ErbB4, are a group of transmembrane tyrosine kinase receptors that 
homo- or heterodimerise in response to ligand binding.  Epidermal growth factor 
(EGF), the ligand for EGFR, promotes chemotaxis in A549 and MDA-MB-231 cells 
and this can be reduced by PKC! siRNA knockdown or chemical inhibition (Sun et al., 
2005, Liu et al., 2008).  ErbB2 forced dimerisation has been shown to disrupt polarity 
in an aPKC dependent manner.  This was demonstrated in 3D cultures of MCF10a cells 
by reversing ErbB2 driven hyperproliferation, loss of apoptosis and disruption of 
apical-basal polarity with a Par6 mutant that was unable to bind to aPKC (Aranda et al., 
2006).  Several other studies have implicated PDGF as an activator of aPKC.  The 
immunocomplex activity of PKC! from COS-1 cells is enhanced following PDGF 
treatment and the PDGF induced proliferation of fibroblasts was inhibited by 
expression of a dominant negative kinase dead mutant of PKC! (Doornbos et al., 1999, 
Diaz-Meco et al., 1994). 
The regulation of aPKCs may also be influenced by external triggers.  Nerve growth 
factor (NGF), that induces differentiation of PC12 cells via the TrkA neurotrophin 
receptor family, has been shown to induce tyrosine phosphorylation of PKC" in a Src 
dependent manner (Wooten et al., 2001).  In an androgen starved prostate cell line, 
LNCaP, addition of a synthetic androgen leads to increased phosphorylation of aPKC 
(T403/410) in a mechanism that seems to be downstream of c-Src activation 
(Kobayashi et al., 2010).  Agonists such as nicotine and glucose also regulate aPKC but 
the mechanisms for this remain unclear (Xu and Deng, 2006, Bandyopadhyay et al., 
2001, Chuang et al., 2003). 
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1.3.3.3  Signal transducers and amplifiers in aPKC signalling  
Ras 
Ras was shown to co-immunoprecipitate with aPKC and bind directly to the regulatory 
domain of PKC! by the Moscat Laboratory in 1994 (Diaz-Meco et al., 1994).  Bjorkoy 
et al showed that constitutive activation of ERK1/2 and Elk1 in response to oncogenic 
Ras could be reversed by transfecting a dominant negative PKC# construct (Bjorkoy et 
al., 1997).  The morphological changes of H-Ras expressing NIH3T3 cells, that include 
dissolution of actin stress fibres, were blocked by dominant negative mutants, RNAi 
and a chemical inhibitor against aPKC (Uberall et al., 1999).  Similarly the inhibition of 
differentiation of mouse skeletal muscle cells induced by expression of oncogenic H-
Ras were overcome with a dominant negative PKC"/# construct or Gö6983, the pan-
PKC inhibitor (Fedorov et al., 2002).  Furthermore, exogenous expression of Ras and 
PKC" in an ovarian cancer cell line has been shown to be synergistic for the size and 
number of colonies in a soft agar assay (Zhang et al., 2006a).  Seemingly, PKC" can 
interact with Ras in multiple cellular contexts and the Ras associated phenotypes are 
PKC" dependent. 
The significance of PKC", downstream of oncogenic Ras, has also been born out of 
murine models.  Expression of a dominant negative PKC" in A549 cells, known to 
harbour a K-ras mutation, resulted in reduced xenograft tumour formation in nude mice 
(Regala et al., 2005a).  In an orthotopic model of pancreatic cancer, using a K-Ras 
mutant cell line, RNAi induced knockdown of PKC" led to decreased tumour burden, 
decreased markers of angiogenesis and fewer distant metastases (Scotti et al., 2010).  
Transgenic mice that contain a latent oncogenic K-ras allele that is activated by 
spontaneous recombination developed aberrant crypt foci (ACF) of the intestine.  ACFs 
are likely precursors to colon cancer in mice and humans (Takayama et al., 1998) and 
their frequency is predictive of colon tumour formation in rodents (Magnuson et al., 
1993).  Bi-transgenic mice that express the latent oncogenic K-Ras and kinase dead 
PKC" developed fewer ACFs than K-Ras mice (Murray et al., 2004).   
Chapter 1. Introduction 
 36 
Transgenic mice that expressed oncogenic K-Ras after Cre-mediated recombination 
developed lung tumours following intra-tracheal Cre-administration.  Bitransgenic mice 
that simultaneously expressed oncogenic K-Ras but lost PKC" expression upon Cre-
delivery had significantly reduced tumour burden (Regala et al., 2009).  Similarly, mice 
expressing oncogenic K-Ras but knock out for p62, an adapter protein that binds to 
aPKC, also has a reduced lung tumour formation (Duran et al., 2008).  On the other 
hand, PKC! would appear to negatively regulate Ras induced tumourigenesis of the 
lung in a bi-transgenic mouse model (Galvez et al., 2009). 
 
SRC 
Src is the prototype of the Src family of non-receptor tyrosine kinases that have dual 
adaptor and kinase functions.  It forms an immunocomplex with PKC" and the TrkA 
neurotrophic receptor and this interaction is enhanced by NGF stimulation of PC12 
cells.  The SH3 binding domain of Src binds to the proline rich motif in PKC" (aa98-
114).  Sites of Src dependent PKC" tyrosine phosphorylation were identified from 
kinase assays performed on a PKC" peptide array (Y256, Y271 & Y325) and the 
functional significance was confirmed using the non-phosphorylatable mutants 
(Tyr>Phe) (Wooten et al., 2001).  Tyrosine phosphorylation of aPKC by Src has been 
shown to be required for an association with Rab2, a small GTPase necessary for 
endocytic transport, and could be inhibited by the Src kinase inhibitor-PP2  (Tisdale and 
Artalejo, 2006).  Several reports have suggested that aPKC is required for Src mediated 
transformation.  Knockdown or inhibition of c-Src led to decreased aPKC activation 
loop phosphorylation in a Rac1 dependant manner and reduced proliferation in 
androgen dependent prostate cancer cells (Kobayashi et al., 2010).  Additionally, 
perturbation of aPKC by dominant negative constructs or RNAi, decreased invasion, 2D 
cell polarity and matrix degradation in v-Src transformed NIH3T3 cells (Rodriguez et 
al., 2009). 
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Raf 
PKC! was reported to phosphorylate and activate Raf-1 (van Dijk et al., 1997).  In COS 
cells, PKC! was reported to immunoprecipitate with Raf-1 and this interaction was 
enhanced by co-transfection of 14.3.3 isoforms, and was weaker for wild type PKC! 
constructs than kinase dead constructs.  These data would suggest that PKC!, Raf-1 
and 14.3.3 form a ternary complex that is phosphorylation dependent (Van Der Hoeven 
et al., 2000).  In the 10 years since this work, however, no group has published on the 
signalling or functional relevance of this interaction.  
 
PKC$II 
Over-expression of PKC$II induced an invasive phenotype in rat intestinal epithelial 
cells (RIE) in a PKC" dependent manner.  Using small G-protein GTP assays 
transfection of PKC$II was shown to increase both Ras and Rac1 activities but not 
RhoA.  Inhibition of PKC$ by LY379196 reduced invasion that could be overcome by 
expression of constitutively active Rac1 suggesting that the Ras effector Rac1 is 
downstream of PKC$II (Zhang et al., 2004).  Taken together with the results discussed 
in the Ras section above, these data would be consistent with a model whereby PKC$II 
induces invasion in RIE cells through activation of a PKC$II>Ras>PKC"/Rac1 
signalling axis. 
 
PKB   
PKC! was reported to co-immunoprecipitate with PKB in COS cells and this 
interaction was mediated by the pleckstrin homology domain of PKB (Doornbos et al., 
1999, Mao et al., 2000).  PDGF induced activation of PKB was negatively influenced 
by PKC! as defined by immunocomplex kinase assays, phosphorylation at its Ser473 
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site and lack of substrate phosphorylation (GSK3).  Further evidence that PKC! acts at 
the same level (or downstream) of the signalling pathways comes from the observation 
that it is still able to inhibit a constitutively active form of PKB whose activity is 
independent of its upstream kinase PI3K (Doornbos et al., 1999).  Contrary to these 
results, more recent studies have suggested that PKC! is able to activate PKB.  
Recombinant PKC! has been shown to directly phosphorylate PKB at 3 separate sites; 
Ser124, Ser473 and Thr308 with a 3:1:1 stoichiometry.  Knockdown of PKC! in 
embryonic fibroblasts significantly reduces phosphorylation of Ser473 and Thr308, the 
principal priming sites of PKB (Joshi et al., 2008, Cantley, 2002).  Knockdown of 
Rictor, a component of TORC2 that regulates PKB Ser473 phosphorylation, prevents 
Ser473 phosphorylation.  One interpretation of these data is that PKC! principally 
phosphorylates PKB at Ser124 which in turn modulates TORC2 regulation of PKB 
Ser473 and PDK1 regulation of Thr308 (Joshi et al., 2008).  Alternatively Rictor may 
be a necessary adaptor protein for aPKC dependent phosphorylation in vivo. 
  
PI3K  
Over-expression of one of the catalytic subunits of PI3K, p110%, increased PKC"/# 
phosphorylation and increased PKC"/# dependent transcriptional activity in a luciferase 
reporter assay in response to PDGF and EGF.  A dominant negative PI3K construct had 
the opposite effect (Akimoto et al., 1996).  The PI3K lipid metabolite, PIP3, was shown 
to promote in vitro activation of aPKC, potentially by direct binding to the cysteine rich 
sequence and resulting release of pseudosubstrate autoinhibition or indirectly via PDK1 
(Standaert et al., 2001).  However, the role of PI3K in the activation of aPKC is likely 
to be via PDK1 as in vitro studies have shown PIP2 to be equally as effective as PIP3 at 
activating aPKC (Palmer et al., 1995).  Chemical inhibition of PI3K by LY294002 
decreased PKC" phosphorylation in glioma cells (Baldwin et al., 2008) and lung cancer 
cells (Liu et al., 2008).  Over-expression of wild type PTEN, a lipid phosphatase that 
promotes the conversion of PIP3 to PIP2, in the glioma cells also resulted in decreased 
PKC" phosphorylation (Baldwin et al., 2008).  PDK1 binds to PIP3 causing co-location 
with target kinases also on membranes; for aPKC this enables efficient phosphorylation 
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of the Threonine in the activation loop (Le Good et al., 1998, Balendran et al., 2000).  
Knockdown of PDK1 by siRNA inhibited priming phosphorylation of PKC" (Thr555) 
and reduced expression levels in glioma cells (Desai et al., 2011).  Increased PDK1 
mRNA expression was commonly indentified in epithelial malignancies such as breast 
cancer, and while not oncogenic it dramatically enhanced the ability of upstream 
oncogenic lesions, such as ErbB2, to form tumours (Maurer et al., 2009). 
 
1.3.3.4 Other lipid metabolites 
The sphingolipid ceramide has been implicated in the regulation of aPKC.  Ceramide 
activates both recombinant and HEK293 cell endogenous aPKC.  In response to insulin 
ceramide promotes phosphorylation of the JNK pathway. (Bourbon et al., 2000).  Using 
lipid vesicle-mediated affinity chromatography ceramide was demonstrated to bind to 
PKC!.  Low concentrations of ceramide were observed to stimulate PKC! activity but 
high concentrations were inhibitory both in vivo and in vitro (Wang et al., 1999).  In 
primitive ectoderm cells that form a central cavitation, pharmacological inhibition of 
ceramide resulted in aPKC mislocalisation, impaired ectoderm morphology and 
increased central apoptosis (Krishnamurthy et al., 2007).  A further lipid that was found 
to associate with PKC! is Phosphatidic acid (PA), a diacylglycerol (DAG) metabolite.   
PA caused autophosphorylation of PKC! immunocomplexes and a mobility band shift 
consistent with a PKC!-PA complex (Limatola et al., 1994)).  Despite an appreciable 
time lapse since some of these reports, publication of corroborative studies are still 
outstanding.   
 
1.3.3.5 Protein-Protein Interactions  
aPKC is comprised of modular protein-protein interaction domains that allow multiple 
interactions that both regulate aPKC function and couple it to various signalling 
pathways.  aPKCs are the only PKC isoforms to have PB1 domains which allow 
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interaction with other PB1 domain containing proteins including Par6 (see section 
1.3.5), ZIP/p62 and Mek5.   
In a yeast-two-Hybrid screen PKC! was found to bind to an adaptor protein termed zeta 
interacting protein (ZIP/p62) (Puls et al., 1997, Sanchez et al., 1998).  ZIP/p62 binds to 
PKC! via the PB1 domain and links upstream transduction to NF-&B (transcription 
factor) signalling via aPKC.  Disruption of the p62-PKC! interaction by ursolic acid 
suppressed NF-&B activity and resulted in down-regulation of MMP-9 protein and 
decreased TNF-% induced glioma cell invasion (Huang et al., 2008).  P62 is up-
regulated in a transcription dependent manner by Ras and is required for lung 
tumourigenesis in a Ras dependent lung cancer mouse model (Duran et al., 2008).  P62 
has also been shown to be required for IKK activation (Duran et al., 2004, Martin et al., 
2006).  MEK5 and aPKCs formed a complex upon EGF stimulation and have been 
implicated in proliferation and anti-apoptotic signalling through the NF-&B pathway 
(Diaz-Meco and Moscat, 2001). 
The cysteine rich region of aPKC (C1-related domain) binds to prostate androgen 
response-4 (PAR-4) and Lambda interacting protein (LIP).  PAR-4 was originally 
identified as an apoptotic gene in prostate cancer and is distinct from the partitioning 
defective 4 gene (Par4) identified in C.Elegans as a polarity regulator (Diaz-Meco et 
al., 1996).  PAR-4 interacts with and inhibits PKC! in vitro and in vivo.  Tissue of 
PAR-4 null mice demonstrated increased levels of activated aPKC, PKB and NF-&B.  
Increased catalytic activity of aPKC was present in immunocomplex kinase assays 
from lung extracts (Joshi et al., 2008).  The interaction of PAR-4 with PKC! in 
immunocomplexes was reported to be mediated by ceramide.  In the absence of PAR-4 
ceramide activated PKC! but in the presence of PAR-4 ceramide led to decreased 
PKC! activity and reduced NF-&B transcription (Wang et al., 2008a). 
Mouse models have demonstrated that PAR-4 knockout results in susceptibility to 
malignancy.  Female mice demonstrated a preponderance for endometrial adenomas 
and male mice showed prostate hyperplasia (Moreno-Bueno et al., 2007, Garcia-Cao et 
al., 2005).  Bi-transgenic mice expressing a conditional Ras oncogene and knockout for 
PAR-4 have a higher lung tumour grade and burden than single transgenic Ras mice 
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(Joshi et al., 2008).  There are also examples of human malignancy where PAR-4 
expression is reduced including lung adenocarcinoma and prostate carcinoma (Joshi et 
al., 2008, Galvez et al., 2009). 
Over-expression studies in cell lines show that PAR-4 inhibition of serum induced PKB 
Ser473 phosphorylation could be overcome by forced over-expression of PKC!.  Taken 
together the results could suggest that PAR-4 negatively regulates PKC! and that is 
then unable to potentiate activation of PKB (Joshi et al., 2008).  These results do not 
exclude the possibility that PAR-4 can also directly inhibit PKB and that the affect of 
PKC! is the sequestration of PAR-4 thus releasing its inhibition of PKB .   
LIP binds to the cysteine rich region of PKC#/" but not that of PKC!.  It was shown to 
activate PKC#/" both in vivo and in vitro but has subsequently been identified as the C-
terminus of Serine/threonine-protein kinase 1 (SMG1).  The function of the full length 
SMG1 has not been assessed in relation to aPKC and is otherwise thought to be 
involved in nonsense-mediated mRNA decay (Diaz-Meco et al., 1996, Yamashita et al., 
2001).  
 
1.3.4 Downstream Effectors of aPKC 
Rho Family Members 
Rac 1 and Cdc42 are functionally similar Rho-GTPases but have distinct functions (Qiu 
et al., 1995).  Both proteins play important roles downsteam of PKC" in cytoskeletal 
remodelling.  Levels of activated Rac1-GTP were suppressed in A549 cells expressing 
the dominant negative PKC" (PKC"-K274W) construct or when treated with the aPKC 
pseudosubstrate inhibitor (Regala et al., 2005a).  Over-expression of PKC"-K274W in 
A549 cells resulted in decreased non-adherent cell growth and tumourigenesis in nude 
mice but both of these phenotypes were recovered by co-expression of a constitutively 
active Rac-1 allele indicating that Rac1 may be required for PKC" dependent 
transformation.  Rac1 is thought to regulate a p21 activating kinase (PAK) that in turn 
phosphorylates MEK1/2.  Expression PKC"-K274W in A549 cells also led to reduced 
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phosphorylation of the downstream effectors of the ERK pathway – MEK1/2 at both the 
Raf and PAK phosphorylation sites and the canonical sites on ERK1/2.  This was 
rescued by activated Rac1 expression (Regala et al., 2005b).  Together this data 
supports a role for an aPKC>Rac1>PAK1>MEK1/2>ERK1/2 signalling axis that plays 
a role in non-adherent growth and tumourigenesis. 
Ect2 is a Rho-GTPase nucleotide exchange factor.  It is located on chromosome 3q26, 
the same region as PKC" that is commonly overexpressed in squamous cell carcinoma 
(Yang et al., 2008).  Both Ect2 and PKC" genes were identified to be the drivers of 
amplicons on chromosome 3q (Haverty et al., 2009).  Ect2 is thought to play a role in 
cytokinesis and has recently been identified, via co-immunoprecipitation with PKC"-
Par6 followed by mass spectrometry, as a PKC" substrate.  PKC" phosphorylated Ect2 
at Thr328 in vitro and siRNA knockdown of PKC" (or Par6) led to decreased 
phosphorylation of Ect2 and decreased activity of Rac1 (Justilien et al., 2010).  Ect2 
RNAi decreased non-adherent lung cancer cell growth (H1703 cell line) and this could 
be rescued by WT Ect2 but not a phosphorylation deficient mutant.  Ect2 has been 
reported to be over-expressed at a protein level in lung cancer (Justilien and Fields, 
2009).  In summary Ect2 is a recently identified human oncogene that requires 
phosphorylation by PKC" for its transformed behaviour.  It should be noted however 
that the sequence flanking Thr328 is a very unusual aPKC substrate site. 
 
Transcription Regulation 
A number of transcriptional targets have been cited as being downstream of aPKC.  One 
of the most extensively studied pathways is that involving NF-&B, a transcription factor 
that is activated by numerous stimuli and is involved in the regulation of processes such 
as immune response, cell survival and angiogenesis (Kisseleva et al., 2006).  There are 
three main families of proteins that comprise the NF-&B signalling pathway; NF-&B, 
inhibitor of NF-&B (I&B) and inhibitor of NF-&B kinase (IKK).  NF-&B is comprised of 
5 family members that form homo or heterodimers and include RelA (p65), RelB, c-
Rel, NF-&B1 (p50) and NF-&B2 (p52).  NF-&B dimers are retained in the cytoplasm by 
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I&B but upon pathway activation IKK phosphorylates I&B and targets it for 
ubiquination and proteasomal degradation.  This releases NF-&B to translocate to the 
nucleus and affect transcription (Karin, 1999).   
Perturbation of PKC" or PKC! via pseudosubstrate inhibitors, antisense 
oligonucleotides or transfection with kinase dead mutants all impair NF-&B activation 
(Dominguez et al., 1993, Diaz-Meco et al., 1996).  PKC! has been reported to regulate 
at least two different parts of the NF-&B pathway.  In mouse embryonic fibroblasts 
PKC! phosphorylated NF-&B (RelA) at Ser311 and established a complex with CBP, a 
coactivator necessary for transcription (Duran et al., 2003).  Additionally PKC! 
interacted with and phosphorylated IKK in TNF-% stimulated HEK293 cells.  
Recombinant protein studies suggest that this interaction could be direct and identified 
the PKC! substrate sites on IKK$ as Ser177 and Ser181 (Lallena et al., 1999).  PKC" 
phosphorylated and activated IKK in TNF-% treated prostate carcinoma cells but not in 
a TNF% treated non-transformed prostate cell line possibly suggesting specificity 
towards transformed cells (Win and Acevedo-Duncan, 2008).  
NF-&B has also been implicated as mediating PKC" dependent chemoresistance.  
Antisense expression of PKC" decreased NF-&B (RelA) transcriptional activity and 
sensitised a chronic myelogenous leukaemia cell line to paclitaxel induced apoptosis 
(Murray and Fields, 1997).  
One of the targets of NF-&B signalling is IL-6, a cytokine involved in immune and 
haematological function.  The IL-6 promoter contains recognition sites for both NF-&B 
and a second transcription factor AP-1.  In hormone refractory prostate cancer high 
levels of AP-1, NF-&B and consequently IL-6 levels were seen and could be reduced 
following PKC" RNAi (Ishiguro et al., 2009).  PKC! has been shown to repress histone 
acetylation of the IL-6 promoter resulting in lower levels of the cytokine (Galvez et al., 
2009).  Seemingly therefore, aPKC can both enhance and repress IL-6 production via 
different pathways.   
Transcription of MMP10, a matrix metalloproteinase, in lung tumours from K-Ras 
over-expressing transgenic mice was elevated upon Cre induction.  The increase in 
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MMP10 mRNA upon Cre induction was negated in a bi-transgenic mouse with 
concomitant PKC" knockout (Frederick et al., 2008, Regala et al., 2009).  Studies in 
human lung tumours with Ras mutations have not corroborated the finding of elevated 
MMP10 mRNA or protein (Zhang et al., 2007).  Using a bioinformatics approach 
employing 3 separate publicly available gene expression data sets, the Fields laboratory 
indentified 4 functionally distinct genes that were co-ordinately expressed with PKC" in 
lung adenocarcinoma.  Knockdown of PKC" reduced transcription of all four genes 
(COPB2, ELF3, RFC4, PLS1). Knock down of each of the four genes phenocopied the 
PKC" knockdown exhibiting a reduction in non-adherent cell growth (Erdogan et al., 
2009). 
 
mTOR/P70S6Kinase 
P70S6 kinase is a ribosomal S6 protein kinase that upon phosphorylation and activation 
in turn phosphorylates the S6 component of the 40S ribosome subunit and leads to 
increased protein synthesis.  mTORC1 is the best described activator of p70S6K but 
there are multiple others that are less well defined, for example aPKC.  PKC# was 
found to directly associate with p70S6K and dominant negative kinase deficient PKC# 
mutants suppress serum activation of p70S6K (Akimoto et al., 1998).  Inhibition of 
aPKC using a myristolated pseudosubstrate (PS) peptide suppressed androgen induced 
phosphorylation of p70S6K.  Phosphorylation of both aPKC and p70S6K proteins were 
correlated in human prostate tissue microarrays (Inoue et al., 2006).  In a follicular 
lymphoma cell line an anti-CD20 antibody, a B-cell surface antigen of uncertain role, 
decreased aPKC and p70S6K phosphorylation and reduced aPKC activity in an 
immunocomplex kinase assay.  The same results were attained with the aPKC PS 
inhibitor and an aPKC kinase dead construct and the anti-CD20 antibody treatment 
affects could be overcome by a constitutively active aPKC construct (Leseux et al., 
2008).  These results suggest that p70S6K may be a down stream effector of aPKC in 
multiple cellular contexts.  
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Apoptosis pathways 
It has recently been demonstrated that aPKC can inactivate the apoptotic machinery 
through its kinase activity.  In glioma cells PKC" formed immunocomplexes with BAD 
(BCL2-associated agonist of cell death) and phosphorylated it at 3 distinct sites 
(Ser112, Ser136 and Ser155).  Usually BAD promotes apoptosis by binding to Bcl-XL.  
Phosphorylation of BAD immunocomplexes by purified PKC" led to BAD/Bcl-XL 
dissociation and promoted the inactive BAD/14.3.3 association.  The phosphorylation 
of BAD by PKC" was shown to be direct in recombinant protein kinase assays.  In cells, 
aPKC was seen to co-localise with BAD and knockdown of PKC" led to increased 
apoptosis (Desai et al., 2011).  
 
Morphological pathways 
aPKC/Par6 inactivated GSK3$ by phosphorylation at Ser9 and prevented GSK3$ 
driven apoptosis (Kim et al., 2007).  Expression of a non-aPKC binding mutant of Par6 
in MDCK cells led to decreased GSK3$ phosphorylation, increased JNK activation and 
increased apoptosis.  In Rat astrocytes exogenous PKC! phosphorylated and dissociated 
from GSK3$.  This process was shown to be vital for directed migration (see section 
1.3.6).  Intriguingly GSK3$ has recently been shown, in a D.melanogaster epidermis 
model, to directly phosphorylate aPKC leading to its ubiquitin mediated proteosomal 
degradation (Colosimo et al., 2010).   
Ezrin is a cytosolic protein that upon phosphorylation of Thr567 becomes localised 
under the cell membrane where it connects actin filaments to membrane proteins (Wald 
et al., 2008).  Ezrin is phosphorylated at the Thr567 by several kinases including 
members of the PKC family (Ng et al., 2001, Ren et al., 2009, Wald et al., 2008).  
Treatment of an osteosarcoma cell line, K7M2, with Gö6976 (a classical PKC inhibitor) 
decreased migration and invasion which could be rescued by expression of a 
constitutively activate Ezrin construct, demonstrating that Ezrin is downstream of PKC 
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in the signalling cascade (Ren et al., 2009).  In differentiating mouse intestinal crypts, a 
temporospatial model, activated PKC" and Ezrin were co-localised apically.  In Caco2 
cells PKC" knockdown led to mislocalisation and decreased phosphorylation of Ezrin 
(Wald et al., 2008).  Recently LGN (named after ten Leucine-Glycine-Asparagine 
tripeptides in its N-terminal region), a protein involved in spindle orientation during 
mitosis, was shown to be phosphorylated by aPKC (for more details see section 1.3.7). 
Numb is an evolutionary conserved signalling adapter that was originally identified in 
Drosophila as a protein involved in asymmetrical cell division and was therefore a cell 
fate determinant (Uemura et al., 1989).  It is therefore considered in this cytoskeletal 
section although it has a complex pattern of functions, probably due to its diverse 
isoforms and heterogeneity of interacting proteins (see (Gulino et al., 2010) for review).  
It contains a phosphotyrosine binding region and a proline rich region.  Numb was 
found to bind to aPKC and Par3 in HeLa cell immune complexes.  It was 
phosphorylated by aPKC at Ser7, Ser265 and Ser284.  Truncation mutants have 
revealed that Numb binds within the C-terminal coiled-coil region of Par3 (aa937-1038) 
(Nishimura and Kaibuchi, 2007).  Src activation or HGF treatment led to increased 
interaction of Numb with aPKC and Par6 but decreased interaction with Par3 and E-
cadherin.  This led to disrupted cell-cell adhesion and is proposed to contribute to Src 
dependent epithelial to mesenchymal transition (EMT) (Wang et al., 2009, Nishimura 
and Kaibuchi, 2007).  In addition to its roles in cell fate determination and cell adhesion 
Numb is involved in integrin endocytosis (Hutterer et al., 2004) and directed cell 
migration (see section 1.3.6). 
Others 
Finally, other proposed downstream substrates of aPKC for which the mechanisms are 
less well described include S-phase kinase associated protein (SKP2) (Liu et al., 2011), 
hASIP (Jin et al., 2008), cdk7 (Win and Acevedo-Duncan, 2009, Acevedo-Duncan et 
al., 2002) and the heat shock protein, HSP70B (Boellmann and Thomas, 2010). 
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1.3.5 Apical-Basal Polarity  
One of the major functions of aPKC is the regulation of polarity.  Deregulation of 
polarity proteins often causes a more invasive phenotype in malignant tumours (Igaki et 
al., 2006, Bilder, 2004).  Loss of the apical-basal polarity in epithelial cells is one of the 
hallmarks of aggressive and invasive cancers (Thiery, 2002).  Cellular polarity refers to 
the restricted pattern of cellular components to regions of the cell.  Polarity is essential 
for a range of normal cellular functions including asymmetric cell division, maintenance 
of epithelial integrity and cell migration.  The core polarity machinery seems to be well 
conserved between cell types and is comprised of a number of protein complexes.  In 
epithelial cells there are three major complexes – Par, Crumbs and Scribble.  aPKC 
interacts with and/or phosphorylates each of these complexes and in doing so specifies 
their cellular localisation.  This section will introduce the architecture of a polarised 
epithelial cell, discuss the polarity machinery, the antagonistic interactions between 
complexes and potential polarity cues. 
 
1.3.5.1 Polarised structure of mammalian epithelial cells 
Mammalian epithelia, such as Mardin Darby canine kidney (MDCK) cells are 
characterised by three different polarised domains; apical, lateral and basal (St Johnston 
and Ahringer, 2010).  The apical domain is made up of the brush border of microvilli 
beneath which lie actin and spectrin filaments.  These filaments are linked to the plasma 
membrane by ezrin, moesin and radixin  (ERM family proteins).  The apical and lateral 
membranes are separated by tight junctions (Tepass et al., 1990).  Tight junctions 
contain a number of homotypic adhesion molecules such as junctional adhesion 
molecules (JAMs), Claudin, Occludin and Tricellium.  These adhesion molecules 
associate with the MAGUK (membrane associated guanylate kinase like homology) 
proteins, ZO-1 and ZO-2, which are able to interact with the cytoplasmic tails of 
Claudin and Occludin via their N-terminal PDZ domains (Tsukita et al., 2001).  It was 
thought that tight junctions formed a physical barrier to the diffusion of cellular 
proteins.  This model has been challenged by the finding that knockdown of MAGUKs 
does not effect the polarised membrane protein distribution despite a loss of tight 
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junctions and altered transepithelial resistance.  Based on the evidence from the 
MAGUK knockout mouse, which are embryonic lethal, tight junctions would be 
predicted to play a fundamental cellular role.  Whether this includes the initiation or 
maintenance of polarity remains to be seen (see Tsukita et al., 2008 for review).  
 
 
Figure 1.4 Architecture of a mammalian epithelial cell   
Adapted from (St Johnston 2010).  Mammalian epithelial cells contain an apical, lateral and basal region.  
Tight junctions act as the partition between the apical and lateral regions and are comprised of JAM, 
claudin, occludin and nectin.  The lateral adherens junctions contain nectin and E-cadherin. Cytoskeletal 
proteins surround the cell cortex (see text). Basally located integrins interact with the extracellular matrix 
(ECM).  
 
 
Below the tight junctions and located in the lateral domain of the cell, lies the adherens 
junctions which provide the main mechanical link between adjacent cells.  These 
junctions are characterised by the presence of calcium dependent adhesion molecules, 
the cadherins, and their adapter proteins beta- and alpha catenin.  The cadherin-catenin 
complex indirectly mediates actin cytoskeleton reorganisation and this process is 
regulated by both phosphorylation and endocytosis (see Nelson, 2008 for review).  
Similarly another class of homophilic transmembrane adhesion molecules, the nectins, 
are found predominantly at the adherens junctions but also play a role in establishing 
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tight junctions (Fukuhara et al., 2002).  At adherens junctions nectins are coupled to the 
cytoskeleton with the help of the adapter protein Afadin/AF-6 (Takai et al., 2008). 
The basal domain of the cell is the interface between the cell and the extracellular 
matrix.  This region is highly enriched in matrix receptors such as the integrins and 
dystroglycan and is depleted of intercellular adhesion molecules (St Johnston and 
Ahringer, 2010).   
 
1.3.5.2 Par Complex 
The ‘Par complex’ is made up of Par3, aPKC, and Par6 proteins (Hung and Kemphues, 
1999, Joberty et al., 2000).  The respective genes were first identified in an RNAi 
screen of defective cell partitioning in C.elegans embryos (Tabuse et al., 1998, Watts et 
al., 1996).  These 3 genes are highly conserved through metazoan evolution (Izumi et 
al., 1998).  The functional importance is also conserved, for example when Drosophila 
Par6 was silenced, cells failed to undergo the normal process of asymmetrical division 
(Petronczki and Knoblich, 2001) and in mammalian cells a dominant negative aPKC 
construct prevented normal tight junction formation (Suzuki et al., 2001). 
aPKC and Par6 form a stable dimer that is capable of interacting with Par3 to form the 
trimeric complex (Joberty et al., 2000).  The interaction between aPKC and Par6 is 
mediated by their respective PB1 domains (see section 1.2.5) (Hirano et al., 2005).  It is 
proposed that Par6 stabilises aPKC, by preventing proteolytic degradation (Durgan et 
al., 2011).  Additionally some studies, but not all, have suggested that Par6 suppresses 
the catalytic activity of aPKC (Lin et al., 2000, Qiu et al., 2000).  Cdc42, a small Rho 
GTPase interacted with Par6 via the partial CRIB/PDZ domain of Par6 and caused 
increased aPKC activity in an immunocomplex kinase assay.  These data could be 
interpreted as Par6 restrains the aPKC kinase domain which is allosterically released 
upon Cdc42 binding (Lin et al., 2000, Yamanaka et al., 2001).  
Par3 interacts directly with the aPKC kinase domain via a 26 amino acid minimal 
binding region of Par3 (aa816-841) and induces phosphorylation in vivo at Ser827.  
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Additionally, Par3 interacts with Par6 via their respective PDZ domains completing the 
trimeric Par complex (Gao et al., 2002)).  The Par complex is apically situated and there 
are a number of features of Par3 that suggest that it is this protein that drives the 
localisation.  Firstly, the N-terminal PDZ of Par3 binds to the c-terminal PDZ binding 
domains of JAM and nectin, the apical-lateral junction proteins (Ebnet et al., 2001).  
Secondly, the next PDZ binds to phosphoinositides located in the membrane lipid 
bilayer (Wu et al., 2007).  Thirdly the N-terminal CR1 domain of Par3 homo-
oligomerises which assists apical localization in Drosophila and mammals and 
potentially provides a large scaffold for binding (Benton and St Johnston, 2003, Feng et 
al., 2007, Mizuno et al., 2003).  Fourthly, upon tight junction association Par3 recruits 
protein phosphatase 1% that protects Par3 from inactivating phosphorylations (Traweger 
et al., 2008).   
When recruited to the apical membrane there is evidence to suggest that Par6-aPKC 
does not remain associated with Par3 and that aPKC-Par6 is dispensable for tight 
junction formation.  Firstly, in contrast to earlier studies that reported aPKC-Par6 and 
Par3 co-localisation, (Hirose et al., 2002) recent work has suggested that they are not 
truly co-localised, in fly and mammals, with the aPKC-Par6 located apical-laterally and 
Par3 slightly basal to this (Morais-de-Sa et al., 2010).  Secondly, aPKC-Par6 dissociates 
from Par3 following aPKC dependent phosphorylation of mammalian Par3 at Serine 
827 and a non-phosphorylation mutation at this site disrupts tight junction formation 
(Nagai-Tamai et al., 2002).  The evidence that tight junction formation may be 
dispensable for Par6-aPKC came from MDCK lacking endogenous Par3.  This caused 
disrupted (delayed) tight junction formation but was rescued by an exogenous Par3-
mutant that was unable to bind to aPKC or Par6.  Furthermore, an alternative complex 
including Par3 and the Rac exchange factor, TIAM1, has been implicated as being 
required for tight junction formation (Chen and Macara, 2005). 
Several recent studies have carefully distinguished between tight junction formation and 
apical domain formation (Horikoshi et al., 2009, Ishiuchi and Takeichi, 2011).  In this 
respect it has been reported that apical membrane formation requires Par6-aPKC 
binding to Par3 in a process that also involves trafficking of Par6-aPKC containing 
vesicle-like structures.  Consistent with the work of Chen et al tight junction formation 
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was independent of Par6-aPKC.  How Par3 recruits the Par6-aPKC containing vesicles 
to an apical region where Par3 is not detected is currently unexplained (Horikoshi et al., 
2009).  A further study has shown that Willin, a FERM domain protein, can recruit 
aPKC-Par6 to apical domain sites independently of Par3 (Ishiuchi and Takeichi, 2011).  
Therefore Par6-aPKC is necessary for apical domain formation and Par3 can direct this 
localisation but redundant pathways may exist. 
Par1, another partition defective protein identified in C. elegans, is a posteriorly 
localised protein kinase that associates with membranes.  It is not part of the Par 
complex but is discussed here as it illustrates well how aPKC is able to spatially restrict 
polarity proteins (Figure 1.5A).  In mammalian cells Par1 is capable of phosphorylating 
Par3 at S144 and S285 creating binding sites for a stable interaction with 14.3.3 protein 
(Hurd et al., 2003, Hurov et al., 2004).  If left unattended Par1 would result in 
sequestration of Par3 from the anterior compartment.  Par1 that strays into the apical 
compartment is phosphorylated at Thr585 and translocates from the membrane to the 
cytosol away from the apical complexes (Hurov et al., 2004).  The human pathogen 
H.pylori CagA abrogates cell polarity by impairing the aPKC induced inactivation of 
Par1, most likely by steric hindrance (Saadat et al., 2007). 
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Figure 1.5 Control of polarity complex localisation by aPKC 
A, the apical Par3 complex can be disrupted by Par1 phosphorylation of Par3 (see text).  This is averted by inhibition of Par1 and stabilisation of membrane associated 
Par3 by aPKC phosphorylation.  Protein phosphatase 1! (PP1!) inhibits Par3 association with 14.3.3. B, The Crb and Par complexes are both apically located and in 
equilibrium.  Changes in the levels of Par3 or Crb would lead to disruption of this balance. C,  LLGL forms a basolateral complex.  It is capable of interacting with 
Par6-aPKC but becomes inactivated and dissociates form the membrane upon phosphorylation by aPKC.  p32 facilitates aPKC-induced phosphorylation of LLGL. 
Thick arrows represent the direction of the reaction. Arrows indicate phosphorylation and blunt arrows represent phosphorylation inhibition.
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1.3.5.3 Crumbs Complex (Crb) 
Closely associated with the Par complex is a second group of apically located proteins 
called the Crumbs complex (Tepass et al., 1990).  The mammalian Crumbs complex 
contains a transmembrane protein (Crb) and two cytoplasmic scaffolding proteins 
(PALS1 and PATJ) (Michel et al., 2005).  Within a centrally conserved region in the 
middle of the Crb protein are two functional subdomains; the FERM binding domain (F 
for 4.1 protein, E for ezrin, R for radixin and M for moesin) that is known to bind 
proteins or phosphoinositides (Chishti et al., 1998) and the PDZ binding motif.  Crb 
binds to PATJ via the PDZ motif and PATJ interacts with the aPKC-Par6 dimer 
facilitating, at least in Drosophila, aPKC mediated phosphorylation of the cytoplasmic 
tail of Crb that is necessary for epithelial cell polarity (Sotillos et al., 2004).  These data 
would suggest that the two apical complexes, Crb and Par, compete for binding of 
aPKC-Par6 and therefore can negatively regulate the other (Figure 1.5B). 
 
1.3.5.4 Scribble Complex 
Scribble, discs large and lethal giant larvae form a group of tumour suppressor proteins 
known as the scribble complex.  They act co-dependently for polarity based on genetic 
and biochemical studies in Drosohila (Bilder et al., 2000b).  Lethal giant larvae has 
been reported to bind to the LRR region of Scribble but aside from this the physical 
interactions of the Scribble complex proteins are not well defined (Kallay et al., 2006).  
In view of the work performed during this thesis the remainder of this section will 
concentrate on Lethal giant larvae. 
 
Discovery and conservation of LLGL 
Drosophila lethal (2) giant larvae (D-Lgl) was the first tumour suppressor gene 
described in modern scientific literature.  In 1933 Bridges identified its chromosome 
locus (Hadorn, 1938), mutant alleles were generated and studied in the 1970’s (Gateff, 
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1978) and the gene was cloned in 1985 (Mechler et al., 1985).  Its descriptive name 
reflects the phenotype seen in mutant Drosophila larvae.  The imaginal disks and brain 
overgrow and the resultant larvae die before entering metamorphosis.  The gene is 
highly conserved between Drosophila and vertebrates (Figure 1.6).  There are 2 
homologs of D-Lgl in vertebrates, LLGL1 and LLGL2.  There are further proteins with 
sequence homology to LLGL1/2 – Sro7 and Sro77 in S. cerevisiae and Tomosyn in 
metazoans.  There are no reports of enzymatic activity of LLGL. 
 
Structure of LLGL 
The structure of LLGL1/2 has not yet been solved but predictions can be made based on 
the published structures of Sro7 and Tomosyn.  The structure of Sro7 reveals two 7 
bladed WD40 !-propellers that would be predicted to be present in LLGL1/2 
(Hattendorf et al., 2007).  Between the two !-propellers the sequence (in Tomosyn and 
LLGL) is a highly positively charged low complexity region (LCR) that contains the 
aPKC phosphorylation sites and may act as a hinge region (Betschinger et al., 2005).  
Sro7 also contains a 60 residue long tail that is bound to the surface of the amino-
terminal propeller but LLGL1/2 lacks sequence homology (Hattendorf et al., 2007). 
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Figure 1.6 Conservation of Lgl family proteins 
The phylogenetic tree of Lgl, Sro7//77 and Tomosyn/Stxbp5 (refer to text). The tree was constructed by aligning the protein sequences with ClustalW and then using 
an Average Distance algorithm based on a BLOSUM 62 distance metric.  Large numbers represent greater phylogenetic distances. 
Chapter 1. Introduction 
 56 
Interactions of LLGL 
D-Lgl from Drosophila embryos is found within large protein complexes after gel 
filtration and demonstrates homotypic binding in a phosphorylated LLGL overlay assay 
suggesting homo-oligomerisation (Strand et al., 1994).  Interspecies co-
immunoprecipitation experiments using species-specific antibodies for Dlgl and human 
LLGL show protein interactions suggesting the possibility of heterocomplex formation 
(Grifoni et al., 2004). 
The requirement for LLGL in normal polarity is extensively described in model systems 
from the initial description of imaginal disc polarity (Gateff and Schneiderman, 1969, 
Manfruelli et al., 1996, Bilder et al., 2000a) asymmetric cell division of Drosophila 
neuroblasts, epithelial polarity in the frog (Dollar et al., 2005) and junctional formation 
in the zebrafish (Sonawane et al., 2009).  There are several overlapping theories by 
which LLGL affects polarity; mutual antagonism (Yamanaka et al., 2003), regulation of 
the actomyosin cytoskeleton (Strand et al., 1994) and regulation of polarised transport 
(Musch et al., 2002). 
Mutual antagonism between LLGL and the Par complex is very similar to the 
mechanism already described for the Par complex and Par1 (Figures 1.5A & C).  
LLGL1/2 co-immunoprecipitates with Par6 in MDCK cells (Yamanaka et al., 2003) and 
recombinant protein studies show that the direct interaction is between the N-terminus 
of LLGL and the CRIB/PDZ region of Par6 (Plant et al., 2003).  Exogenous LLGL2 in 
MDCK cells competes with Par3 for Par6-aPKC binding (Yamanaka et al., 2003, 
Horikoshi et al., 2009) and similarly, D-Lgl binds to Par6 exclusive of Par3 in 
Drosophila (Betschinger et al., 2003).  LLGL is therefore capable of disrupting the 
apically localised Par3 complex and Crb complex. 
Atypical PKC has been shown in a number of studies to phosphorylate and mislocalise 
LLGL.  It does this by phosphorylating the LLGL hinge region at multiple sites, 
possibly resulting in an inhibitory intramolecular interaction between the C- and N- 
termini, leading to a change of cellular location from the cortex to the cytoplasm 
(Betschinger et al., 2005, Hutterer et al., 2004).  By doing so aPKC is able to exclude 
active LLGL from the apical region. The aPKC-induced phosphorylation of LLGL is 
Chapter 1. Introduction 
 57 
potentiated by interaction between aPKC and the LLGL-associated p32, a novel 
regulatory protein that causes actin-enrichment of the apical membrane and is required 
for MDCK cyst polarity (Bialucha et al., 2007).   
A potential role in cytoskeletal regulation was proposed when myosin II, a motor 
protein and actin crosslinker, was found to be the most abundant D-Lgl binding protein 
in co-immunoprecipitation studies in Drosophila (Strand et al., 1994).  In normal 
metaphase Drosophila neuroblasts myosin II is located in an apical crescent.  The D-Lgl 
hypomorphic mutant neuroblast shows membrane associated myosin that is not apically 
restricted.  The constitutively phosphorylated D-Lgl mutant shows cytosolic myosin 
distribution (Barros et al., 2003).  The C-terminus of D-Lgl interacts with myosin II and 
is located cortically but, as previously mentioned, phosphorylation of D-Lgl results in 
detachment from the membrane and actin cytoskeleton.  It may be speculated therefore 
that D-Lgl negatively regulates the localisation of myosin II which, through it motor 
protein function, effects the polarisation of other proteins. Similar interplay between 
LLGL and myosin have not so far been reported in mammalian epithelium.  
The close homologs of LLGL, Sro7/77 and Tomosyn, have both been implicated in 
regulating polarized exocytosis (Lehman et al., 1999, Sakisaka et al., 2004).  
Mammalian LLGL may also contribute to epithelial polarity by interacting with 
Syntaxin-4 (and SNAP-23) which has been demonstrated in MDCK cell lysates.  
Syntaxin-4 is a basolaterally located t-SNARE that has been implicated in promoting 
exocytosis and thus the polarised delivery of molecules to the cell (Musch et al., 2002).  
In MDCK cells, vesicles containing apical proteins form upon depolarization with 
calcium depletion.  In LLGL knockdown MDCK clones, however these intracellular 
vesicles fail to form and the apical proteins remain apical (Yamanaka et al., 2006).  
Upon repolarisation by calcium switch the trafficking back to the membrane is Par3 
dependent but is unaffected by LLGL knockdown (Yamanaka et al., 2006, Horikoshi et 
al., 2009).  LLGL is known to compete with Par3 for complex formation so it is 
possible that LLGL negatively regulates Par3 dependent polarized exocytosis.  
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Tumour Suppressor role. 
It is well established through the genetic manipulation of Drosophila that Dlgl is a 
tumour suppressor gene (Bilder, 2004).  Loss of function Dlgl mutants in Drosophila 
lead to loss of polarity, proliferation and growth of neoplastic lesions.  This phenotype 
is rescued by expression of human LLGL1 indicating conservation of function across 
the species (Grifoni et al., 2004).  LLGL2 knockout Zebrafish are unable to form 
hemidesmosomes (that connect the epidermis to the basement membrane), and display 
hyperproliferation and disorganization of the basal epidermis (Sonawane et al., 2009).   
Whether the effects of LLGL manipulation are conserved in mammals is less well 
documented.  The mammalian LLGL studies have been conducted principally in 
MDCK cells.  Stable knockdown of LLGL in MDCK led to an early selective relocation 
of apical proteins to the basal membrane while those basal proteins stained for were 
unaffected.  Subsequent cystogenesis and lumen formation were perturbed resulting in a 
cell aggregate predominant phenotype  (Yamanaka et al., 2006).  Overexpression of 
wild type LLGL results in abnormal tight junction formation in MDCK cells 
(Yamanaka et al., 2003) and abnormal lumen formation in MDCK cysts (Horikoshi et 
al., 2009).  Expression of non-phosphorylatable, membrane localized (active) LLGL 
mutant (LLGL-3A) also disrupts tight junction formation in MDCK cells and decreases 
the ability of mouse embryonic fibroblast cells to polarise in a scratch wound assay 
(Plant et al., 2003).  Both over-expression and under-expression of LLGL in MDCK 
cells seems to result in similar defects in polarised protein localisation suggesting a 
threshold behaviour.   
Studies in mammals have also explored the role of LLGL knockout.  LLGL1 knockout 
mice develop severe brain dysplasia and die shortly after birth from hydrocephalus 
(Klezovitch et al., 2004).  Surprisingly, in view of the Zebrafish data, LLGL2 knockout 
mice are viable and only have a mild phenotype.  The pups are initially small due to 
placental defects caused by impaired polarised invasion of trophoblasts during placental 
development (Sripathy et al., 2011).  
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A few studies have looked at whether LLGL is altered in human cancer.  LLGL1 
mRNA and protein was decreased in melanoma cell lines and most tumour samples.  
Over-expression of LLGL1 in these cell lines reduced invasion and migration but 
proliferation and non-adherent growth were unaffected (Kuphal et al., 2006).  Loss of 
LLGL1 is associated with advanced stage, particularly lymph node metastases, in 
colorectal cancer (Schimanski et al., 2005).  Mutant LLGL1 transcripts were identified 
in 32.5% of 80 sequenced hepatocellular carcinoma  samples most of which were 
predicted to disrupt WD40 interaction domain folding.  Mutant transcripts correlated 
with larger tumour size and worse histological grade.  Over-expression of mutant 
LLGL1 proteins in an HCC cell line promoted invasion, migration and tumorigenicity 
in nude mice but wild type LLG1 had the opposite effect (Lu et al., 2009).  Serous and 
mucinous ovarian carcinomas were shown to have cytoplasmic distribution of LLGL1 
whereas the normal ovarian tissue showed polarised basolateral membranous 
localisation (Grifoni et al., 2007).  LLGL2 protein expression is lower in gastric 
dysplasia and adenocarcinoma compared to normal matched tissue (Lisovsky et al., 
2009).  Low grade pre-malignant pancreatic lesions express basolateral LLGL whereas 
highly dysplastic and malignant pancreatic lesions have lost or aberrantly located 
LLGL2 (Lisovsky et al., 2010).  The published evidence to date, while limited to a 
select few tumour types, suggests that both human LLGL1 and LLGL2 act as tumour 
suppressors. 
 
1.3.6 Migration 
Atypical PKC has been shown to be involved in migration in multiple contexts.  In 
vivo, aPKC as part of the activated Par complex is required for migration of neuroblasts 
in C Elegans (Welchman et al., 2007), control of X. laevis gastrulation (Hyodo-Miura et 
al., 2006) and border cell migration in D. melanogaster (see (Boeckeler et al., 2010) for 
review).  In mice the migration of granule cell precursors (GCP) in the developing 
cerebellum in response to growth factors such as BDNF was dependent on the 
activation of aPKC and its interaction with the adaptor protein Numb and the TrkB 
nerve growth factor receptor (Zhou et al., 2011). 
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In cancer specific cell models PKC! was required for EGF induced migration of human 
breast cancer and lung cancer cells and CSF-1 chemotaxis of macrophages and acute 
monocytic leukaemia cells (Sun et al., 2005, Liu et al., 2008, Guo et al., 2009).  
Following EGF stimulation aPKC! recruited Smurf1, a HECT domain E3 ubiquitin 
ligase, to cellular protrusions where it negatively regulated the local levels of RhoA, a 
small GTPase protein that regulates the actin cytoskeleton.  PKC" has been shown to 
promote nicotine-induced migration and invasion of lung cancer cells via 
phosphorylation of m- and µ-calpains and this was blocked by PKC" inhibition (Xu and 
Deng, 2006).  aPKC phosphorylation of Numb during cervical cancer cell migration 
resulted in dissociation from integrins and clathrin-coated structures, integrin 
endocytosis and thus enabled migration. (Nishimura and Kaibuchi, 2007).  
In an astrocyte scratch wound assay, cdc42 and Rac were recruited to the wound edge.  
The recruitment of cdc42 was triggered by integrin induced Src signalling and 
activation by the #PIX exchange factor (Osmani et al., 2006).  #PIX also recruited Rac1 
but did not activate it.  #PIX recruitment was dependent on Arf 6, a small GTPase that 
regulates membrane endocytosis and recycling (Osmani et al., 2010).  Cdc42 recruited 
and activated Par6/PKC! to the leading edge where it phosphorylated and inactivated 
GSK#.  Adenomatous polyposis coli tumour suppressor protein (APC), a substrate of 
GSK#, consequently associated with microtubule plus ends at the leading edge and 
enabled centrosome and golgi reorientation (Etienne-Manneville and Hall, 2003)).  For 
polarisation of the microtubule cytoskeleton it was necessary for APC to interact with 
puncta in the plasma membrane containing discs large protein, Dlg1.  This interaction 
was also promoted by cdc42 at the leading edge (Etienne-Manneville et al., 2005). 
Distinct aPKC dependent migratory pathways that do not involve cdc42/Par6 have been 
identified using scratch wound assays in Normal Rat Kidney cells (NRK).  Using 
siRNA and chemical inhibitor approaches, aPKC was shown to be required for 
migration (Rosse et al., 2009).  Localisation at the membrane of aPKC was mutually 
dependent on the Exocyst complex, a complex of 8 proteins mainly associated with 
membranes (Rosse et al., 2006).  During cell migration Kibra, a scaffold protein, 
formed a complex with aPKC-Exocyst and translocation of this complex coincided with 
activation of ERK, JNK and the focal adhesion protein Paxillin.  Inhibition of aPKC 
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decreased ERK and paxillin phosphorylation (Rosse et al., 2009).  The compartment 
specific requirement of aPKC in ERK pathway dependent paxillin phosphorylation was 
demonstrated by means of a Rapalogue dimerisation approach.  Using this approach 
exogenous paxillin, which becomes located at the leading edge of migrating cells, was 
inducibly coupled to an upstream effector of the ERK pathway, MEK1, resulting in 
paxillin phosphorylation and increased focal adhesion turnover despite global aPKC 
blockade (Boeckeler et al., 2010).  This provides direct evidence that aPKC is required 
for activation of ERK at the plasma membrane of migrating cells. 
In summary aPKC is critical to polarized migration both in vivo and in a number of cell 
based models.  It promotes signalling at the migration front by its direct interaction with 
migration effectors and through its regulation of endo and exocytosis. 
 
1.3.7 Mitotic spindle orientation 
Formation of epithelial sheets requires that cell division occurs in the plane of the sheet.  
Several polarity proteins have been implicated in spindle pole orientation during 
epithelial cell division including LGN , LLGL2, aPKC, cdc42 and the cdc42 specific 
exchange factors Tuba and Intersectin-2.  Activated cdc42 can bind to the par6-aPKC 
complex and activate aPKC (Jaffe et al., 2008, Qin et al., 2010, Rodriguez-Fraticelli et 
al., 2010, Yasumi et al., 2005, Liu et al., 2006).  Knockdown of Par3 or Par6 disrupts 
spindle orientation and aPKC localization but does not disrupt apical basal polarity per 
se (Durgan et al., 2011, Hao et al., 2010).  LGN, the human homologue of 
D.melanogaster Pins, is able to bind to NuMA, a microtubule binding protein, and thus 
attach astral microtubules to the cortex ensuring correct orientation of the mitotic 
spindle (Du and Macara, 2004, Zheng et al., 2010).  LGN’s localization at the 
membrane is determined by its interaction with cortical G$I.  aPKC has recently been 
shown to phosphorylate LGN at Ser401 resulting in binding of the adaptor protein 
14.3.3 (Hao et al., 2010).  This inhibits LGN’s interaction with G$I consequently 
restricting LGN to the cytoplasm.  In this way, apically located aPKC excludes LGN 
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and astral microtubules from the apical surface ensuring that mitosis only occurs in the 
plane of the epithelial sheet (Hao et al., 2010) 
 
1.3.8 Polarity Cues 
While the identification of polarity molecules and their complexes has been widely 
cited the cues that initiate the process for tissues are less well defined.  Extracellular 
cues are obtained from cadherin-dependent cell-cell interactions and adhesion to the 
extracellular matrix (Yeaman et al., 1999).  The intercellular interactions involve the 
homophilic binding of the extracellular domains of nectin.  This therefore defines the 
site of cell-cell interaction and Par3 is known to bind to the intracellular domain of 
nectin via N-terminal PDZ thus localising the polarity machinery to this site. 
Integrins bind to the extracellular matrix and provide a spatial polarity cue.  Sites of 
Integrin-ECM interaction provide another likely spatial polarity cue.  Laminin, an 
extracellular matrix protein, binds and activates integrin signalling.  In MDCK cysts 
embedded in collagen dominant negative Rac1 led to a reversal of apical-basal polarity 
with apical protein being detected at the basal (outside in contact with the ECM) 
membrane.  Deficient laminin assembly was identified on the cyst surface and correct 
apical-basal polarity could be rescued by exogenous laminin (O'Brien et al., 2001).  
MDCK cysts deficient of #-Integrin or grown in suspension cultures, and therefore 
lacking the influence of the ECM, also had reversed polarity.  Taken together this would 
suggest that integrin-ECM interaction signals to Rac1 that is required for normal 
extracellular laminin assembly and basal membrane determination.   
Clearly the identification and mechanistic basis behind polarity cues are vital to our 
understanding of the process.  There is a great deal still to uncover in this field of 
research. 
 
Chapter 1. Introduction 
 63 
1.3.9 Asymmetric cell division  
The role of aPKC in the asymmetric cell division in C.elegans and D.melanogaster 
neuroblasts is well characterised.  While the molecules implicated in this process are 
well conserved in vertebrates it is less clear if this function is preserved.  Recently a 
study explored stem cell fate determination in mammalian adult stem-cells.  Using 
haematopoietic specific deletions of PKC! and/or PKC% the function including 
polarisation, self renewal, engraftment and differentiation were assessed and shown to 
be entirely unaffected (Sengupta et al., 2011).  Further studies will be required in 
different cellular contexts to address whether this function holds true in mammals. 
 
1.3.10 PKC"  and PKC!  functional redundancy  
PKC" and PKC!, the two mammalian isoforms of aPKC, demonstrate marked overall 
amino acid sequence homology (72%) and strong sequence homology of the kinase 
domain (86%).  What is more, the features identified from the respective crystal 
structures of the PKC" and PKC! are highly conserved (communication with the 
Structural Biology Laboratory).  Northern blot studies performed by the Ohno 
Laboratory showed that PKC% RNA was ubiquitously expressed in mouse tissue 
whereas PKC! was largely confined to brain, intestine, kidney and testes (Akimoto et 
al., 1994).  Numerous cell-based and xenograft studies have suggested that the two 
isoforms play divergent functional roles.  There are a number of reasons to interpret 
these data with caution as firstly these are inter-experimental comparisons.  Secondly, 
the reagents used to assign isoform specific function were often of poor quality.  
Assessment of commonly used PKC" and PKC! antibodies have been shown to be non-
isoform specific (Appendix 1) and the same applies to the ! pseudosubstrate inhibitor.   
More robust genetic techniques have been utilized and provide further insight.  The 
PKC" knockout mouse is embryonic lethal at day 9.5 whereas PKC! knockout mice 
display mildly impaired NF-&# and IL-4 signalling only.  Cell lines derived from viable 
chimeric PKC" deficient mice showed alterations in stress fibres and focal adhesions but 
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responded normally to activators of NF-&# such as TNF, serum and lipopolysacchride 
(Soloff et al., 2004).  The critical experiment to elicit whether the apparent differences 
are due to expression patterns or intrinsic structural properties would be to place the 
PKC! allele downstream of the PKC" promoter in a PKC" and PKC! null background 
and see if embryonic lethality can be rescued.   
The most convincing cell based study to date to assign a tumour suppressor phenotype 
to PKC! was from the Moscat Laboratory.  They crossed mice with lung specific 
inducible oncogenic Ras and PKC! knockout or wild type mice.  After 2 months there 
was a 4 fold increase in total lung tumour area in the PKC! knockout strains and at 3 
months all the knockout mice demonstrated worse histological grade of lung tumour.  
They went on to show that the Oncogenic Ras/PKC! knockout mice had high levels of 
IL-6 staining.  Use of IL-6 RNAi decreased the rate of subcutaneous tumour formation 
in nude mice inoculated with embryonic fibroblasts lacking PKC! (Galvez et al., 2009).  
 
1.3.11 The role of PKC"  in human cancer 
The literature overwhelming supports the oncogenic role of PKC".  An oncogene is a 
gene that, when mutated or over-expressed transforms a normal cell into a malignant 
cell (see (Croce, 2008)for review). 
PKC" is located on chromosome 3q26, one of the most frequent amplicons in human 
cancer (Han et al., 2002).  While there are several potentially important cancer 
associated genes within this region, including PIKC3A, Ect2 and MDS1 a direct link 
between 3q26 amplification, PKC" and transformed cell growth has been established in 
several studies.  In ovarian cancer tissue high PKC" gene copy number was associated 
with increased mRNA and protein expression.  siRNA inhibition of PKC" in an ovarian 
cancer cell line decreased non-adherent cell growth confirming the transforming 
function of PKC" (Zhang et al., 2006a).  Using a high resolution SNP array dataset in 52 
ovarian tumours an analysis showed that the genes for PKC" and Ect2 were putative 
drivers of two distinct amplicons on chromosome 3q (Haverty et al., 2009).  The high 
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PKC" copy number and protein expression was correlated to a short progression free 
survival (Eder et al., 2005).  High PKC" protein expression correlates with gene 
amplification in lung squamous cell carcinoma (SCC) but not lung adenocarcinoma 
(Regala et al., 2005b).  In oesophageal squamous cell carcinoma a FISH analysis 
identified that the PKC" gene was frequently amplified and the protein expression, from 
a 180 patient tissue microarray, was correlated to stage and lymph node metastasis 
(Yang et al., 2008).  PKC" gene amplification and protein over-expression are correlated 
with hepatocellular carcinoma grade, stage and junctional markers (Wang et al., 2008b).  
Chromosome 3q amplification has also been reported in SCC of the head and neck 
(Snaddon et al., 2001) and cervix (Sugita et al., 2000). No oncogenic mutations of PKC" 
have been reported to date. 
There are multiple reports where PKC" protein is elevated in the absence of any genetic 
aberrations.  High PKC" protein expression was found in lung adenocarcinoma and 
correlates with patient survival.  It is worth mentioning here that the K-Ras mutation, 
that has been shown to drive PKC" dependent oncogenesis in cell and murine models, is 
commonly found in lung adenocarcinoma and not lung SCC (Regala et al., 2005b).  
Other immunohistochemistry based studies have shown a link between protein 
expression and patient prognosis or grade in tumours of the breast (Kojima et al., 2008), 
pancreas (Scotti et al., 2010), stomach (Takagawa et al., 2009), bile duct (Li et al., 
2008) and brain (Patel et al., 2008) (Table 1.3). 
What accounts for the apparent discrepancy between elevated PKC" protein and lack of 
genetic abnormalities?  Mutational analyses of cancer patient samples to date tend not 
to have been exhaustive so important mutations in PKC" may have been missed 
particularly if they are of low frequency.  Alternatively the increased PKC" protein 
expression in these tumours may be due to post-translational modifications or signal 
cross-talk at a transcription level that have not yet been identified.  One example of the 
latter is that the Bcr-abl fusion protein was able to up-regulate PKC" transcription in 
Chronic myelogenous leukaemia cells by induction of the PKC" promoter (Gustafson et 
al., 2004).  In view of the compelling link between the increased expression of PKC" 
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and worse cancer prognosis, studies designed to identify somatic PKC" mutations and 
signal cross talk in human cancer are warranted. 
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Table 1.3 PKC!  expression in human cancer 
Immunohistochemical studies comparing PKC! protein expression with clinicopathological outcomes.  Unless stated these studies are normal vs cancer.  mRNA or 
copy number information is indicated if performed.  ND, not done; RR, relative risk; MS, median survival; PSA, prostate specific antigen. 
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1.3.12 PKC!  and therapeutics 
The identification of PKC! as an oncogenic kinase that correlates with prognosis in a 
range of human malignancies has directed research towards its affect on conventional 
cancer therapy and development of new therapeutics. 
PKC! was found to be activated upon paclitaxel treatment in a Chronic Myelogenous 
Leukaemia (CML) cell line containing Bcr-Abl, a chimeric oncogenic tyrosine kinase 
that mediates chemotherapy resistance (Murray and Fields, 1997).  Over-expression of 
PKC! in a CML cell line lacking Bcr-Abl also resulted in insensitivity to paclitaxel 
induced apoptosis.  An aPKC inhibitor was found to have a synergistic affect on 5-
fluorouracil induced apoptosis in human breast cancer cell lines that overexpress 
hASIP, a PKC! substrate (Jin et al., 2008).  Zhang et al were unable to induce 
chemoresistance to cisplatin by overexpressing PKC! in ovarian carcinoma cell lines 
and there was no correlation between PKC! mRNA expression and platinum sensitivity 
in a panel of ovarian cancer cell lines (Zhang et al., 2010).  Taken together this would 
suggest that PKC! expression in cancer cells can lead to chemoresistance and that PKC! 
inhibition may act synergistically with conventional chemotherapies but the effects are 
likely to be cell type and chemotherapy specific. 
Aurothiomalate (ATM) was identified in a fluorescence resonance energy transfer 
(FRET) assay as an inhibitor of PKC!-Par6 interactions.  ATM inhibition of this PB1-
PB1 domain interaction reduces colony formation in soft agar and tumourgenicity in 
vivo (Stallings-Mann et al., 2006).  ATM has been widely used in the treatment of 
rheumatoid arthritis and it is thought that it works by the formation of gold-cysteine 
adducts with cellular targets (see Messori and Marcon, 2004 for review).  The crystal 
structure of PKC!-Par6 has been solved and molecular modelling of this structure 
combined with ATM predicts adduct formation between ATM and Cys69, a cysteine 
unique to the PKC! PB1 domain.  Mutation of Cys69 to either an isoleucine or valine 
retains Par6 binding but renders it ATM insensitive (Erdogan et al., 2006).  In a lung 
cancer cell line panel, sensitivity to ATM correlated with PKC! mRNA and protein 
expression (Regala et al., 2008).  Based on the proposed selective inhibition of PKC!-
Par6 and the in vitro and in vivo suppression of cell transformation phase I clinical trials 
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of the ATM compound in cancer are currently in accrual.  Oncrastin-1 is a small 
molecule inhibitor identified in a synthetic lethal screen in immortalised mutant K-ras 
ovarian epithelial cells.  While the precise mechanism of action of Oncrastin-1 is 
unknown, PKC! and mutant Ras expression were required for its cytotoxic activity.  
Additionally upon Oncrastin-1 treatment there was nuclear accumulation of PKC! (Guo 
et al., 2008). 
A number of other groups, including our collaborators at Cancer Research Technology 
have active drug development programs for ATP competitive PKC! inhibitors.  To date 
the only compound to be published in this drug class is ICA-1 that has a biochemical 
IC50 of 100nM and is at least 50 fold more potent against PKC! than PKC".  In 
neuroblastoma cells ICA-1 was shown inhibit phosphorylation of cdk7, a cell cycle 
regulator shown to be a PKC! substrate (Pillai et al., 2011) (Acevedo-Duncan et al., 
2002).  In this neuroblastoma cell line ICA-1 inhibited proliferation and induced 
apoptosis but this did not occur in a non-transformed neuronal cell line suggesting 
possible specificity for transformed cells (Pillai et al., 2011). 
It is anticipated that over the next few years, several PKC! inhibitors will be tested in 
clinical trials, either in combination with chemotherapy or as a single agent, and 
hopefully identify a clinical benefit for cancer patients. 
 
1.4 Overarching aims of this thesis 
The work carried out in this thesis was stimulated by the role of PKC! in epithelial 
malignancy and the ambition to drive rational therapeutic design through a greater 
understand of PKC! biology.  This work sought to identify a robust cancer dependent 
PKC! cell phenotype in which to analyse potential PKC! activators and to establish a 
platform for identification of clinically relevant PKC! downstream effectors.  
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Chapter 2. Materials and Methods 
 
2.1 Materials 
2.1.1 Reagents 
Agarose 
Ampicillin 
dNTP 
Enhanced Chemiluminesce (ECL) solution – Amersham 
Filter Paper (3MM) – Whatman 
Full Range Rainbow marker  (RPN800E, Amersham) 
GFP-TrapM (Chromotek) 
Immobilon-FL PDVF membranes IPFL00010 Millipore 
Immobilon-P PDVF membranes IPVH00010 Millipore 
Kanamycin  
Matrigel Growth factor reduced BD 354230  
Mini Trans Blot Electrophoretic transfer cell – Bio Rad 
NuPAGE 4-12% Bis-Tris Gels Invitrogen NP0335BOX 
NuSEP 8-16% NuSEP NH21-816 
Photographic Film – Fuji 
Pfu Turbo 
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Pfu Ultra 
QIAquick PCR purification kit (28104), QIAquick Gel Extraction Kit (28704) 
QIAFilter Plasmid Maxi Kit (12263)  
Restriction Enzymes – NEB 
SDS Page Electrophoresis mini tank – Invitrogen 
TopTEN chemically competent E. coli - Invitrogen 
 
2.1.2 Plasticware 
All plasticware was purchased from Corning international unless otherwise stated.  
Polypropylene round bottom tubes, 8-well chamber slides and polystyrene round 
bottom tubes with cell strainers and gel loading pipettes were obtained from BD Fisher.  
Microscope cover glass 24x60 #1 were obtained from Erie Scientific Company. 
 
2.1.3 Buffers 
Colloidal Comassie Buffer: GelCode Blue Stain Reagent (ThermoScientific 24590) 
DNA loading Buffer (x2): 13% (w/v) sucrose, 2mM Tris-HCl (pH 7.5), 2mM EDTA, 
0.06% (w/v) Bromophenol Blue.  This was a 1:5 dilution of BlueJuice (Invitrogen) in 
D20. 
LDS loading Buffer(x2): 50% (v/v) 4xLDS Nupage buffer (Invitrogen) in D20 
supplemented with 100mM DTT (Melford) 
TAE: 0.04M Tris, 0.1% glacial acetic acid, 1mM EDTA (pH 8.0) 
TBS:  0.9% (w/v) NaCl, 20mM Tris 
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TBS-T: TBS and 0.1% (v/v) Tween-20 
Running Buffer1 TRIS-HEPES-SDS (NuSEP, BG-163) 
Running Buffer2 MOPS-SDS (NuPAGE, Invitrogen NP0001), 500µl of Antioxidant 
(Cat no. NP0005, Lot no. 283034; Store at +4oC) 
5xTrypsin/EDTA: 2.5g/l Trypsin, 8g/l NaCl, 1.15g/l Na2HPO4, 200mg/l KH2PO4, 
1g/l EDTA and 1% v/v Phenol Red, pH 7.2. (Cell Services, CRUK) 
Transfer Buffer: 25mM Tris, 192mM glycine, 10% methanol 
Kinase Dilution Buffer: 5% glycerol v/v, 50mM Tris, 1mM EDTA, 1mM DTT 
Substrate Dilution Buffer: 100mM HEPES (pH 7.5) and 2mM EGTA 
L-Broth (LB): 10g/l Bacto-Typtone, 5g/l Yeast extract, 10g/l NaCl 
L-Agar: 15g agar/l.  Autoclaved for 15 mins 
Distilled Water (D2O): Ultra-pure Millipore water, autoclaved for 20 mins 
Stripping Buffer: 5% (v/v) acetic acid in D2O 
S.O.C Medium: 2% Tryptone, 0.5% Yeast Extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4, 20mM glucose (Invitrogen) 
Phosphate Buffered Saline – Ca2+/Mg2+ free (PBS): 8g/l NaCl, 250mg/l KCl, 1.43g/l 
NaHPO4, 250mg/ml KH2PO4, pH 7.2 (Cell Services, CRUK) 
Dulbecco’s PBS (DPBS): PBS, 534mg/l CaCl2, 400mg/l MgCl2, pH7.2 (Cell Services, 
CRUK) 
Mounting Medium: Prolong Gold antifade reagent, Invitrogen P369343 
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Co-Immunoprecipitation Lysis Buffer: 1%Triton X 100, 20mM Tris (pH 8), 130mM 
NaCl, 1mM DTT, 10mM NaF, Protease Inhibitor (CoMplete, Roche) and Phosphatase 
Inhibitors (Calbiochem, II & IV) 
Co-Immunoprecipitation Wash Buffer: 1%Triton X 100, 20mM Tris (pH 8), 130mM 
NaCl, 1mM DTT, 10mM NaF, Protease Inhibitor (CoMplete, Roche) 
Immunofluorescence (IF) Buffer: 0.2% Triton X-100, 0.04% Tween-20, 130mM 
NaCl, 13mM Na2HPO4, 3.5mM NaH2PO4 , pH 7.4 and filter sterilized 
Matrigel washing buffer: 5mM EDTA, 1mM Na3VO4, 1.5mM NaF, Phosphatase 
inhibitor cocktail sets II & IV (Calbiochem) 
Permeabilization buffer: 0.5% Triton X-100 in PBS 
IF-Blocking buffer: IF buffer, 10% goat serum (v/v) 
Primary Antibody Blocking Buffer: 3% (v/v) BSA in TBS-T 
Secondary Antibody Blocking Buffer: 5% (w/v) dried skimmed milk powder 
(Marvel) in TBS-T  
PolyLysine-PBS: 10% (v/v) Poly-L-lysine (Sigma P4707) in PBS 
PBS-EDTA: 5mM EDTA, 1mM Na3VO4, 1.5mM NaF in PBS 
Transfer Buffer:  25mM Tris, 150mM Glycine, 20% (v/v) methanol in D20. 
Pfu Buffer: Stratagene 
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2.1.4 Antibodies 
Table 2.1 Primary Antibodies 
Name Description Source & code Use 
 
Dilution 
#-Tubulin Mouse 
monoclonal [B-5-
1-2] 
Sigma 
T5168 
WB 1:10000 
PKC$ 
 
Mouse 
monoclonal 
BD 
610608 
WB 
IF 
1:500 
1:300 
aPKC 
 
Rabbit polyclonal  
[C-20] 
Santa Cruz 
216 
WB 
IF 
1:500 
1:100 
PKC" Goat polyclonal Santa Cruz 
7262 
1/1000 1/500 
PKC" Mouse 
monoclonal 
[H1] 
Santa Cruz 
17781 
WB 
IF 
1:1000 
1/50 
PKC" Rabbit 
monoclonal 
Cell Signaling 
C24E6 
WB 1:1000 
aPKC Mouse 
monoclonal 
CRUK 
524/1 
WB 1:1000 
ZO-1 Rabbit polyclonal Zymed 
40-2200 
IF 1/100 
Cleaved Caspase-3 Rabbit polyclonal 
(Asp175) 
Cell Signaling 
9661S 
IF 1:100 
Ki-67 Rabbit polyclonal Zymed 
18-0191Z 
IF 1:100 
pPKC![p555] Rabbit polyclonal Invitrogen 
44-968G 
WB 1:500 
pPKC"/$ 
[T410/403] 
Rabbit polyclonal Cell Signaling 
Technology 
9378 
WB 1:1000 
#-6-Integrin Rat monoclonal 
[Go H3] 
Abcam 
ab  19765 
 
IF 1:200 
%-catenin Mouse 
monoclonal 
BD 
610154 
IF 1:100 
GM130 Mouse 
monoclonal 
BD  
610823 
IF 1:100 
LLGL2 Mouse 
monoclonal 
Abcam 
ab55423 
WB 1/500 
pLLGL1/2  
[S650/654] 
Rabbit polyclonal Abnova 
PAB4657 
WB 1:500 
pSrc [Y416] Rabbit Polyclonal Cell Signaling 
Technology 
2101 
WB 1:1000 
PI3 Kinase p110#  Rabbit 
monoclonal 
[C73F8] 
Cell Signaling 
Technology 
4249 
WB 1:1000 
Pan-Ras Mouse 
monoclonal 
[RAS 11] 
Calbiochem 
OP41 
WB 1:500 
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Her2 Rabbit 
monoclonal 
[29D8] 
Cell Signaling 
Technology 
2165 
WB 1:1000 
Par3 Rabbit polyclonal Millipore 
07:330 
WB 1:1000 
Par6 Rabbit Polyclonal 
[H64]  
Santa Cruz 
67392 
WB 1:500 
C-Raf Mouse 
monoclonal 
Cell Signaling 
610151 
WB 1:1000 
B-Raf Rabbit polyclonal Upstate 
07-453 
WB 1:1000 
pErk[T202/204] Rabbit 
monoclonal 
Cell signaling WB 1:500 
GST Rabbit Polyclonal Sigma Protein overlay 1:1000 
 
Table 2.2 Secondary Antibodies 
Name Description Source & code 
 
Use Dilution 
Alexa Fluor 555 Goat anti-rabbit Invitrogen 
A21429 
IF 1:300 
Alexa Fluor 555 Goat anti-mouse Invitrogen 
A21422 
IF 1:300 
Alexa Fluor 488 Goat anti-mouse Invitrogen 
A11001 
IF 1:300 
Alexa Fluor 488 Goat anti-rabbit Invitrogen 
A11008 
IF 1:300 
ECL Mouse HRP Sheep anti-mouse 
IgG linked to 
HRP 
Amersham 
NA931V 
 
WB 1:5000 
ECL Rabbit HRP Donkey anti-
rabbit IgG linked 
to HRP 
Amersham 
NA934V 
WB 1:5000 
Goat HRP Donkey anti-goat 
IgG linked to 
HRP 
Santa Cruz 
2020 
WB 1:5000 
LI-COR 800 Goat anti-Mouse 
IRdye 
LI-COR 
926-3221G 
WB 1:4000 
Alexa Fluor 680 Goat anti-Rabbit 
IgG 
Invitrogen  
A21109 
WB 1:4000 
IgG F(ab’)2 Goat anti-mouse Jackson 
ImmunoResearch Labs  
115-007-003 
Blocking 1:100 
FITC anti-rat Donkey anti rat 
linked to FITC 
Jackson Laboratories 
712-095-150 
IF 1:200 
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2.1.5 Immunofluorescent Probes 
Table 2.3 Immunofluorescent Probes 
Name Structure stained Source & code Use 
 
Dilution 
Phalloidin Alexa 
Fluor 546  
F-actin Invitrogen 
A22283 
 
IF 1:200 
Hoechst 
 
DNA Invitrogen IF  1:5000 
DAPI DNA Invitrogen FACS 
 
1:5000 
TOPRO-3 
(642/661) 
DNA Invitrogen IF  1:5000 
 
2.1.6 Pharmacological Agents 
Table 2.4 Pharmacological Agents 
Name Source Action 
Go6983 Calbiochem Pan-PKC inhbitor 
BimI Calbiochem Inhibits cPKC & nPKC (not aPKC) 
CRT66854 CRT aPKC specific inhibitor 
CRT31 CRT aPKC specific inhibitor 
CRT92 CRT aPKC specific inhibitor 
MG132 Calbiochem Proteosome inhibitor 
PP1 TOCRIS Selective inhibitor of Src 
NaPP1 TOCRIS Selective inhibitor of Src 
PP2 TOCRIS Selective inhibitor of Src 
 
2.1.7 Media and Growth Supplements 
DMEM, DMEM/F12 and McCoys’s 5A media were obtained from GIBCO.   PenStrep 
was also obtained from GIBCO and used at a final concentration of 100U/ml penicillin 
and 100mg/ml streptomycin.  Foetal bovine serum (FBS) was obtained from PPA and 
Horse serum (324831), Hydrocortisone (H-0888), Cholera toxin (C-8052) and Insulin 
(1882) were purchased from Sigma. EGF was obtained from Calbiochem.  Media 
Filtration products were obtained from Nalgene. 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Parental Cell Lines 
Mardin Darby Canine Kidney (MDCK), HeLa, HEK293 and A549 cells were obtained 
from CRUK cell production services and cultured in DMEM  supplemented with 10% 
FBS and PenStrep.  HCT116 cells were also obtained from CRUK cell production 
services but cultured in McCoy’s 5A Media supplemented with 25mM HEPES, 10% 
FBS and PenStrep. 
MCF10a cells were a gift from Joan Brugge, Harvard Medical School.  Maintenance of 
these cells, such that they are suitable for 3D cultures, has been described in detail 
elsewhere (Debnath and Brugge, 2005).  In brief, cells were cultured in DMEM/F12 
supplemented with 5% Horse serum, 20ng/ml EGF, Hydrocortisone, 100ng/ml Cholera 
toxin, 10µg/ml Insulin and PenStrep.  Importantly, early passage cells were maintained 
in log phase growth and discarded if they reached confluence. 
MDCK cells were obtained from Cell Production, cancer research UK.  Isoenzyme and 
SNIP analysis was performed by cell services to authenticate the origin of these cells.  
Cells were maintained in DMEM  supplemented with 10% FBS and PenStrep. 
 
2.2.1.2 Stable Cell lines 
Stable MDCK cell lines expressing V12-Ras, p110 CD2, v-Src or Raf-CAAX were a 
gift from Julian Downward, London Research Institute (Khwaja et al., 1997).  Further 
MDCK cell lines were generated by reverse transfection of MDCK cells in a poly-L-
Lysine coated dish.  For a 35mm dish 3µg of cDNA, 10µl of Lipofectamine 2000 
(Invitrogen) and 5x105 MDCK cells were used.  After 24h the cells were trypsinised 
(Cell services CRUK) and re-plated in a 10cm dish containing appropriate antibiotic-
resistance markers, typically 750µg/ml G418 (GIBCO) or 5mg/ml Puromycin (Sigma 
P9620).  Subpopulations of these polyclonal cell lines, expressing similar levels of GFP, 
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were established by 2 successive rounds of Fluorescent Activated Cell Sorting (FACS, 
CRUK FACS facility). 
 
Table 2.5 Stable cell lines obtained during this thesis 
Stable Cell Line Expression vector 
 
Source 
MDCK-p110* pcDNA3- myc-p110#-CAAX Julian Downward 
MDCK-V12-Ras pcDNA3- V12-Ras Julian Downward 
MDCK-Raf-CAXX pEFH6 PLINK - Raf-CAXX Julian Downward/ 
Richard Morais 
MDCK-vSrc pSG5- vSrc Julian Downward 
 
Table 2.6 Stable cell lines made during this thesis 
Stable Cell Line Expression vector Mammalian resistance 
marker 
MDCK-EV pEGFP-C1  G418 
MDCK-PKC! pEGFP-FL.PKC! G418 
MDCK-PKC!(DN) pEGFP-FL.PKC! (D368N) G418 
MDCK-PKC!(CA) pEGFP-FL-PKC!(A120E) G418 
MDCK-PKC!(AIPA) pEGFP-FL.PKC!(D471A/D474A) G418 
MDCK-PKC!(DIM) pEGFP-FL.PKC!(D330A/D373A) G418 
GFP-MDCK-V12-Ras pBABE-GFP-CAAX-puro Puromycin 
Cherry-MDCK-V12-Ras pBABE-Cherry-puro Puromycin 
GFP-MDCK-vSrc pBABE-GFP-CAAX-puro Puromycin 
Cherry-MDCK-vSrc pBABE-Cherry-puro Puromycin 
GFP-MDCK pBABE-GFP-CAAX-puro Puromycin 
Cherry-MDCK pBABE-Cherry-puro Puromycin 
MDCK-ErbB2-YVMA pEGFP G418 
 
2.2.2 Protein Overlay 
The peptide array was obtained from the Peptide Synthesis Laboratory at Cancer 
Research UK.  The array was designed to have sequential overlapping PKC! peptides of 
20 amino acids each differing from the previous peptide by a single amino acid.  
The membranes were blocked in 3% BSA/DTT/Tween for 1 hour.  This was followed 
by a 20 minute incubation with both recombinant GST tagged PKC! kinase domain 
(50ug/ml, 1ml total volume) and CRT66855 (1.2µM, obtained from Cancer Research 
Technology) in 3%/BSA/DTT/Tween.  The membranes were then rapidly washed in 
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3% BSA/DTT/Tween, cross linked with 0.5% Formaldehyde in D2O for 5 minutes and 
quenched with 2% glycine – PBS for 5 minutes. 
 
The arrays were washed a further 2 times, firstly in 3%-BSA/DTT/Tween and then in 
PBS/Tween.  The membranes were incubated with anti-GST antibody  (Sigma) 
overnight at 4 degrees and detected using a rabbit-HRP secondary antibody and 
chemiluminescence (see section 2.2.20.3). 
 
2.2.3 Polymerase Chain Reactions 
Polymerase Chain Reaction (PCR) mix consisted of 1U Pfu Turbo, 1xPfu buffer, 
0.2mM dNTP mix, 0.3µM of forward primer, 0.3µM of reverse primer and 20ng DNA 
template made up to 50µl with distilled water.  The mix, in a polypropylene tube tube, 
was placed in a thermocycler (DNA Engine DYAD, MJ Research) and the following 
program used: 
Step 1: 95oC, 5 mins 
Step 2: 95oC, 30 secs 
Step 3: Lowest primer Tm -4oC, 30 secs 
Step 4: 70oC, 1 min per kBase 
Step 5: Repeat steps 2-4 x25 
Step 6: 70oC, 10 mins 
Step 7: 6oC, Forever 
 
2.2.4 Agarose gel electrophoresis 
PCR products were identified by agarose gel electrophoresis. The gel consisted of 1% 
agarose (w/v) and 6% (v/v) ethidium bromide in TAE buffer.  Samples were mixed 3:1 
with DNA loading buffer (x2), run along side a 1kb DNA ladder and separated at 100V.  
Bands were identified using the uv transilluminator, excised and purified using 
QIAquick gel extraction kit (Qiagen). 
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2.2.5 Restriction Digests 
In separate reaction mixes 2µg purified insert and the vector DNA were mixed with 
restriction enzymes, appropriate buffer and BSA according to the manufacturers 
guidelines.  Typically the mix was incubated at 37oC for 1-2h.  The vector mix alone 
was then mixed with calf intestine alkaline phosphatase at 37oC for 30mins.  The 
solutions were again purified using QIAquick spin (Qiagen). 
 
2.2.6 Ligation Reactions 
The ligation mix was comprised of 400U T4 DNA ligase, 1 x ligase buffer, 100ng 
digested vector and insert DNA.  Typically a 3:1 molar ratio of vector to insert was 
used.  As a control a vector only reaction was concomitantly performed.  The reaction 
mixes were incubated overnight at 16oC and terminated by heating at 65oC for 10 mins. 
 
2.2.7 Transformation 
50 µl of chemically competent E.coli (Top10, Invitrogen) were mixed with 150ng of 
plasmid DNA or 3µl of ligation reaction and incubated on ice for 25mins. DNA uptake 
into the cells was promoted by heat shock in a 42oC water bath for 30 secs. The cells 
were incubated on ice for 2 mins and then 250µl of SOC was added and the mix placed 
on a shaker at 37oC for 1h.  Cells were then plated onto LB containing plates with an 
appropriate selection antibiotic (100µg/ml Ampicllin or 50µg/ml Kanamycin) and 
incubated overnight at 37oC. 
 
2.2.8 Plasmid DNA preparation 
A transformed E.coli colony was picked from the LB selection plate and grown 
overnight in 5 ml of LB containing appropriate selection antibiotics.  1 ml of this 
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bacterial preparation was retained in the fridge while 4ml was used to generate a small 
quantity of DNA using the mini-prep kit (Qiagen).  The correct plasmid DNA was 
confirmed either by a unique restriction digest pattern on an agarose gel or, in the case 
of mutagenesis, by sequencing (see below). DNA preparations were then scaled up by 
using the retained 1ml bacterial prep to inoculate 200ml LB and further incubation 
overnight on the shaker at 37oC.  The DNA was prepared using a plasmid maxi-prep kit 
(Qiagen).  DNA concentration was confirmed using Nanodrop ND-1000 UV-Vis 
Spectrophotometer at 280nm, and the quality was deemed acceptable if the 
OD260/OD280 ratio was between1.6-1.8.  
 
2.2.9 DNA Sequencing 
DNA sequencing was performed using the ABI BigDye Terminiator v3.1 system as per 
the manufacturers guidelines.  Typically the reaction mix comprised of 150ng plasmid 
DNA, 3.2pmol primer, 1x BigDye Terminator Mix made up to a volume of 20µl with 
distilled water.  The following programme was used on the thermocycler: 
Step 1: Ramp to 96oC at 2.5oC/sec  
Step 2: 95oC, 1 mins 
Step 3: 95oC, 10 secs 
Step 4: Ramp to (primer Tm -3) oC at 1oC/sec 
Step 5: (primer Tm -3) oC, 5 secs 
Step 6: Ramp to 60 oC at 1oC/sec 
Step 7: 60oC, 4 mins 
Step 8: Repeat steps 3-7 x 24 
Step 9: 2oC, forever 
 
Sequencing products were purified using the DyeEx 2.0 Spin Kits (Qiagen) and 
sequenced by CR-UK services on an Applied Biosystems 3730 DNA Analyser.  
Sequencing results were viewed and analysed using EditView and ClustralX software 
respectively. 
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2.2.10 Cloning  
PKC iota constructs were cloned by PCR using human PKCi cDNA in pcDNA3.1 as a 
template (from Dr Scott Parkinson).  The Entrez Nucleotide accession number is 
NM_002740.5.  The cDNA contains two start codons at bp1-3 and bp28-30.  For 
consistency with published literature the second methionine is denoted as the first 
amino acid of the protein.  PCR primers (see Table 2.7) were used to introduce 5’-SalI 
and 3’-BamHI sites to the PKC! sequence to allow ligation into the corresponding 
restriction sites in pEGFP-C1.  In addition the PCR primers were used to introduce a 5’ 
Myc tag sequence. 
PKC zeta constructs were cloned by PCR using human PKC" cDNA in pMT2 vector 
(from Dr Sven Kjaer).  The Entrez Nucleotide accession number is NM_002744.4.  Our 
stock contains a silent mutation at G1164A and a gly>asp mutation resulting from 
G18A substitution (note the asp is present in rat PKC").  PCR primers were used to 
introduce 5’SalI and 5’XmaI restriction sites to the PKC" sequence to enable ligation 
into pEGFP-C1.  The PCR primers were also designed to add 5’ Myc tag sequence. 
 
Table 2.7 Cloning primers 
Name Primers (5’!3’) 
 
Key 
FL.PKC! 
Forward 
taatGTCGACgccaccATGGAGCAGAAGCTGATCTCA
GAGGAGGACCTGccgacccagagggacagcag 
SalI, Kozak, MYC 
TAG, PKC! 
FL.PKCi 
Reverse 
attaGGATCCtcagacacattcttctgcag BamHI, PKC! 
KDom.PKC! 
Forward 
tgcGTCGACctcgccaccatgagtctaggtctcagg SalI, Kozak, PKC! 
FL.PKCi 
Reverse 
cgGGATCCtcagacacattcttctgc BamHI, PKC! 
PKC" 
Forward 
acgcGTCGACgccaccATGGAGCAGAAGCTGATCTC
AGAGGAGGACCTGcccagcaggaccggccc 
SalI, Kozak, MYC 
TAG, PKC" 
PKC" 
Reverse 
tcccCCCGGGtcacaccgactcctcggtgg 
 
XmaI, PKC" 
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2.2.11 Constructs 
Table 2.8 Cloning and expression vectors 
Vector Selection (bacterial/mammalian) Source 
 
pEGFP-C1 Kanamycin/G418 Clontech 
pcDNA3.1 Ampicillin/Neomycin Invitrogen 
pBABE-GFP(CAAX) Ampicillin/puromycin Erik Sahai 
pBABE-Cherry Ampicillin/puromycin Erik Sahai 
 
Table 2.9 Constructs obtained during the course of this thesis 
Name Expression vector Restriction sites Source 
 
LLGL2 pEGFP-C1  EcoR1-SalI Tony Pawson 
 
PKC! pCDNA3.1 XhoI-XbaI Scott Parkinson (PP 
Lab) 
ErbB2-YVMA pEGFP-N1 (A206K) XhoI - HindIII Tony Ng 
 
PKC! pEGFP-C1 BspEI - Sal I Gavin Greenland, CRT. 
PKC! (D330A) pEGFP-C1 BspEI - Sal I Gavin Greenland, CRT. 
PKC! (I323A) pEGFP-C1 BspEI - Sal I Gavin Greenland, CRT. 
 
2.2.12 Mutagenesis 
Mutants were generated using QuikChange site directed mutagenesis according to the 
manufacturers guidelines.  In brief the mutant DNA was sythesised by PCR (see 2.2.3) 
using high fidelity DNA polymerase and purified plasmid DNA as a template.  A 
typical reaction mix contained 1xPfu buffer, 250µM dNTP, 400ng/ml template DNA, 
2% v/v Pfu Ultra and 500nM of a forward primer, and the reverse complements, 
containing the desired point mutations.  The reaction mix was made up to 50µl with 
distilled water and the following program was used on the Thermocycler. 
Step 1: 95oC, 30 secs 
Step 2: 95oC, 30 secs 
Step 3: 55oC, 1 min 
Step 4: 68oC, 8min 
Step 5: Repeat steps 2-4 x 18 
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The methylated DNA template was then digested with 1µl of Dpn1 at 37oC for 1 hour.  
The newly synthesised non-methylated DNA was then transformed, purified and 
sequenced (see 2.2.7, 2.2.8 & 2.2.9) to confirm the presence of the intended mutation. 
Table 2.10 Constructs generated by mutagenesis during this thesis 
Template Derived Mutant 
 
Primers 
GFP-myc-
FL.PKC! (A120E) 
F: atctaccgtagaggtgAacgccgctggagaaag 
 
GFP-myc-
FL.PKC! (R471A/R474A) 
F:gttattttggaaaaacaaattgccataccagcttctctgtctgtaaaa
gc 
 
GFP-myc-
FL.PKC! (D368N) 
F:gagcgagggataatttatagaaatttgaaactggacaatgtattact
gg 
 
GFP-myc-
FL.PKC! (K274M) 
F: cgtatttatgcaatgaTGgttgtgaaaaaagagc 
 
GFP-myc-FL.PKCi 
(S477A) 
F: caaattcgcataccacgttGCctgtctgtaaaagc 
 
GFP-myc-FL.PKCi 
(S477E) 
F: caaattcgcataccacgttTCctgtctgtaaaagc 
 
GFP-myc-FL.PKCi 
(R471C) 
F: ggaaaaacaaattTgcataccacgttctctg 
 
pEGFP-myc-
FL.PKC! 
GFP-myc-FL.PKCi 
(Y421C) 
F: gaggagaagattGtggtttcagtgttgactgg 
 
 GFP-myc-FL.PKC 
(D373A) 
F: agagatttgaaactggCcaatgtattactggac 
 
GFP-myc-
KDom.PKC! (A120E) 
F: atctaccgtagaggtgAacgccgctggagaaag 
 
GFP-myc-
KDom.PKC! (R471A/R47
4A) 
F:gttattttggaaaaacaaattgccataccagcttctctgtctgtaaaa
gc 
 
pEGFP-myc-
KDom.PKC! 
GFP-myc-
KDom.PKC! (D368N) 
F:gagcgagggataatttatagaaatttgaaactggacaatgtattact
gg 
PKC! (D368N) F:gagcgagggataatttatagaaatttgaaactggacaatgtattact
gg 
pcDNA3-PKC! 
PKC!(R471A/R474) F:gttattttggaaaaacaaattgccataccagcttctctgtctgtaaaa
gc 
 Myrist-GFP-myc-PKCi  
pEGFP- 
PKC!(D330A) 
PKC! (D330A/D373A) F: agagatttgaaactggCcaatgtattactggac 
 
 
2.2.13 In Vitro Kinase Assay 
In this thesis 2 different in vitro kinase assay protocols were adopted that I have called 
the Classical and the Modified Kinase Assays.  The classical kinase assay utilised 
ATP[&-32P] and has been extensively used to assess AGC kinases (Hastie et al., 2006)
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The second modified protocol was developed in order to test the activity of high 
concentrations of PKC!.  In essence this necessitated a lower temperature, shorter 
incubation time and smaller reaction volumes. Recombinant human PKC! kinase 
domain was expressed in and purified from insect cells (Protein Production Laboratory, 
CRUK).  As a substrate for the reaction either PKC' pseudosubstrate peptide (PKC'PS , 
produced by Peptide Synthesis Laboratory, CRUK) or purified LLGL2 (made by Phil 
Knowles form the Structural Biology Laboratory, CRUK) was used. 
 
2.2.13.1 Classical Kinase Assay 
The final reaction mix contained 200µM ATP, 10mM MgCl2, 2.5-5µg/ml PKC! in 
kinase dilution buffer and 250-1000µg/ml of substrate in substrate buffer.  Typically the 
reaction was carried out in 40µl.  The kinase was made up to 10µl in kinase buffer and 
placed in a screw cap tube on ice.  A Master Mix containing the ATP, magnesium and 
substrate was spiked with 0.25µl of ATP[&-32P]((0.125µCi).  30µl of this mix was 
added to the enzyme to start the reaction and incubated at 30oC with shaking 
(Thermoshaker) for 10 minutes.  This procedure was applied to the different samples 
sequentially and carefully timed.  The reaction mix was then spotted onto pre-cut p81 
filter paper tabs and the reaction terminated by washing in 30% acetic acid.  
Alternatively the reaction was stopped by adding LDS loading Buffer(x2) directly to the 
reaction mix, boiling for 10 minutes, resolving by SDS PAGE and drying overnight 
(Gel-Dry solution, Invitrogen).  The p81 tabs or cut gel bands were placed in a 
scintillation vial and incorporated &-p32 was measured over 1 minute in a Beckman 
Scintillation LS6000IC machine.  A known volume of the spiked Master Mix was 
placed directly onto the p81 tab and scintillations counted so that the specific activity 
(SA) of ATP in the mix could be calculated. 
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SA (ATP) = CPM/pmol dNTP 
 
From the scintillation counts for the experimental reaction mixes, the concentration of 
ATP incorporated into substrate could be calculated and thus the specific activity of the 
kinase. 
 
SA (kinase) = µMol substrate/mg kinase/min of reaction 
 
 
2.2.13.2 Modified Kinase Assay 
The final reaction mix contained 500µM ATP, 12mM MgCl2, 5-3000µg/ml 
PKC! kinase domain in kinase dilution buffer and 1200µg/ml of PKC'PS in substrate 
buffer.  The reaction was carried out in a 96-well PCR plate on ice.  To facilitate high 
kinase concentration assays it was necessary to scale down the reaction volumes to 10µl 
and limit the incubation time to 15secs.  As with the Classic Kinase Assay, the reaction 
was commenced by adding the Master Mix to the kinase.  However, unlike the Classic 
Assay the reaction was terminated by directly adding concentrated acetic acid to give a 
final concentration of 30% acetic acid.  To minimise differences in these short 
incubation times the different samples were processed concomitantly, in groups of 
eight, using a multi-channel pipette.  Scintillation counting and subsequent specific 
activity calculations were carried out as described for the Classical Kinase Assay. 
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2.2.14 Immunocomplex Activity and Inhibition Assays 
HEK293 cells were reversed transfected with GFP tagged cDNA (see transfection of 
DNA) and after 36 hours was co-immunoprecipitated using the GFP-TrapM system (see 
co-IP section).  After the final wash of the co-immunoprecipitation the 
immunocomplexes were resuspended in 40µl of kinase dilution buffer and placed on 
ice.  This provided enough protein for 3 Classical Kinase Assays (10µl each) and 10µl 
that was mixed with LDS Sample Buffer (x2), separated by SDS PAGE and 
immunoblotted.  In immunocomplex drug inhibition experiments, 30µl of spiked 
Master Mix containing 100µM ATP, 10mM MgCl2 and 250µg/ml of PKC'PS in 
substrate buffer was added to 5µl immunocomplex in kinase dilution buffer and 5µl of 
inhibitor at various concentrations.  Scintillation counting was performed and a relative 
activity was calculated and adjusted for protein loading as determined by densitometry 
of the resulting Coomasie gel or PKC! immunoblot. 
 
2.2.15 Co-Immunoprecipitation 
Immunoprecipitation of GFP tagged proteins was performed using GFP-TrapM.  GFP-
TrapM is a 13kD single domain antibody from Lama Alpaca that is stable, has a 
dissociation constant with GFP of 0.59nM and is coupled to magnetic beads. HCT116 
or HEK293 cells were seeded (eg. 3x106 HCT116 cells /10cm dish) and transfected (see 
transfection section) with cDNA in a pEGFP-C1 vector.  36 hours after transfection 
cells were washed twice in DPBS and then extracted from the dish with Co-
Immunoprecipitation Lysis Buffer and a cell scraper.  The lysate was incubated on ice 
for 10mins and then spun at 1300g for 10minutes at 4oC.  The supernatant was 
transferred to a pre-cooled eppendorf of which 50µl was retained for analysis by 
Western Blot.  The pellet was discarded.  The GFP-TrapM beads were washed twice in 
Wash Buffer and 20µl (original GFP-TrapM volume) was added to the supernatant 
followed by gentle rotation for 90 minutes at 4oC.  After 3 quick washes with the Wash 
Buffer the beads were resuspended in 40µl LDS loading Buffer(x2).  For protein 
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identification a high concentration (30µl) was loaded onto a NuPAGE gel and for 
Western Blotting 5µl of immunocomplexes was loaded onto a NuSEP gel. 
 
2.2.16 Mass Spectrometry 
Mass spectrometric was performed by the Protein Analysis and Proteomics Laboratory 
at CRUK London Research Institute.  Co-immunoprecipitation samples were separated 
by mass on a polyacrylamide gel and protein was stained with GelCode Blue to look for 
any differences between the experimental conditions.  Single differential bands or 
whole lanes were cut from the gel and sent for analysis.   
Polyacrylamide gel slices (1-2 mm) containing the purified proteins were prepared for 
mass spectrometric analysis using the Janus liquid handling system (PerkinElmer, UK).  
Briefly, the excised protein gel pieces were placed in a well of a 96-well microtitre plate 
and destained with 50% v/v acetonitrile and 50 mM ammonium bicarbonate, reduced 
with 10 mM DTT, and alkylated with 55 mM iodoacetamide.  After alkylation, proteins 
were digested with 6 ng/!L Trypsin (Promega, UK) overnight at 37 °C.   The resulting 
peptides were extracted in 2% v/v formic acid, 2% v/v acetonitrile.  The digest was 
analysed by nano-scale capillary LC-MS/MS using a nanoAcquity UPLC (Waters, UK) 
to deliver a flow of approximately 300 nL/min.  A C18 Symmetry 5 !m, 180 !m x 20 
mm !-Precolumn (Waters, UK), trapped the peptides prior to separation on a C18 
BEH130 1.7 !m, 75 !m x 100 mm analytical UPLC column (Waters, UK).  Peptides 
were eluted with a gradient of acetonitrile.  The analytical column outlet was directly 
interfaced via a modified nano-flow electrospray ionisation source, with a hybrid linear 
quadrupole fourier transform mass spectrometer (LTQ Orbitrap XL/ETD, 
ThermoScientific, San Jose, USA).  Data dependent analysis was carried out using a 
resolution of 30,000 for the full MS spectrum, followed by eight MS/MS spectra in the 
linear ion trap.  MS spectra were collected with an automatic target gain control of 
5x105 and a maximum injection fill time of 100 ms over a m/z range of 300–2000.  
MS/MS scans were collected using an automatic gain control value of 4x104 and a 
threshold energy of 35 for collision induced dissociation.  LC-MS/MS data were then 
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searched against a protein database (UniProt KB) using the Mascot search engine 
programme (Matrix Science, UK) (Perkins et al., 1999).  Database search parameters 
were set with a precursor tolerance of 5 ppm and a fragment ion mass tolerance of 0.8 
Da.  One missed enzyme cleavage was allowed and variable modifications for oxidized 
methionine, carbamidomethyl cysteine, pyroglutamic acid, phosphorylated serine, 
threonine and tyrosine were included.  MS/MS data were validated using the Scaffold 
programme (Proteome Software Inc., USA) (Keller et al., 2002).  All data were 
additionally interrogated manually.  
Following identification of peptides in individual samples, a subtractive approach was 
employed to identify proteins that were specifically purified in the PKC! or 
PKC!(RIPR>AIPA) pulldowns and not in the control pulldowns.  Data were then 
consolidated by identifying proteins that were both common in independent 
experiments and abundant (>3 separate unique peptides identified).  Candidate 
immunoprecipitations were carried out to validate the findings (see 2.2.15). 
 
2.2.17 Transfections 
The optimal transfection reagents and conditions were determined for individual cell 
lines as described below. 
 
2.2.17.1 Transfection of Plasmid DNA 
Transient reverse transfections of HEK293 and MDCK cells were performed using 
Lipofectamine 2000 and Poly-L-lysine precoated plates.  DNA and lipofectamine 2000 
were mixed together in a 1:1 (µg:µl)ratio in Optimen, incubated for 20 mins and added 
directly to cells recently plated in antibiotic free media. HCT116 and HeLa cells were 
transfected 24hours after plating using FuGENE HD.  DNA and FuGENE at a 1:3 ratio 
were added to Optimen, incubated for 15 mins and then added to the adherent cells. For 
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both transfection conditions media was refreshed after 20h and typically further 
manipulation took place after 36h post transfection. 
 
2.2.17.2 Transfection of siRNA 
Reverse transfections of MDCK were performed using Lullaby and Poly-L-Lysine 
precoated plates.  For a six well plate, 25nM siRNA and 10µl Lullaby were mixed 
together in Optimen, incubated for 20 mins and added to 2-3 x105 cells/well. HeLa cells 
underwent reverse transfection using HiPERFECT and 10-20nM siRNA.  Media was 
refreshed at 20h and typically further manipulation took place 72h post transfection. 
 
Table 2.11 Short Interfering RNAs 
Name Source 
 
Target DNA sequence (5’)3’)* 
HsPKCi.Q5 Qiagen AACAGGTGGTACCTCCCTTTA 
HsPKCi.Q8 Qiagen ACGCCGCTGGAGAAAGCTTTA 
HsPKCi.Q10 Qiagen CAGATTGTTCTTTGTTATAGA 
HsPKCi.Q11 Qiagen GTGCCGGTACATTTACTTAAA 
HsPKCz.Q1 Qiagen CACCGACAACCCGGACATGAA 
HsPKCz.Q3 Qiagen CACGCGTTCTTCCGCAGCATA 
HsPKCz.Q5 Qiagen CGGAAGCATGACAGCATTAAA 
HsPKCz.Q6 Qiagen GACCAAATTTACGCCATGAAA 
cfPKCi.1 Qiagen AGTTCTGTTGGTGCGATTA 
cfPKCi.2 Qiagen AAGCTCTGATAACCCGGATCA 
cfSCRAM.1 Qiagen AATGAGTGAGTAGTCTTTGCT 
cfSCRAM.2 Qiagen AAGGCCCAACGAAACCATACA 
HsPKCi.D4 Dharmacon CAAAUTCGCATACCACGTT 
* The antisense and sense RNA strands were designed based on the Target DNA 
sequence. 
 
2.2.18 Soft Agar Assay 
HeLa cells in log phase growth were trypsinised and resuspended at a concentration of 
3x103 cells/ml in 2 x RPMI supplemented with 20% FCS.  The cell suspension was 
mixed in a 1:1 ratio with 0.7% molten agarose cooled to 37oC in a waterbath.  3ml of 
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the agarose-cell mix was added to each 35mm well that had been pre-coated with 1.5ml 
of 0.5% agarose.  Plates were incubated at 4oC for 20 mins to allow the agarose to set 
before placing in the 37oC incubator for 10-14 days.  Colonies were stained with 
0.005% crystal violet for 1h after which images were taken using light microscope 
(Zeiss Axiovert 40 CFL) and colony number was quantified using ImageJ (version 
1.40g) analysis. 
 
2.2.19  Three Dimensional Cultures in Matrigel 
The 3D culture of MCF10a and MDCK cells were performed as previously described 
by the Laboratories of Joan Brugge, Mina Bissel and Keith Mostov (Debnath et al., 
2003, Lee et al., 2007, O'Brien et al., 2001)  As this technique formed an integral part of 
the work in this thesis a detailed overview is presented.  Further information may be 
obtained from my methods file stored in the Protein Phosphorylation laboratory. 
Cells in log phase growth were trysinised and resuspended in standard media.  The cell 
suspension was mixed well at a 1:1 ratio with standard media supplemented with 4%- 
low growth factor Matrigel in order to form a single cell suspension with a final 
Matrigel concentration of 2%.  Each well of an 8-well chamber slide was pre-coated 
with 30µl of 100% Matrigel to which 400µl of the cell suspension-Matrigel mix was 
added (see table for cell numbers). After 4h a further 300µl of media-2% Matrigel was 
added.  The cultures were maintained for up to 12 days and the media-2% Matrigel was 
replenished on alternate days.   
 
2.2.19.1 Immunofluorescence  
At the end of the assay the media was removed by inverting the chamber slide and the 
cultures were fixed using 400µl of 2% formaldehyde-PBS for 20 minutes.  They were 
then washed 3 times, for 3 minutes each, with 400µl PBS and gentle agitation. 400µl of 
permeabilisation buffer was then added followed by 2 further quick washes with PBS.  
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At this stage the cultures were either directly stained with fluorescent dyes or 
immunostained.   
 
2.2.19.1.1 Fluorescent Dye staining 
Hoechst, TOPRO-3 or Phalloidin dyes were diluted (see table 2.3 for concentrations) in 
IF-Blocking buffer and incubated with the cultures for 30-60mins at room temperature.  
After a quick rinse with PBS the cultures were mounted (see below). 
 
2.2.19.1.2 Immunostaining 
IF-Blocking buffer supplemented with 20µg/ml F(ab’)2 goat anti mouse Fab fragments 
was added for 1h following which the cultures were incubated with primary antibody 
diluted in the IF-Blocking buffer/anti-Fab.  
Incubation conditions varied for individual antibodies but typically it was overnight at 
4oC with gentle agitation.  The cultures were then washed 3 times for 10 mins each with 
IF buffer and incubated with the secondary antibody in IF-Blocking buffer for 1h at 
room temperature.  Subsequent manipulations proceeded under low light conditions to 
prevent photobleaching.  The cultures were washed a further 3 times, for 10 mins each 
with IF buffer.  The cultures could then be counterstained with Fluorescent dyes or 
proceed straight to mounting. 
 
2.2.19.2 Mounting of chamber slides 
Chamber slides were inverted on filter paper to rid of excess buffer.  The chamber 
compartment was cleaved off the slide using the accompanying plastic guillotine and 
residual liquid at the edge of the slide was removed with a tissue.  The specimen was 
mounted with a hard set mounting medium. To avoid crushing of the specimen a drop 
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of nail polish was applied to the four corners of the slide and a coverslide was added.  
The specimens were allowed to cure at room temperature in the dark for 48h prior to 
confocal imaging. 
 
2.2.19.3 Scoring of Apical Lumen 
MDCK cysts that had their F-Actin stained with Phalloidin were visualised with a 
confocal microscope (Zeiss 510) and an apical lumen assessment made.  The middle of 
a cyst in the z plane was identified and the following criteria applied to determine 
whether the cyst has a ‘predominantly single lumen’: 1) there must have been a clear 
continuous F-actin defined lumen 2) The luminal actin staining must have been more 
intense than the basal (outside) staining 3) The uni-dimentional measurement of this 
lumen must have been at least 1/3rd of the cyst diameter and 4) the uni-dimentional 
measurement of the lumen must have been at least twice the size of any other luminal 
structure. 
 
2.2.19.4 Image Acquisition of 3D Cultures 
High resolution confocal microscope (Zeiss 510) images were acquired using x25, x40 
or x63 oil objectives.  Typically the images were taken of the middle of a spheroid 
where the lumen is its largest.  To enhance image quality the following parameters were 
used: 1 airy unit pinhole, low speed imaging, averaging image x8 and a pixel resolution 
of at least 512x512. 
 
2.2.19.5 Protein Analysis of 3D Cultures 
Cells in log phase growth were diluted in 1.5ml of 2% Matrigel-media and pipetted into 
a 6 well plate pre-coated with 600µl of 100% Matrigel.  An additional 1 ml of 2% 
Matrigel-media was added after 4h and then replenished on alternate days.  At the end 
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of the experiment the media was aspirated and rinsed with ice cold DPBS twice.  2ml of 
ice cold Matrigel washing buffer was added and using a p1000 pipette with a cut off tip 
the cell/Matrigel mixture was dislodged and transferred to a pre-cooled 15ml conical 
tube.  This was repeated 2-3 times until all the cell-gel mixture was transferred.  The 
tubes where shaken in the cold room for 1h to dissolve the Matrigel and then 
centrifuged for 5 minutes at 1000rpm at 4oC.  The supernatant was aspirated, 2xLDS 
loading buffer was added and then the sample was frozen at -20oC 
 
2.2.20 Western Blot Analysis 
2.2.20.1 Protein Extraction and SDS Electorphoresis 
Adherent cells were washed once with cold PBS and then solubilised using LDS 
loading buffer (x2). Samples were boiled for 10 mins followed by sonication for 6 
seconds to shear genomic DNA.  Samples were centrifuged at 13,000rpm for 60 
seconds and loaded, along with Rainbow marker, onto a SDS page gel in running 
buffer. Electophoresis was set to run at 90V (150-80mA).  
 
2.2.20.2 The Transfer of Proteins form the Gel to the Solid Support 
Gel sized 3MM filter paper and fibre pads were soaked in distilled water and PDVF 
membranes were hydrated in methanol.  On the black cathode of the mini-transblot 
cassette was placed: 1)fibre pad 2)Filter paper 3) the gel 4) PDVF membrane 5)the 
another filter paper and 6)another fibre pad, that was in contact with the red anode.  To 
ensure good contact between the gel and the nitrocellulose any air bubbles were 
extruded using a plastic tube.  The cassette was placed in the Mini Trans Blot 
Electrophoretic transfer cell containing transfer buffer and a cooling pack and transfer 
took place in the cold room at 250mA for 2.5h or 100mA overnight. 
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2.2.20.3 Western Blotting Probing and Development 
After electrode disassembly the PDVF membranes were labelled, rehydrated with 
methanol and placed in 3% BSA-TBST  for 1h at RT. The membranes were incubated 
with primary antibody in 3% BSA-TBST overnight at 4oC (Table 2.1 Primary 
Antibodies), washed 3 times with TBST and then incubated with species-specific 
secondary antibody in blocking buffer for 1h.  Standard blots were then washed thrice, 
incubated with ECL solution and immunoreactive bands were visualised by 
autoradiography on film.  On blots where quantification was sought, the Infrared 
emitting secondary antibodies were used and florescence detected on the LiCOR 
Oddessy.  The quantification of the bands was performed using the Gel function on 
ImageJ version 1.40g. 
 
2.2.20.4 Stripping and Reprobing Membranes 
To allow blots to be re-probed the antibodies (predominately secondary antibodies) 
were removed from the PDVF membrane by submerging in stripping buffer for 20 mins 
followed by D20 washes for 30 mins.  At this stage membranes could be re-blocked and 
the Western Blotting protocol followed once again.   
 
2.2.21 Immunofluorescence 
Cells grown on a coverslip or Matex dish were fixed using 4% paraformaldehyde.  Cells 
were permeabilised with 0.5% triton for 10 mins, washed 3 times with PBS and then 
blocked using 10%FCS-PBS for 1 h.  Cells were incubated overnight with primary 
antibodies in blocking solution, washed 3 times with PBS and incubated with species-
specific fluorescent secondary antibody in blocking solution for 1h.  The cells were then 
washed 3 times in PBS and mounted with Prolong Gold. 
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2.2.22 Short-term Lung Colonisation Assay (STLCA) 
Animal experimentation was carried out under the UK Home Office Project Licence 
PPL80/2329.  Animals were maintained in specific pathogen free conditions in the 
CRUK Biological Resources Unit. 
The methods for the STLCA were adapted form those developed by Eric Sahai 
(Medjkane et al., 2009)(Cancer Research UK).  For the assay fluorescently labelled 
Ras-MDCK cells were used that had been transfected with siRNA 48h before use.  
PKC!-depleted and control cells (0.5x106 each and labelled with different fluorophores), 
were injected into the tail vein of NOD-SCID mice and 5x104 cells from the mix were 
seeded on a poly-lysine coated Matex dish and fixed in paraformaldehyde as an input 
control.  After 48 h the mice were culled, the lungs dissected, washed in cold PBS and 
confocal images were taken of the fluorescent cells present in the lungs.  The total sum 
of cell area from at least 10 separate images was derived using Volocity software. A 
ratio between the control and siRNA treated cells was obtained and this was normalised 
to the ratio obtained in the input control. 
 
2.2.23 Proliferation assay 
10µl of 5mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
was added to each well of a 96 well plate and incubated for 30minutes at 37oC.  The 
media/MTT mix was removed by inversion of the plate and tapped 3 times.  50µl of 
DMSO was added to each well to solubilise the mitochondrial dependent formazan 
product and incubated for 10mins at 37oC followed by 10mins of agitation at 37oC.  The 
absorbance was measured using a spectrophotometer at 570nm.  Linearity of the MTT 
assay was tested for each cell line by performing a serial dilution of cells and then 
adding the reagent once cells had become adherent. 
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Chapter 3.  Establishment of a PKC!  dependent 
cancer-related cellular model  
 
3.1 Introduction 
Genetic manipulations in Drosophila have identified a clear role for aPKC in cell 
proliferation and polarity.  In mammalian cells, multiple groups have also implicated 
PKC! in control of proliferation and apoptosis, although these older studies tend to use 
dominant negative PKC! constructs and non-specific PKC inhibitors.  The role of aPKC 
has often been extrapolated from observing the phenotypic affects of inhibitors such as 
Gö6983 (inhibits all PKC classes) and BIM1 (inhibits classical and novel PKCs) and 
any difference between them attributed to aPKC function.  Through collaboration with 
Cancer Research Technology (CRT) access was provided to a number of more specific 
atypical PKC inhibitors based on a favourable inhibition profile against a commercial 
kinase panel.  
The work conducted in this chapter utilized siRNA/RNAi technology and the novel 
specific inhibitors in order to confirm or refute the principles of previous published 
work.  The main aim was to identify a robust PKC! dependent cancer associated 
phenotype. 
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3.2 Results 
3.2.1 HeLa cell proliferation is unaffected by PKC!  inhibition 
Adherent cell growth has previously been described as being aPKC dependent. Initial 
experiments set out to confirm these results in a cell model.  The HeLa cell line, derived 
from cervical epithelial cancer, was chosen to study due to its known high PKC! protein 
expression and its tractability as a cell culture model.  HeLa cells were treated for 24, 48 
or 72 hours with three structurally distinct PKC! inhibitors.  An MTT assay, which was 
shown to be linear between 2x103 and 7.5x104 cells/well, was used to estimate relative 
cell number at each time point (figure 3.1A).  There was a similar trend for decreased 
cell number associated with inhibitor treatment at all three time points.  The 24-hour 
time point is represented (see figure 3.1B) but in an analysis of variance no statistical 
difference was demonstrated.  To ensure that a true inhibitor effect on adherent 
proliferation was not being missed, the cell cycle profile was assessed using 
fluorescence activated cell sorting analysis (see figure 3.1C).  For this analysis adherent 
HeLa cells were treated with the competitive PKC! inhibitor, CRT66854, at two 
contrasting doses.  At 48h there was no difference in G1/G2 ratio between inhibitor 
treated and DMSO control cells at either dose.  Nor was there a substantial pre-G1 
(apoptotic) population of cells.  To corroborate these findings, siRNA against aPKC 
were employed.  Maximal knockdown of PKC! in HeLa had previously been 
demonstrated to occur at 72h (communication from Dr Carine Rosse , Protein 
Phosphorylation Laboratory).  Reverse transfection was performed and the level of 
knockdown and cell number in a MTT assay were assessed.  Up to 75% knockdown of 
PKC! was attained (see figure 3.1D) but no evidence of any effect on cell number was 
seen (figure 3.1E). 
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Figure 3.1 PKC!  is dispensable for adherent HeLa cell growth.   
A, HeLa cells were seeded over a range of concentrations in a 96 well plate and after 2h an MTT assay 
was performed and absorbance measured at 570nm. B, HeLa cells were seeded at 1x104 cells/well and 
treated with PKC! inhibitors.  Relative cell number after 24 hours of inhibitor treatment was estimated 
with the MTT assay and the mean ! SEM is presented of 3 separate experiments.   C, Cells fixed in 
ethanol were treated with propidium iodide and DNA content at a wavelength of 670nm (FL3-H) was 
measured using FACS.  Shown are cell cycle profiles for the HeLa cells treated with DMSO (Left panel), 
3µM CRT66854 (Middle panel) or 12µM CRT66854.  The profiles are representative of 2 separate 
experiments.  D, Western blot of PKC! knockdown by different aPKC siRNAs after 72h of transfection.  
E, The effect of 72h of siRNA-aPKC on the cell number as determined in an MTT assay.  Mean ! SEM is 
presented of 3 separate experiments.  No statistically significant differences were detected. 
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3.2.2 HeLa cell colony formation is reduced by PKC!  inhibition 
The most prominent reported role of aPKC is in the regulation of 3D growth and 
polarity (see section 1.3.5).  To test whether PKC! plays a role in non-adherent growth, 
a soft agar assay was carried out in six well plates.  HeLa cells were seeded as a single 
cell suspension in agarose and treated with 3 structurally distinct atypical PKC 
inhibitors of varying potency.  After 12 days colonies were stained with crystal violet 
solution, a CCD image was taken (Figure 3.2A) and colony number was estimated 
using image J software.  Initial experiments showed that the automated counting 
technique was consistent with manual counting of the digital image and was robust for 
colony numbers of 0 to 400.  The higher potency compounds, CRT31 and CRT54, 
caused a reduction in colony formation even at the lowest treatment concentration of 0.1 
!mol whereas the less active enantiomeric pairs, CRT15 and 90, only resulted in a 
statistically significant reduction in colony formation at 10µM (figure 3.2B).  CRT92, a 
non-ATP competitive compound, was the least potent compound and this was reflected 
by the low extent of colony growth inhibition.  There was a strong relationship between 
the biochemical inhibition of PKC! kinase activity and the reduction in colony 
formation in this assay (R2=0.89, p<0.05) (see figure 3.2C).  Gö6983 and BIM1 were 
used at 1µM, which is 15 times and one fifth of their reported IC50s respectively 
(Gschwendt et al., 1996).  At these concentrations it was predicted that Gö6983 would 
inhibit PKC! whereas BIM1 would not.  However, no differential affect on colony 
inhibition was seen between the two agents.  Again, in an attempt to corroborate the 
findings of a possible aPKC dependence on non-adherent growth, siRNAs against 
aPKC were used.  The siRNA treated cells used in the soft agar assay were also seeded 
on plastic in a 6-well plate for assessment of the 72h transfection knockdown efficiency.  
At 12 days there was no difference in non-adherent colony formation.  The lack of 
effect seen with the PKC! siRNA was not unexpected as the half-life of the siRNA is 
likely to be significantly shorter than the duration of this 12 day soft agar assay and the 
extent of the knock-down was not complete.  This result therefore, while not 
collaborating the inhibitor induced 3D growth suppression results, is not contradictory. 
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Figure 3.2 Structure-activity relationship of PKC!  inhibitors 
A, 4.5x103 HeLa cells were cultured in soft agar for 14 days, stained with crystal violet and images of the 
35mm well taken using a digital camera with a 18-55mm lens.  B, The affect of aPKC inhibitors, 
replenished on alternate days, on HeLa colony growth was quantified and the mean !  SEM is calculated 
from 3 separate experiments.  Each CRT inhibitor was doses at 0.1, 1 or 10µM as indicated by the 
increment bar.  C, The mean colony number present with 1µM of the CRT inhibitors is plotted as a 
function of the biochemical IC50.  Bim1 and Go6983 are not plotted as their Biochemical IC50s were not 
evaluated in this experiment.  The R2 calculated from Pearson coefficient is 0.89.  
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The use of the soft agar assay had provided inhibitor-derived evidence that non-
adherent HeLa cell growth is PKC! dependent.  Attempts were therefore made to 
develop a model that could provide morphological information in a physiologically 
relevant context.  The model chosen for development was the growth of MCF10a acini 
in Matrigel.  MCF10a are human non-transformed immortalised mammary cells that 
recapitulate characteristics of mammary ducts when cultured in Matrigel.  Collaboration 
with the Bentires-Alj Laboratory provided instruction on the assay, some reagents and 
advice.  Using early passage MCF10a cells from the Brugge Laboratory, and in 
collaboration with the Bentires-Alj Laboratory, 7 batches of low growth factor Matrigel 
were tested for the characteristic morphological development.  While the cells did form 
spheroids with a clear basal aspect, as demonstrated by #-6-intergrin or %-catenin 
(basolateral) staining, the spheroids did not demonstrate significant caspase 3 staining 
or cell clearance in the central region (central apoptosis) which made assessment of the 
apical domain difficult (see figure 3.3A&B).  In addition, the spheroids did not exhibit 
terminal growth arrest as demonstrated by the persistence of Ki67 staining at days 12 
and 18 (Figure 3.3C).  In an attempt to identify a cause for this aberrant growth pattern, 
aside from Matrigel constituents, a separate batch of MCF10a cells (from cell services 
at the London Research Institute), a different serum batch, a new Epidermal Growth 
Factor (EGF) batch and a range of EGF concentrations were tried in sequential studies.  
The optimal EGF concentration for central lumen formation was 5ng/ml, the same as 
the original protocol (see Figure 3.3D).  The serum batch made no difference and the 
new MCF10a cells demonstrated no lumen formation at all. 
 
Chapter 3. Results 
 103 
 
 
Figure 3.3 Three-dimensional cultures of MCF10a cells on Matrigel 
MCF10a cells were cultured on Matrigel in an 8 well chamber slide. Representative confocal images of 
cross-sections through the middle of acini are shown.  Day 8 acini are stained with A, the basal marker #-
6-Intergrin (green), the apical marker GM130 (red) and Dapi counter stain (Blue); B, the basolateral 
marker %-catenin (green), cleaved caspase 3 (red) and Dapi counter stain (Blue).  C, Acini cultured for 6, 
12 or 18 days were stained with #-6-Intergrin (green), the proliferation marker Ki67 (red) and Dapi 
counter stain (Blue).  D, Acini were incubated with the indicated concentrations of EGF for 12 days and 
the acini morphology is represented by nuclear staining (white).  Scale bars, 20µm. 
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3.2.3 Attempted long-term knockdown of PKC!  
In parallel to the MCF10a studies, RNAi systems for long-term knockdown were 
explored.  The RNAi system investigated was human TRIPZ shRNA from Open 
Biosytems; constructs that are both doxycycline inducible and have turbo-RFP marker.  
In order to optimise transfection and induction conditions, prior to embarking on viral 
infections, 2 constructs were chosen (1 PKC! and 1 PKC" oligo) and transiently 
transfected into HEK293 cells.  24h post transfection 2 separate doses of Doxycycline 
induction was commenced and 48h post transfection tRFP fluorescence could be 
visualised.  There was no difference in the total fluorescence between 1mg/ml and 
2mg/ml Doxycycline.  In the absence of doxycycline induction no tRFP was detected 
and the optimal ratio of DNA to transfection reagent (Fugene) was 1:3 (Figure 3.4A).  
Despite the bright signal only about 10% of cells were positive for RFP.  When 
knockdown of PKC! protein was analysed 72h post induction there was no evidence of 
protein silencing (Figure 3.4B).  In case this lack of efficacy was as a result of the poor 
transfection efficiency, cells were FACS sorted for RFP after 72h of induction, 
centrifuged and total cell extracts were made.  The FACS sorting confirmed the low 
transfection efficiency of 10% but there was still no knock down of PKC! protein on an 
immunoblot using the pure RFP cell population.  A further 4 constructs were tested by 
transient transfection without any evidence of PKC! knockdown. 
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Figure 3.4 Transfection of PKC!  shRNA in HEK293 cells.   
HEK293 cells were transiently transfected with selected shRNA for PKC! and PKC" in TRIPZ 
constructs.  A, 24h post transfection the cells were induced with 2mg/ml of doxycycline or vehicle 
control.  The level of transfection was estimated by counting the number of tRFP positive cells in a x10 
objective field using an epi-fluorescent microscope.  The images presented are representative of 2 
separate experiments.  B, Knockdown of PKC! and PKC" were assessed 72h post doxycycline induction 
by Western Blot.  The blots are representative of 2 separate experiments. 
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3.2.4 MDCK cells grown in Matrigel provide a robust model for apical 
lumen formation 
In view of the significant difficulties in attaining a MCF10a acini model with a well-
defined apical lumen, the cell type was switched to Mardin Darby canine kidney cells 
(MDCK).  MDCK have long been shown to be a robust model for cell polarity.  
Typically, when grown in collagen, these cells develop hollow spheres (known as cysts) 
that recapitulate the morphological features of the renal collecting ducts from which 
they derive.  To facilitate the use of a siRNA intervention the MDCK cells were 
cultured in Matrigel rather than collagen as this has previously been shown to expedite 
cyst formation. 
MDCK cells grown in Matrigel rapidly formed cysts that can be identified by phase 
contrast microscopy as containing an apical lumen as early as 4 days.  The lumen 
becomes more pronounced with time and growth arrest occurred by day 10 (Figure 
3.5A).  To characterise the apical domain, cysts were stained for actin (phalloidin stain) 
or labelled with antibodies for ZO-1, GM130 and aPKC, all previously demonstrated to 
define the apical region (Day6, Figure 3.5B; Day12, Figure3.6A).  To enable the 
antibody staining, MDCK cysts required detachment from the Matrigel using ice cold 
EDTA-PBS.  The detached cysts were then placed on a poly-L-Lysine slide and gently 
centrifuged (115g) to encourage attachment.  The apical pattern of the ZO-1, GM130 
and aPKC correspond to the actin staining.  Actin and DNA (Hoechst) staining were 
robust for the Matrigel (Figure 3.5B, Far Right panel).  Following centrifugation of the 
cysts the mechanical force results in slightly flattened cysts at D6 and collapse of the 
larger D12 structures.  This gives the mistaken impression at D6 of incomplete luminal 
clearance and at D12 of a double ring of cells (Figure 3.6B).  Taken together, the data 
shows that actin staining is representative of the apical lumen, and can be used to 
robustly stain cysts embedded in Matrigel ensuring retained structural integrity.  The 
combination of actin and DNA staining was therefore used in all subsequent MDCK 3D 
growth studies. 
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Figure 3.5 Three-dimensional cultures of MDCK cells on Matrigel at day 6   
A, MDCK cells embedded in Matrigel form cysts.  Phase images were taken at multiple time points as 
indicated.  B, Day 6 MDCK cysts were washed in ice-cold PBS and attached to poly-L-lysine coated 
slides by centrifugation.  The cysts were stained or immunostained for apical markers as indicated. The 
images are representative of at least 3 separate experiments. 
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Figure 3.6 Three-dimensional cultures of MDCK cells on Matrigel at day 12.  
A, Day 12 MDCK cysts were washed in ice-cold PBS and attached to poly-L-lysine coated slides by 
centrifugation.  The cysts were stained or immunostained for apical markers as indicated. The images are 
representative of at least 3 separate experiments.  B, Schematic depiction of a large MDCK cyst in z-
plane revealing the basis of the artifactual double ring cysts.  B1, appearance of a MDCK cyst embedded 
in Matrigel in both X-Y and Z axis.  B2, Z-stack appearance of MDCK cyst washed and spun onto the 
slide.  B3, The X-Y appearance of the cyst described in B2. 
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3.2.5 The altered catalytic activity of PKC!  mutants is confirmed by 
phosphorylation of LLGL2 
In order to investigate the role of PKC! in the MDCK model, mutants were generated of 
wild-type PKC!, constituently active PKC! (A120E) and a kinase dead PKC! (D368N).  
To test the effectiveness of these mutations an assay was developed exploiting the fact 
that LLGL2 is phosphorylated by PKC! and antibodies exist for the phosphorylation 
site.  As levels of LLGL2 are low or LLGL2 reagents are of poor sensitivity, exogenous 
co-expression was required for PKC!-WT induced phosphorylation of LLGL2 to be 
detected in HEK293 cells.  Accordingly, the A120E mutant led to an increased 
phosphorylation signal and the D368N mutant almost abolished the signal. Transient 
expression of PKC! constructs showed equal protein expression (Figure 3.7).  
Moreover, both constitutively active and kinase dead mutants had comparable priming 
phosphorylation levels to the wild-type, suggesting that mutations did not disrupt the 
structural competence of the protein. 
 
Figure 3.7 Phosphorylated LLGL2 is a marker of PKC!  activity.   
A, In polarized epithelial cells polarity complexes compete for aPKC interaction and this interaction 
contributes to complex localisation.  aPKC dependent phosphorylation of LLGL, which may be assisted 
by p32, results in LLGL inactivation and exclusion from the apical cortex of the cell.  B,  GFP-LLGL and 
GFP-PKC!/PKC! mutants were co-expressed in HEK293 cells and the affect on phosphorylation of 
LLGL was measured at 36h.  The blot is representative of at least 3 separate experiments.  Blot 
fragmentation is due to editorial removal of bands not relevant to this section. 
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3.2.6 Altered PKC!  expression effects MDCK polarity 
The effects of exogenous PKC!, PKC! kinase activity mutants and siRNA knockdown 
on apical lumen formation in MDCK cysts were investigated.  Stably transfected PKC! 
and PKC! mutant cell lines that were twice FACS sorted for GFP demonstrated equal 
PKC! protein expression (Figure 3.8A).  GFP vector control MDCK cells grown for 6 
days in Matrigel form cysts with an actin defined apical lumen in 45% of cysts (Figure 
3.8B).  For PKC!-WT cysts there was a trend for a higher proportion of cysts with a 
normal lumen.  There was inter-experiment variability and no statistically significant 
difference was demonstrated.  The exogenously expressing PKC!-WT MDCK cysts 
appeared generally larger.  Surprisingly, the A120E and D368N PKC! mutants resulted 
in a similar phenotype with the loss of normal apical lumen and larger multi-cystic 
structures.  The differences in apical lumen formation were quantified by counting at 
least 100 cysts per condition per experiment through the eye-piece of the confocal 
microscope that allowed scanning through the Z axis for each cyst (see figure 3.8B).  In 
keeping with the results for the dominant negative PKC! construct, use of the canine 
PKC! directed siRNA also disrupted normal acini formation (Figure 3.8D).  The level 
of knockdown was confirmed by western blot analysis using a mouse PKC$ antibody 
the epitope of which is entirely homologous to both human and dog (Figure 3.8E).  
Densitometry of the Western blots demonstrated 65% knockdown.  Unlike the cysts 
resulting from over-expression of the dominant negative PKC!, the size of the cysts 
were observed to be unchanged. 
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Figure 3.8 Manipulation of PKC!  impacts on apical lumen formation in MDCKs. 
A, Western blot showing the level of exogenous protein in MDCK cells transfected with PKC!/PKC! 
mutants.  B, Quantification of the number of normal apical lumens.  At least 100 spheroids were counted 
per condition and the results of 3 separate experiments are presented. Error bars represent the SEM. One 
way ANOVA was used to determine statistical significance of difference *, p<0.05.  C & D, 
Representative single confocal images of actin staining (red) are presented.  Scale bars represent 50µm.  
E, Western blot showing the level of knockdown of endogenous PKC! by siRNA.  The blot is 
representative of more than 3 separate experiments. 
Chapter 3. Results 
 112 
3.3 Discussion 
Using 2 separate systems to perturb PKC! function, chemical inhibition and siRNA 
knockdown, it was demonstrated that PKC! is dispensable for 2D growth but may play 
a role in 3D growth.  There was a strong structure-activity relationship (SAR) between 
the known biochemical IC50s of a range of relatively specific PKC! inhibitors and the 
colony formation in a 3D growth assay, indicating that the PKC! is required for non-
adherent growth.  The exceptions to the SAR were the competitive inhibitors BIM1 and 
Gö6983.  It was anticipated that at a concentration of 1µM, the pan-PKC inhibitor 
Gö6983 would inhibit PKC! dependent colony formation but that BIM1, which lacks 
PKC! inhibition, would not.  In fact no difference between the two agents was seen.  It 
is possible that the doses were too low for this analysis as for competitive inhibitors 
there is typically a 10 to 100 fold drop off in potency in cells compared to the 
biochemical assay.  
This inhibitor-induced effect, however, was not reproduced by the siRNA knockdown.  
The knockdown efficiency of the HeLa cells used in the colony assay were assessed 72h 
post transfection in adherent cells in log phase growth.  The transfection efficiency of 
about 70% may be an underestimation as the PKC! antibody also detects PKC" albeit 
with a 10-fold lower potency (Appendix 1). Combined knockdown of PKC! and " may 
help address this issue or alternatively mRNA could be assessed although this does not 
necessarily reflect protein expression levels, probably due to post transcriptional 
changes (Anderson and Seilhamer, 1997).  It is also possible that knockdown efficiency 
is affected by the 3D matrix and therefore not truly represented in this experiment.  The 
most likely explanation for the lack of colony inhibition, however, is that a short-term 
intervention was being used in a long-term assay (12 days).  siRNA typically has a 
maximal protein silencing between 2-3 days and duration of action of no longer than 5-
7 days.  Only if the role of PKC! is critical in the initiation phase of transformed growth 
would an siRNA induced effect be seen, for example if knock-down led to apoptosis in 
3D culture this would have been evident.   
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This observed difference between adherent and non-adherent growth is consistent with 
results from the Fields Laboratory who demonstrated that PKC! was necessary for lung 
adenocarcinoma cell colony formation in soft agar but was dispensable for their growth 
on plastic (Regala et al., 2005b)(see section 1.3.11).  These data are further supported 
by the finding that transcription is dramatically altered in 3D cell culture compared to 
2D.  For example, the Eskelinen Laboratory recently demonstrated a robust induction of 
an additional 118 genes in v-Src transformed MDCK cells in 3D culture compared to 
2D (Toyli et al., 2010). 
The first attempted technique to investigate the role of mammalian PKC! in 3D growth 
was the MCF10a 3D morphogenesis assay.  This is an elegant assay that has previously 
been used to study polarity (Debnath et al., 2003, Aranda et al., 2006).  Furthermore, 
MCF10a are immortalized non-transformed human mammary cells that recapitulate the 
mammary duct architecture when grown in Matrigel.  A human study of predominantly 
invasive ductal carcinomas of the breast had demonstrated a correlation between high 
PKC! expression and decreased disease free survival (Kojima et al., 2008).  During this 
thesis it was not possible to optimize the model in order to provide a robust polarized 
morphology.  While there are a multitude of possible variables that could account for 
this failure of technique, the 4 most critical were explored; Matrigel batch, cells, serum 
and EGF but this proved to be to no avail.  It is most likely that the assay was 
compromised due to Matrigel variability.  Matrigel is secreted by Engelbreth-Holm-
Swarm (EHS) mouse sarcoma cells, and although a low growth factor version was used, 
the precise growth factor and protein composition is not controlled for.  In hindsight, a 
critical aspect of this assay is to procure samples of reagents from a Laboratory actively 
performing the technique.  This would help limit the fruitless testing of different 
variables.  A very useful collaboration was established with the Bentires-Alj Laboratory 
at the Fredrich Miescher Institute(FMI) in Basel and during a visit to this lab the 
nuances of the technique were demonstrated and a number of reagents were gifted.  
Unfortunately their working Matrigel stocks, a very precious commodity, were low and 
could not be spared.  It is also well recognised that normal polarization of MCF10a is 
lost upon cell confluency or late passage.  The combination of potential pitfalls makes 
this assay challenging to set up, an experience shared by a number of different groups 
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subsequently encountered (personal communications).  As the MCF10a polarity assay 
take at least 12 days, durable shRNA knockdown strategies are necessary.  Given the 
requirements of early passage number and avoidance of confluence for the MCF10a 
cells, there is a significant risk of clonal drift during longer term culture required for 
transfection and selection of shRNA.  These concerns could be partially negated by the 
use of inducible shRNAs and without this, MCF10a polarity studies should be viewed 
with caution. 
To develop a long-term knockdown of PKC! it was decided to embrace the up to date 
shRNA technology and use the Expression Arrest microRNA adapted shRNA (shRNA 
mir) library.  shRNAmir system is based on the endogenous micro-RNA biogenesis 
pathways.  The constructs are designed to mimic natural microRNA primary transcripts, 
enabling specific processing by the endogenous RNAi pathway and thus more effective 
knockdown (Stegmeier et al., 2005).  The doxycycline induction of turbo-RFP was 
successful but with no resulting knockdown of the target genes (aPKC).  Presumably, 
despite the launch of whole genome libraries for both human and mouse, the algorithms 
for developing shRNA-mir sequences are not yet advanced enough.  Analogous to 
siRNA, the development of shRNA-mir may require several years of investigator driven 
validation.  Consistent with this statement and the results fed back to the proprietor, the 
7 shRNAs tested during this work have since been withdrawn from sale. 
Fortunately, despite being unable to use the MCF10a acini assay, it was possible to 
directly apply the methodology and reagents to an MDCK cyst assay.  Parental MDCK 
reliably formed cysts with an outer layer of cells and a single lumen that stained with 
typical apical markers.  About 50% of parental MDCK cysts in Matrigel formed with a 
single lumen.  This is consistent with Zheng et al who have also cultured MDCK cells 
in Matrigel, but substantially lower than reported for MDCK cysts grown in collagen 
gels (Zheng et al., 2010, Yamanaka et al., 2006).  Such differences are not surprising as 
it has long been recognised that the ECM is critical for cyst morphogenesis.  For 
example, MDCK cells exposed to Hepatocyte growth factor further differentiate into 
tubes grown in collagen type I, but fail to do so cultured in Matrigel (Santos and Nigam, 
1993).  Staining of MDCK cysts with antibodies required detachment from the Matrigel 
and thorough washing.  However, Zheng et al were able to stain the apical lumen of 
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Matrigel embedded MDCK cysts to good effect and there are no reported differences in 
the growth assay or staining protocol to explain this difference (Zheng et al., 2010). 
For functional assessment of PKC! in the MDCK assay catalytic mutants were 
generated.  A point mutation of the conserved pseudosubstrate region within the 
regulatory domain of PKC! was made (A120E) and has previously been shown to be 
constitutively active (Pears et al., 1990).  For the kinase dead mutant an ATP trans-
phosphorylation mutant (D368N) was made rather than the more common mutation of 
the ATP coordinating lysine (K274M).  This action was taken because ATP-
coordinating lysine mutants of other PKC family members have been demonstrated to 
have lower protein expression than wild type PKCs and would not be desirable for 
functional comparisons.  The reason for this has recently been shown to be as a result of 
decreased protein stability due to lack of nucleotide pocket occupation (Cameron et al., 
2009)(see section 1.3.1).  The PKC!-D368N kinase dead mutant, that was predicted to 
bind to ATP, had comparable expression to the PKC!-WT mutant.  To validate the 
(in)activity of the mutant’s phosphorylation, a PKC! substrate was sought.  
Phosphorylation of endogenous LLGL by exogenous aPKC was previously 
demonstrated by immunodetection of immunocomplexes in HEK293T cells (Plant et 
al., 2003).  In the experiments presented here, phosphorylation of exogenous LLGL2 
acted as a good marker of expected activity of the exogenous PKC! proteins and 
validated the use of the D368N as a kinase dead mutant.  Unless more sensitive and 
specific antibodies to pLLGL1/2 are generated, it is unlikely that endogenous LLGL 
phosphorylation could be used as a marker of PKC! activity (biomarker). 
Over-expression mutants of PKC! have a profound impact on apical lumen formation in 
MDCK cells.  While over-expression of wild type PKC! demonstrated a trend to an 
increased proportion of cysts with a normal apical lumen, over-expression of the 
constitutive active PKC! or kinase dead PKC! mutant led to a significant reduction in 
the proportion of normal apical lumen cysts.  The reduction in apical lumen formation 
was also seen with siRNA-aPKC gene silencing.  These data suggest that that PKC! 
may demonstrate multiple-threshold signalling for polarity.  Such multiple-threshold 
signalling usually requires coordination of several signalling pathways that are linked 
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by negative and/or positive feedback mechanisms (see section 1.2.7).  Intriguingly, 
there is the possibility that the regulation of polarity is distinct to the growth regulation, 
as while use of siRNA PKC! disrupted apical lumen formation and had no effect on cyst 
size, the dominant negative PKC! construct disrupted apical lumen formation but led to 
increased growth of the multi-cystic structures.  One explanation for such a difference 
may be that growth signalling is dependent of a PKC! scaffold function, whereas the 
apical lumen formation requires the catalytic activity. Uncontrolled secondary effects of 
the forced over-expression of the PKC! constructs should also be considered, for 
example the localization of the over-expressed protein could be erroneous and sequester 
proteins required for normal polarity signalling away from the endogenous PKC!. 
The activity of PKC! has been difficult to assess in vivo.  Unlike other AGC kinases, 
the PKC family of kinases are constitutively phosphorylated at the activation loop and 
this is therefore likely to be an unreliable marker of activity.  At the current time, over-
expression of activity mutants remains an important tool in the characterization of PKC! 
behaviour.  The identification of robust biomarkers of PKC! activity is the subject of 
chapter 6. 
In summary, a model of MDCK cell 3D morphogenesis in Matrigel has been 
established and shown to be PKC! dependent.  Due to the relatively short duration of 
the assay, it is amenable to both stable and transient transfection interventions.  
Manipulation of PKC! in the MDCK cyst model has suggested possible threshold 
signalling of polarity.
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Chapter 4. PKC!  is a downstream effector of 
oncogenic Ras that controls MDCK polarity 
 
4.1 Introduction 
PKC! is has been reported to be over-expressed in human malignancy (Regala et al., 
2005b, Eder et al., 2005).  In the previous chapter it was suggested that there is a PKC! 
threshold requirement for normal MDCK cystogenesis, a system commonly used to 
evaluate polarity.  A number of studies have demonstrated an association of aPKC and 
bona fide human oncogenes such as PI3 Kinase, Ras, Raf, ErbB2 and Src (see section 
1.3.3.3).  Little is know about potential role of PKC! in collaboration with these 
oncogenes in the regulation of epithelial cell polarity.  Results from a genetic screen in 
D.melanogaster suggested that aberrant expression of polarity genes alone led to 
tumour formation whereas the cooperation between aberrant polarity gene expression 
and oncogenic Ras led to invasive and metastatic tumours (Pagliarini and Xu, 2003).  
The aim of this chapter was to establish whether literature-based candidate oncogenes 
led to PKC! dependent abnormal polarity in the MDCK model. 
 
4.2 Results 
4.2.1 Oncogene expression in MDCK cells disrupts morphology 
MDCK cells cultured on plastic grew as epithelial clusters and at confluence adopted a 
cobblestone appearance (Figure 4.1A).  MDCK variants that expressed V12-H-Ras, 
p110a-CAAX and v-Src activated oncogenes became more fibroblastic in appearance 
and lost their direct cell-cell contacts.  This phenotype was most pronounced in V12-H-
Ras MDCK.  The MDCK cells that expressed Raf-CAAX and ErbB2 activated 
oncogenes grew in 2-D as epithelial sheets, but unlike the parental line, small epithelial 
clusters or islands were not seen even at low confluence. 
To identify if the oncogenes impact on normal MDCK cyst formation in 3D, cells from 
the oncogenic MDCK cell panel were cultured in Matrigel.  All the oncogenic MDCK 
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cells tested resulted in larger cysts or aggregates.  In particular V12-Ras-MDCK, 
ErbB2-MDCK and p110a-MDCKs grew as large spherical aggregates that lacked an 
apical (central) lumen and an apical actin ring.  The v-Src cells developed with a large 
central lumen surrounded by a ring of smaller lumens.  The Raf-CAAX cells formed as 
large but otherwise normal cysts (Figure 4.1A).  As many of these structures derived 
from the oncogenic MDCK cell panel were not cysts, the collective term of oncogenic 
MDCK spheroids is used for the remainder of this thesis. 
 
4.2.2 Oncogenic MDCKs do not have altered expression of PKC!  
As the oncogenic MDCK spheroids had clear differences in their ability to develop an 
apical ring and lumen the possible role of PKC! in this process was explored.  Firstly 
the defining protein expression (for example v-Src or ErbB2) of the respective 
oncogenic MDCK cells was determined.  With the exception of p110# a strong signal 
was seen for their defining protein for each member of the oncogenic MDCK cell panel 
(see figure 4.1B).  Appropriately, phosphorylation of Src at tyrosine 527, that is 
inactivating and absent in the v-Src mutant, was not elevated in the v-Src-MDCK cells.  
Using a p110# antibody a 110kD band was detected in each of the oncogenic MDCK 
cell lines from the panel, but this was not elevated in the p110#-MDCKs.  There was, 
however, a unique unknown band in the p110#-MDCK at 65kD.  Total PKC! levels 
were similar between the parental MDCK cells and the oncogenic MDCK cell panel.  
Phosphorylation of the activation loop of PKC! at Threonine 403 is a possible marker of 
PKC! activity but this was also uniform for the MDCK cell panel and parental MDCK.  
To identify whether PKC! expression or phosphorylation at T403 was altered in the 
context of 3D cultures, protein was harvested from the Matrigel cultures but the 
immunoblots using the resulting total cell extracts were un-interpretable as they had 
significant background and poor detection of PKC!. 
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Figure 4.1 Characterisation of Oncogenic MDCK cells 
A, MDCK cell variants cultured in Matrigel (3-D) for 6 days alongside phase images of their growth in 2-
D.  Phalloidin (Red) stained Actin and Hoechst (Blue) identified nuclei.  Scale bars represent 50µM.  B, 
Lysates of MDCK cell variants in log phase growth were immunoblotted for defining proteins. 
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4.2.3 Knockdown of PKC!  in H-Ras and ErbB2 spheroids restores an 
apical lumen 
To test further whether PKC! is involved in signalling downstream of key oncogenic 
proteins a siRNA approach was adopted to transiently knock down PKC! in the 
oncogenic MDCK series and then culture in Matrigel for 6 days.  Initial experiments 
showed that the best transfection efficiency without significant cell death was obtained 
at 72hours using Lullaby transfection reagent.  The knockdown efficiency of two 
separate siRNA oligomers ranged from 30% to 80% depending on cell type (see figure 
4.2B).   
Oncogenic spheroids treated with siRNA-PKC! compared to scrambled control siRNA 
were generally smaller and had a distinct appearance with regards to their apical actin 
ring.  In a pilot study the apical rings of ErbB2 spheroids with and without siRNA-
PKC! were analysed and differential criteria were defined – predominantly single apical 
lumen (PSAL) (see section 1.2.19.3).  
In both H-Ras and ErbB2-MDCK, knockdown of PKC! resulted in smaller spheroids 
with significantly more PSALs (see figure 4.2A).  The v-Src spheroids were smaller in 
size and lost many of the small lumens in the outer ring.  They continued to have a 
PSAL and therefore no differences between siRNA-PKC! and scrambled siRNA were 
scored.  Although this trend was consistent between experiments the magnitude of the 
effect was variable between experiments, which is reflected in the wide standard error 
of the mean. 
There was no difference in PSALs between Raf spheroids with and without PKC! 
knockdown. The percentage of spheroids with PSAL was uniformly high at about 80%. 
It is worth noting that the average knockdown of PKC! in Raf-MDCK cells was the 
lowest among the oncogenic MDCK panel although at this level an effect on 
proliferation was still seen. In the p110 spheroids, there was no difference in PSAL 
between the siRNA-PKC! and scrambled control but unlike the Raf-MDCK spheroids 
apical lumens were rarely present. 
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Upon PKC! knockdown of the parental MDCK cells the spheroids remained a similar 
size but had a PSAL in less than 50% spheroids.  This is compared to over 70% in the 
group treated with the scrambled control siRNA. 
Chapter 4. Results 
 122 
 
Figure 4.2 (PANEL 1) The effect of PKC! knockdown in oncogenic MDCK.   
LEFT COLUMN, MDCK variant cells treated with siRNA-PKC" for 24h prior to culture in Matrigel for 6 
days.  Single confocal images with phalloidin (Red) stained actin and Hoechst (Blue) identified nuclei.  
Scale bars represent 50µm.  RIGHT COLUMN, Quantification of number of Predominantly Single 
Apical Lumens (PSALs).  The x-axis is labelled with the cell type and siRNA used.  At least 100 
spheroids were counted per condition and the results of at least 3 separate experiments are presented.  
Error bars represent the SEM. One way ANOVA was used to determine statistical significance of 
difference between PKC" knockdown and the scrambled controls ; *, p<0.05; **, p<0.01;  ***, p<0.001. 
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Figure 4.2 (PANEL 2) The effect of PKC! knockdown in oncogenic MDCK.                                       
A (LEFT COLUMN), MDCK variant cells treated with siRNA-PKC" for 24h prior to culture in Matrigel 
for 6 days. Single confocal images with phalloidin (Red) stained actin and Hoechst (Blue) identified 
nuclei.  Scale bars represent 50µm. A (RIGHT COLUMN), Quantification of the number of 
Predominantly Single Apical Lumens (PSALs).  The x-axis is labelled with the cell type and siRNA used.  
At least 100 spheroids were counted per condition and the results of at least 3 separate experiments are 
presented. Error bars represent the SEM. One way ANOVA was used to determine the statistical 
significance of any differences between PKC" knockdown and the scrambled controls ; *, p<0.05; **, 
p<0.01;  ***, p<0.001.  B, MDCK variant cells treated with siRNA-PKC" for 24h were seeded in 6-well 
plates and total cell extracts were prepared after 48h (72h post transfection).  The Western blot is 
representative of 3 separate experiments. 
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4.2.4 Expression of PKC!  can partially rescue the PKC!-siRNA induced 
lumen formation 
To determine the specificity of the siRNA utilised in the knockdown studies an attempt 
was made to rescue the siRNA induced phenotype with siRNA resistant cDNA of PKC! 
(see figure 4.3).  The interspecies sequence differences were exploited as the human 
PKC! sequence was distinct from the canine siRNA-PKC! sequences used and should 
therefore be resistant.  In view of the emerging data to support a functional interaction 
between oncogenic Ras and PKC! and the implications that this may have for human 
malignancy the H-Ras-MDCK cell line was selected to test the rescue experiment.  H-
Ras-MDCK cells were transfected sequentially, first with siPKC! and then after 24 
hours with the human cDNA for PKC!.  The co-transfection with siPKC!.1 and cDNA-
PKC! resulted in considerable cytotoxicity and as such it was not possible to achieve 
co-transfection with this oligonucleotide. 
Following co-transfection of H-Ras-MDCK cells with siPKC!.2 and empty vector, there 
was a three-fold increase in the number of spheroids with a predominantly single apical 
lumen (PSAL) compared to the scrambled control (Figure 4.3C).  When the Ras-MDCK 
cells were treated with siPKC!.2 and cDNA-PKC! the increase in spheroids with PSAL 
was less than 2 fold.  Addition of PKC! to scrambled control had little effect on the 
number of PSALs.  Thus a good partial rescue of the siRNA- PKC! induced phenotype 
with cDNA-PKC! was attained. 
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Figure 4.3 PKC!  rescue system 
A, H-Ras-MDCK cells were sequentially transfected with siRNA-PKC! followed by siRNA resistant 
PKC!-cDNA.  Cells were seeded in 6 well plates and total cell extracts made after 24h.  The levels of 
endogenous PKC! knockdown and GFP-PKC! over-expression were determined by Western blot using 
the LiCOR system.  B, densitometry was performed on the resulting blots.  C, the sequentially transfected 
cells were seeded in Matrigel and after 6 days were fixed and stained for actin (Red) and DNA (blue). 
Representative single confocal images are presented.  D, Quantification of the number of predominantly 
single lumens is shown.  At least 100 spheroids were counted per condition and the results of 3 separate 
experiments are presented.  EV, Empty vector. 
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4.2.5 PKC!  inhibitors can restore apical lumens in MDCK cells 
To attempt to further characterise PKC! as an essential component of polarity signalling 
downstream of Ras in MDCK spheroids, PKC! chemical inhibitors were employed.  H-
Ras-MDCK spheroids were grown in Matrigel in the presence of either Gö6983, a pan-
PKC inhibitor, or CRT66854, a structurally distinct atypical PKC inhibitor.  Inhibitors 
were added on the day of seeding a single cell suspension in Matrigel and replenished 
on alternate days for 6 days. The inhibitor doses used for compounds were determined 
based on their individual, previously defined cellular EC50s.  Both inhibitors 
phenocopied the siRNA-PKC! intervention resulting in the induction of apical lumen 
formation in the spheroids and a reduction in the spheroid size (see Figures 4.4A&B).  
The maximal effect of Gö6983 on PSALS was at 2!M resulting in a 6 fold increase.  At 
a dose of 3.6 !mol there was extensive cell death making scoring of apical lumens 
unfeasible.  The maximal proportion of PSALs was seen with CRT66854 at the lower 
dose of 1.2 !M.  Above this dosing level the apical lumen formation was impaired and 
extensive cytotoxicity occurred at 3 !M (see figure 4.4C&D). 
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Figure 4.4 PKC!  inhibitors induce lumen formation in H-Ras-MDCK spheroids.  
H-Ras-MDCK were cultured in Matrigel for 6 days and treated with inhibitors at a range of 
concentrations.  Representative single confocal images of H-Ras-MDCK treated with; A, 2.0µM Go6983 
and B, 1.2µM CRT66854 is presented.  Spheroids were fixed and stained for actin (Red) and DNA (blue).  
C&D, Quantification of number of Predominantly Single Apical Lumens (PSALs) at different inhibitor 
concentrations.  At least 100 spheroids were counted per condition and the results of at least 3 separate 
experiments are shown. 
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4.2.6 Short-term lung colonisation of H-Ras MDCK cells may be PKC!  
dependent 
As loss of normal polarity is associated with high-grade, poorly differentiated tumours 
and epithelial to mesenchymal transition we hypothesised that restoration of polarity in 
H-Ras cells, by knockdown of PKC!, may lead to fewer lung metastases.  H-Ras or v-
Src MDCK cells were injected subcutaneously into the flank of NOD-SCID mice.  The 
H-Ras group developed rapidly growing tumours at the site of inoculation and required 
culling at day 22 as they had reached the permitted maximal tumour burden (1.44cm3).  
The time from detection of a palpable tumour to maximal tumour burden was only 6 
days.  No lung metastases were detected following Hematoxylin and Eosin (H&E) 
staining at multiple levels.  V-Src MDCK tumours grew considerably slower with a 
median time to maximal tumour burden of 6 weeks.  Again no lung metastases were 
detected in these mice. 
In view of the rapid growth of the H-Ras MDCK cells we postulated that there was 
insufficient time for the cells to invade and intravasate into blood vessels.  To overcome 
this, a short-term lung colonisation assay was performed.  H-Ras-, vSrc- and parental 
MDCK cells were transfected with GFP-pBABE or Cherry-pBABE empty vectors and 
selected with puromycin to generate stable fluorescent cells lines.  Initial investigations 
were carried out to detect whether lung colonisation occurred 48 hours after tail vein 
injection using the fluorescent cell lines.  At this time point a high burden of fluorescent 
cells was seen in the H-Ras MDCK group but no lung colonisation was apparent for the 
mice injected with v-Src or parental MDCK cells. 
The effect of PKC!-siRNA knockdown in H-Ras MDCK cells on lung colonisation was 
tested relative to scrambled control-siRNA.  If for example, the GFP-H-Ras MDCK 
cells were treated with PKC!-siRNA then the Cherry-H-Ras MDCK cells were treated 
with siRNA-scrambled control.  The experiment was also conducted with the coloured 
labels switched, i.e. PKC!-siRNA in the Cherry cells and scrambled-siRNA in GFP.  
48h after transfection a 1:1 mix of the two conditions was injected into the mice tail 
veins.  After a further 48h the ratio of siPKC!.2 to siScrambled was decreased 
suggesting a reduction in lung metastasis when PKC! is depleted.  This finding, 
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however, was not corroborated with a second oligonuclotide (PKC!.1) and in fact the 
inverse result was observed. 
 
Figure 4.5 Short term lung colonisation may be affected by PKC! knockdown.   
A, Fluorescently labelled H-Ras-MDCK cells transfected with siPKC" or siScrambled control were 
injected into mice tail veins.  Representative confocal images (x0.7 magnification) of the lungs 48h post 
injection are presented.  Control siScrambled cells (Red & Green, LEFT) and control (Red) and siPKC" 
(Green) cells (RIGHT).  B, For quantification of lung colonisation the sum area of at least 10 separate 
images per mouse was calculated for both green and red cells.  At least 5 mice are presented for each 
condition in at least 2 separate experiments.  One way ANOVA was used to determine the statistical 
significance of differences between PKC" knockdown and the scrambled control ; **, p<0.01;  ***, 
p<0.001. C, the level of knockdown was confirmed by Western blot and D, normalised densitometry was 
calculated. 
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4.3 Discussion 
MDCK cells that over-express activated H-Ras, C-Raf, p110#, v-Src and Her2 proteins 
grow with an altered morphological appearance in 2-D and have clearly distinguishable 
morphologies in 3-D. Using an assessment of predominantly single apical lumens 
(PSAL) as an indicator of polarity it was demonstrated that the aberrant polarity of H-
Ras MDCK and ErbB2-MDCK spheroids could be partially reversed by knock down of 
PKC! using two separate siRNAs. 
Uniform knockdown of PKC! was not achieved between the different cell lines with the 
more fibroblastic cells (H-Ras, p110# and v-Src) having a better transfection efficiency.  
The level of knockdown did not exceed 80% for any of the MDCK cell lines despite 
observing phenotypic effects.  From screening of the PKC! antibodies against 
recombinant PKC! and PKC" it was demonstrated that the most specific PKC! antibody 
still cross-reacted with PKC" at about one tenth of the potency (see appendix 1).  It is 
possible that the knockdown efficiencies are higher than reported and that some of the 
residual protein identified is in fact PKC".  The reverse cross-reactivity existed for the 
preferred PKC" antibody making it difficult to test out this theory for protein 
expression.  The siRNAi.2 silenced PKC! with greater efficiency than PKC!.1 but this 
difference in knock down did not correlate with the extent of polarity reversion.  This 
lack of correlation could be explained by a threshold effect (as discussed in chapter 3).  
For example, in this case if both knockdowns reach the threshold a comparable 
phenotype rather than one that is proportional to the knockdown level is seen.  C-Raf 
expressing spheroids maintained normal polarity.  The c-Raf cells had a poor 
transfection/knock-down efficiency with both PKC! oligonucleotides.  Therefore it may 
be concluded that activated c-Raf does not drive apical lumen disruption in MDCK cells 
but the role of PKC! in polarity signalling downstream of c-Raf remains uncertain.  This 
finding may well be cell type specific as it has recently been published that an 
inducible, activated kinase domain of c-Raf is able to disrupt apical-basal polarity in 
non-transformed human mammary spheroids (s1 cells) (Beliveau et al., 2010).  Using a 
completely different model system, Raf was also required for establishing dorsoventral 
polarity during Drosophila development (Brand and Perrimon, 1994). 
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In this thesis the aberrant polarity induced by activated P110# was not dependent on 
PKC!.  Confirmation of the 110 kD protein expressed in these cells was not obtained.  
This was not unexpected as the p110# subunit of PI3K requires binding to the p85 
subunit to form a stable heterodimeric complex (Yu et al., 1998).  The mesenchymal 
appearance, compared to the epithelial control, provides a level of confidence that this is 
indeed the p110# over expressing cell line but mRNA expression should be sought to 
confirm this.  Others have demonstrated that the addition of Ly294002, the pan PI3K 
inhibitor, is able to reverse the disrupted polarity of T4-2 spheroids, derived from a 
human mammary tumour (Liu et al., 2004).  This effect may be cell type specific, due to 
inhibition of other PI3K isoforms or could be due to greater functional inhibition by the 
inhibitor as compared to siRNA. 
Although multiple oligonucleotides had demonstrated the same phenotype, we set about 
minimising the risk of off target siRNA effects by performing a rescue experiment.  
Sequential transfections proved too toxic for experiments involving siPKC!.1.  The 
cDNA transfection reagent used, Lipofectamine 2000, is toxic at low seeding densities 
and following the slight antiproliferative effect of PKC!.1 the combination of PKC! 
knockdown and overexpression resulted in cell death.  SiPKCi.2 transfection, followed 
by overexpression human PKC! cDNA gave a good partial rescue of the siRNA 
phenotype providing a further level of confidence as to the PKC! specific function 
downstream of Ras in polarity signalling. 
Further evidence of an atypical PKC dependent process was provided by inhibitor 
experiments. Both Gö6983 and CRT66854 were able to revert the aberrant polarity of 
H-Ras MDCK cells. The dose required for maximal phenotypic effect was higher for 
Gö6983 than CRT66854.  This is not consistent with the reported biochemical IC 50s 
for these drugs that is 60nM for Gö6983 (Gschwendt et al., 1996) and 161nM for 
CRT66854 (Barton et al., 2009a).  This discrepancy may be a consequence of inhibitor 
cell permeability, the dosing strategy, drug metabolism or differences in the in vitro 
kinase assay protocol compared to the published studies.  In this experiment 
media/inhibitor was empirically replenished on alternate days but little is know about 
the most appropriate dosing strategy or whether these drugs accumulate in Matrigel.  In 
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addition, it is possible that other members of the PKC family, which are also inhibited 
by Gö6983, impact on polarity signalling.  
H-Ras disrupts polarity in MDCK and this may be mediated by PKC!. The three most 
notable isoforms of Ras (H-Ras, K-Ras and N-Ras) share similar catalytic domains and 
are thought to differ by virtue of their membrane association and thus activating 
partners.  The G12V-Ras mutant used in this study is insensitive to inactivation by 
GAP, remains bound to GTP and is therefore constitutively active. In this G12V-Ras 
form the isoform differences are blurred and it is commonly referred to as oncogenic 
Ras.  
The short-term lung colonisation assay is a useful model to test acute interventions, 
such as siRNA and single doses of inhibitor, in vivo.  The readout from the assay 
(relative lung fluorescence) is a composite endpoint of multiple processes that occur 
during metastases but after intravasation; anoikis, endothelial adhesion, invasion and 
proliferation within the lung.  To minimise the impact of proliferation on the readout the 
lungs were examined 48 hours after tail vein injection.  To control for any differences in 
the number of GFP and mCherry labelled H-Ras-MDCK cells injected into the mouse, 
cells were plated on a Mattex dish, allowed to adhere overnight, fixed and examined by 
a confocal microscopy. The results obtained from the lung were then adjusted for this 
input control.  This does make an assumption that the interventions are not having a 
significant effect on proliferation in the short term Mattex dish culture.  To circumvent 
this problem cells could be seeded onto Poly Lysine and immediately fixed or 
alternatively the cell populations could be assessed by Fluorescence-activated cell 
sorting (FACS).  The results of this colonisation experiment showed opposing effects 
for the two PKC! oligonucleotides.  To uncover if this is due to off target effects further 
PKC! oligonucleotides, an in vivo rescue of a siRNA phenotype experiment or an 
independent mode of intervention (inhibitors) should all be considered.  The 
preliminary results obtained after treatment with CRT66854, an atypical PKC! inhibitor, 
are consistent with siPKCi.2 (validated by rescue in vitro) in that it decreases early lung 
colonisation.  This experiment was performed by 12 hours inhibitor treatment prior to 
tail vein injection at which time it would be anticipated that the competitive inhibitor 
disengages from the PKC! complex.  In carrying out this experiment therefore, an 
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assumption was made that this period of inhibitor pre-treatment was sufficient to alter 
the transcription of the PKC! signalosome.  This could be tested by RNA based micro-
arrays over a time course.  Alternatively the phosphorylation of an abundant PKC! 
substrate could be monitored, if such a molecule could be identified.  The in vivo rescue 
would be technically difficult and would require a large cohort of mice.  Currently the 
use of further PKC! oligonucleotides in the short-term lung colonisation assay are 
planned. 
PKC! has been associated with polarity signalling in model organisms, human 
neuroblasts and in migration studies see Chapter 1.  Separately, PKC! protein 
expression has been shown to be prognostic in a number of human malignancies and in 
a mouse cancer model to function downstream of K-Ras.  This study provides, for the 
first time, the evidence that PKC! dependant polarity signalling is downstream of 
oncogenic Ras in mammalian epithelium.  PKC! is currently one of the most hotly 
pursued targets in early stage drug development . Target validation has relied on non-
adherent growth assays.  Whilst these are extremely important in drug development, in 
the absence of a robust PKC! biomarker, they are susceptible to the common 
antiproliferative off-target effects of siRNAs and shRNAs.  An MDCK polarity assay 
provides defined morphological information that is likely to be more target-specific 
than 3D growth alone.  The results obtained in this study may also prove valuable for 
stratification of patients likely to benefit from anti- PKC! therapy, particularly selecting 
patients with oncogenic Ras and ErbB2.  Preliminary in vivo results suggest that the 
strategies to reverse aberrant polarity in vitro may correlate with a decrease in early 
experimental lung metastasis.  The mainstay of treatment of localised primary tumours 
is surgical resection but it is well recognized that despite expert surgical technique, 
surgery itself can lead to the dissemination of microscopic disease (Sheen et al., 2004).  
The in vivo results therefore, if confirmed, would point to a possible role for peri-
operative anti-PKC! treatment that would be predicted to reduce tumour recurrence. 
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Chapter 5. Identification of an aPKC-specific 
recruitment site for LLGL, essential for MDCK polarity  
 
5.1 Introduction 
The recent crystal structure determination of PKC! bound to the CRT66854 inhibitor 
by the Structural Biology Laboratory (SBL) at the LRI defined (1) a detailed 
interaction map of contacts between chemical ligand and PKC! (2) identified a 
putative protein interaction motif within the PKC! C-lobe as discussed below.  
Collaboration with the SBL has provided unique insights into the structure of PKC! 
and therefore a platform for functional assessment.  An intriguing aspect of the 
66854-bound PKC! kinase domain structure was the nature of the crystal contacts 
within the crystal lattice.  Each of the three copies of PKC! within the crystal 
asymmetric unit made equivalent contacts from an Arg-Ile-Pro-Arg motif (RIPR; 
amino acids 471 to 474) from the C-lobe of one molecule to the B-helix within the N-
lobe of an adjacent symmetry-related molecule (see figure 5.1A).  This interaction 
involved a network of hydrogen bonds involving one of the arginine side-chains, 
phospho-T403, the B-helix and the second arginine making contacts close to where a 
gamma-phosphate of ATP would lie (see figure 5.1B).  Surprisingly, the motif lies 
between the H and I helices at exactly the same position on the EGFR that makes a 
trans-activating contact in a trans-activating EGFR dimer.  The symmetry contact in 
PKC! also stabilises the B-helix, which is partially unfolded and not helical in all 
other PKC! structures (Takimura et al., 2010, Messerschmidt et al., 2005).  In 
contrast, the B-helix is well formed in all previously determined AGC kinases.  It was 
therefore hypothesised that this RIPR motif could be an important protein-protein 
interaction determinant and may be involved in stabilising a higher-order PKC! kinase 
structure that plays a crucial functional role. 
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Figure 5.1 PKC!  kinase domain crystal lattice 
A, The first PKC! kinase domain (grey) is using the RIPR motif (red) to bind the second PKC! kinase 
domain (cyan).  B, the RIPR containing loop (brown) of a PKC! kinase (mainly out of picture) makes 
contacts with the pT403, the B-helix and close to where the &-phosphate of ATP would lie.  C, In 
CRT66854 bound PKC! structure (cyan) a formed B-helix is seen in contrast to all other aPKC 
structures determined, for example PKC" kinase domain (pink). 
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5.2 Results 
5.2.1 The RIPR region is required for PKC!  dependent 
phosphorylation of LLGL but not in vitro phosphorylation of PKC'  
pseudosubstrate 
To test whether the activity of PKC! in cells was dependent on the RIPR motif, a 
double arginine mutant (R471A/R474A, creating the sequence AIPA) was made. For 
the remainder of this thesis this mutant will be referred to as the AIPA mutant.  Using 
phosphorylation of LLGL2 (pLLGL) as a read out of PKC! activity (as validated in 
chapter 3), GFP-LLGL was co-transfected in HEK293 cells with the full-length PKC! 
mutant series- GFP-PKC!-WT, GFP-PKC!-AIPA, GFP-PKC! -D368N (kinase dead) 
or empty vector.  Under these conditions pLLGL detected by Western was reduced by 
94% with PKC!-D368N and 82% with PKC!-AIPA compared to PKC!-WT (Figure 
5.2A).  This experiment was repeated using the kinase domain (aa.239-587) versions 
of the PKC! mutant series and the results mirrored those of the full-length constructs. 
To demonstrate that the low activity of the AIPA mutant was a protein autonomous 
function, HEK293 cells were transfected with the same PKC! mutant series, immuno-
complexes were precipitated via the GFP tag and assayed in a classical kinase assay 
using PKC' pseudosubstrate (PKC'PS) as the substrate.  In this assay the PKC!-AIPA 
had slightly lower activity than PKC!-WT but it was not comparable to the decrease 
in pLLGL in cells.  Both the vector control and the kinase dead had no activity above 
baseline levels in the kinase assay (Figure 5.2B). 
In order to explain this discrepancy between the cell-based phosphorylation and the 
immunocomplex kinase assay results, a number of different hypotheses were 
proposed: 1) The RIPR region could participate as a donor in an activating 
intermolecular interaction.  This transactivation would be predicted to require a high 
localised protein concentration, mimicking the concentrations found in a cellular 
membrane (2D) but is too weak an interaction to be detected in vitro, 2) the AIPA 
region may provide a docking site for proteins that inhibit activity – these proteins 
being present in the cell but not the kinase reaction mix, or 3) The RIPR region could 
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be required for substrate binding but is not required by the short PKC'PS peptide 
substrate used in the in vitro kinase assay. 
 
 
Figure 5.2 In vivo and in vitro substrate phosphorylation by PKC!-AIPA 
A, Empty Vector, PKC!-WT, PKC-AIPA (RIPR>AIPA mutant) or PKC-D368N were co-transfected 
with LLGL2 in HEK293 cells and the phosphorylation of LLGL2 was measured after 36h. Constructs 
from the PKC! mutant series were co-transfected at a 1:1 ratio along with LLGL2.  Total DNA 
transfected was kept constant for all conditions.  Lysates were immunoblotted for pLLGL and PKC! 
and the densitometry of the pLLGL/PKC! signal is shown.  B, PKC!-WT, PKC-AIPA, PKC-D368N 
and empty vector were transfected in HEK293 cells, immunoprecipitated via their GFP tags and 
immunocomplex kinase assays were performed.  Activity was adjusted for PKC! protein concentration.  
Both graphs show the mean±SEM of 3 separate experiments normalised to PKC!-WT.  
 
5.2.2 PKC!-DN is unable to rescue PKC!-AIPA activity in HEK293 
cells 
If the activity of PKC!-AIPA mutant was diminished in cells because it lacked the 
putative RIPR transactivation region (which by inference might not be operating in an 
immune complex kinase assay) then the activity might be rescued by a mutant with an 
intact RIPR region but lacking kinase activity (PKC!-D368N).  The two mutant 
constructs, PKC!-AIPA and PKC!-D368N were mixed at a 1:1 ratio with a constant 
DNA concentration in the LLGL co-transfection experiment.  No appreciable increase 
in pLLGL was demonstrated compared to PKC!-AIPA alone (figure 5.3).   
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Figure 5.3 Attempted rescue of PKC!-AIPA activity with a kinase dead mutant 
HEK293 cells were co-transfected with LLGL and a 1:1 mix of PKC! or PKC! mutants maintaining a 
constant DNA concentration per condition.  After 36h total cell lysates were analysed for pLLGL.  As a 
positive control the PKC!-WT/LLGL co-transfected cells were treated with a specific PKC! inhibitor.  
The blot is representative of 3 separate experiments. 
 
This lack of rescue could have been a consequence of disproportionate expression of 
the two proteins or due to an inadequate localised concentration of PKC!.  To address 
the issue of disproportionate expression the experiment was performed mixing GFP-
tagged constructs with non-tagged constructs so each could be identified by 
separation of mass on an SDS-PAGE gel.  When expressed individually the PKC! 
mutant series expressed equally well in both pEGFP-C1 and pcDNA3.1 vectors and 
had the same effect on LLGL phosphorylation.  Initial results indicated that when the 
2 vectors were mixed the expression of proteins from pcDNA3 were markedly lower 
than from pEGFP and this discrepancy could not be overcome by increasing the ratio 
of construct DNA in favour of pcDNA3.1. 
As an alternative strategy to enable the protein ratio to be quantified, full length or 
kinase domain alone was expressed in the same pEGFP vector.  To ensure high-
localised concentrations, that were predicted to be required for transactivation, the 
proteins were myristolated at the N-terminus of the GFP tag.  These myristolated 
proteins were localised to membranes (Figure 5.4A) and had a more robust pLLGL 
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signal compared to the non-myristolated counterparts (Figure 5.4B).  When co-
expressed the myristolated kinase domains of the PKC! mutant series expressed 
slightly better than the myristolated full-length PKC! mutant series and therefore 
influenced the pLLGL to a greater extent.  Despite these optimisations the PKC!-
D368N was unable to rescue PKC!-AIPA activity in cells (Figures 5.4C&D). 
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Figure 5.4 Attempted activity rescue following membrane localisation 
A, HEK293 were transiently transfected with GFP-PKC!, myristolated GFP-PKC! and myristolated 
GFP-PKC! kinase domain and fixed after 36h.  Representative single confocal images of the GFP 
(white) are shown. B, HEK293 cells were co-transfected with LLGL2 and different PKC! mutants that 
were membrane targeted or not.  After 36h total cell lysates were analysed for pLLGL. C, Myristolated 
full length or kinase domain PKC! constructs were co-transfected with LLGL in HEK293 cells. The 
effect on pLLGL was assessed by immunoblot at 36h. D, Myristolated full length or kinase domain 
PKC! constructs were co-transfected with LLGL and a 1:1 mix of PKC! mutants maintaining a 
constant DNA concentration per condition. After 36h total cell lysates were analysed for pLLGL.  All 
blots are representative of 3 separate experiments.  
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5.2.3 PKC!  has concentration dependent specific activity but this 
does not require the RIPR region 
To more directly assess whether high PKC! concentrations were required for optimal 
activity, recombinant kinase domain was assayed over a broad range of 
concentrations.  To facilitate the high kinase concentrations a modified kinase assay 
was developed (see section 2.2.13.2).  Increased wild type PKC! did indeed result in 
an increased specific activity reaching a maximum activity at a kinase concentration 
of 1000 !g/ml (Figure 5.5).  If the modified kinase assay was performed without 
substrate or with BSA as a control for the total protein concentration in the reaction, 
no increase in specific activity was detected.  To investigate whether the RIPR region 
was necessary for this effect on specific activity, recombinant PKC!-AIPA was used 
in the reaction.  This protein did not result in any impairment in concentration 
dependent specific activity, and if anything, the relative specific activity was slightly 
higher.  A protein autonomous concentration dependent activation of PKC! was 
therefore identified in vitro but this was independent of the RIPR region. 
 
 
Figure 5.5 Concentration dependent specific activity 
Recombinant PKC! and PKC!-AIPA kinase domains (0-2500µg/ml) were used in a modified kinase 
assay. Data represent mean and the range for at least 2 separate experiments normalised to the median 
of all experimental data. 
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A protein overlay strategy was adopted to elicit potential sites of homotypic PKC! 
protein interactions that could explain the concentration dependent behaviour.  To 
improve the likelihood of detecting interactions, a dimeric form of the kinase was 
used – recombinant fusion protein of GST and PKC!.  Initial experiments have 
identified 3 possible regions of homotypic PKC! interaction (Appendix 3). 
 
5.2.4 The PKC!  RIPR motif is a protein-interaction site.  
As the hypothesis that the PKC! RIPR motif was required for allosteric activation was 
rejected, the possibility that it was involved in protein-protein binding was pursued.  
Co-immunoprecipitation experiments of exogenously expressed GFP-PKC!-WT, 
GFP-PKC!-AIPA or GFP alone were performed in HCT116 cells.  Protein staining of 
the resulting SDS page gel did not reveal any clear differentiating bands between the 
three conditions but demonstrated equal protein loading (Figure 5.6A).  Consequently 
a whole lane mass spectrometry approach was adopted.  In total 1194 different 
proteins were identified. Subtraction of the GFP control interacting proteins reduced 
the list to 321(Appendix 2).  A further 67 proteins that were enriched in unique 
peptides by at least three times in the experimental groups compared to the GFP-
control were also included. To increase the confidence of the reported hits, this list of 
388 proteins was filtered based on abundance and reproducibility.  To meet the 
abundance criteria at least three unique peptides must have been identified for each 
protein and 70 proteins fulfilled this. These 70 proteins were stratified based on the 
relative abundance of unique peptides after pull down with PKC!-WT or PKC!-AIPA.  
In this list there were 38 proteins that were at least 3 times more abundant in the 
PKC!-WT pull down compared to the PKC!-AIPA and the remaining 32 were 
considered to be similar between the two conditions.  There were no proteins in this 
selection of hits that were 3 times more abundant in the PKC!-AIPA pull down 
compared to the PKC!-WT. 
In parallel, a separate PKC!-based whole lane mass spectrometry experiment was 
performed in the lab by Dr Philippe Riou.  The two independent experiments used the 
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same cell type, IP protocol and shared two experimental conditions - PKC!-WT and 
GFP vector control.  This separate screen was used to test reproducibility. The 
recognised PKC! binding proteins, Par3 and Par6 were present in both screens. Of the 
38 proteins shown to preferentially bind PKC!-WT over PKC!-AIPA, 5 were present 
in both screens (Figure 5.6B & Table 5.1).  Intriguingly, one of these hits was 
LLGL2.
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B 
  
Figure 5.6 Mass spectrometry ‘hit’ stratification 
A, PKC!-WT and PKC!-AIPA immunocomplexes on a Coomassie gel.  B, Schematic of the mass 
spectrometry screening cascade.  Number of proteins is in brackets.
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Table 5.1 Stringent Hits from the Immunocomplex-mass spectrometry screen. 
 
Abundance of unique peptides Entry Name & 
Accession No. 
Protein ID 
GFP PKC!-WT PKC!-AIPA 
L2GL2_HUMAN 
Q6P1M3 
 
 
Lethal(2) giant larvae 
protein homolog 2  
 
1 16 5 
FARP1_HUMAN 
Q9Y4F1 
 
FERM, RhoGEF and 
pleckstrin domain-
containing protein 2  
 
0 5 0 
MAGI1_HUMAN 
Q96QZ7 
 
Membrane-associated 
guanylate kinase, WW and 
PDZ domain-containing 
protein  
0 5 1 
MTA2_HUMAN 
Q94776 
Metastasis-associated 
protein MTA2  
 
0 4 0 
PDIA3_HUMAN 
P30101 
 
Protein disulfide-
isomerase A3  
 
2 8 2 
 
To validate that LLGL2 preferentially binds to PKC!-WT over PKC!-AIPA, reciprocal 
pull down experiments were performed.  Subsequent immunoblotting for LLGL2 
demonstrated a loss of signal in the PKC!-AIPA pull down (Figure 5.7A) and GFP-LLGL 
was able to pull down PKC!-WT but not PKC!-AIPA (Figure 5.7B).  Par3 and Par6B, 
known to form a trimeric complex with PKC!, were present in both PKC!-WT and PKC!-
AIPA pull downs.  The antibody specificity for LLGL2 was demonstrated by loss of the 
band in GFP- PKC!-WT immunocomplexes pre-treated with siRNA-LLGL2 (Figure 
5.7C).  When this blot was re-probed for Par6 the level was enhanced in PKC!-WT 
treated with LLGL siRNA compared to the scramble control in 2 separate experiments.  
Additionally, the PKC!-WT and PKC!-AIPA pull down experiment was performed and 
duplicate SDS PAGE gels were run.  One gel was used for a Western Blot with a 
phospho-serine-PKC (pPKC) substrate antibody.  A prominent 130kD band was 
identified in the PKC!-WT lane only (Figure 5.7D).  The immunoblot was used to guide 
the dissection of the equivalent band in the duplicate gel and this was sent for mass 
spectrometry.  This band was also identified as LLGL2.
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Figure 5.7 Co-immunoprecipitation experiments of the PKC!-AIPA mutant.   
A, HCT116 cells were transiently transfected with GFP, GFP-PKC! or GFP-PKC!-AIPA.  
Immunocomplexes were separated by gel electrophoresis and immunoblotted for LLGL2 and then re-
probed for Par6 and Par3.  B, cells were co-transfected with GFP-LLGL and empty vector (EV), PKC! or 
PKC!-AIPA.  Immunocomplexes were immunoblotted for PKC!.  C, HCT116 cells were reverse-
transfected with siRNA-LLGL2 or scrambled siRNA and after 24h transfected with PKC!.  After a further 
48h immunocomplexes were generated and immunoblotted for LLGL2 and then re-probed for Par6 and 
Par3.  D, Immunoblot from (A) was stained with colloidal coomassie (left and center panel) and 
immunoblotted with pPKC substrate antibody (right panel) that demonstrated a differential band (arrow). 
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As the AIPA mutant is deficient in LLGL binding this could provide an explanation for 
the difference in the in phosphorylation of LLGL in the cell and phosphorylation of 
PKC' pseudosubstrate peptide (PKC'PS) in vitro (described in section 5.2).  To test this 
directly, an in vitro kinase assay was performed using recombinant kinase domain PKC!-
WT, kinase domain PKC!-AIPA and either recombinant full-length LLGL2 or the 
PKC'PS.  There was no difference between the activity detected between PKC!-WT and 
PKC!-AIPA when PKC'PS was used as substrate but a decrease of 60% for PKC!-AIPA 
when LLGL was used as substrate for the reaction (Figure 5.8). 
 
Figure 5.8 Substrate phosphorylation by PKC!  - revisited 
The effects of mutating the RIPR motif on PKC! induced substrate phosphorylation.  A, classical kinase 
assays were performed using recombinant PKC!, PKC!-AIPA and full length recombinant LLGL as 
substrate.  B, historical control of the classical kinase assay for PKC! and PKC!-AIPA with PKC'PS as 
substrate.  The data is from two separate experiments and represent the mean and the range.  Students-t test 
was used to determine statistical significance of any difference **, p<0.01; n.s, no statistical difference. 
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5.2.5 The RIPR region is a predicted PKN substrate motif. 
A substrate screen of PKN1 and 3, protein kinases closely related to PKC!, performed in 
the lab by Dr Alejandra Collazos defined their substrate motifs.  An arginine at the -3 
position and a hydrophobic residue at the +1 position flank Serine 477 of PKC! and 
predict that it would be a good PKN substrate.  The arginine (R) at -3 is the second R of 
the RIPR motif.  Putative phosphorylation deficient (S477A) and phosphomimetic 
(S477E) mutants were used to interrogate whether phosphorylation at this site controls 
protein interactions at the RIPR region.  Using the cell based pLLGL assay, no 
differences were observed between myristolated PKC!-WT and the S477A or S477E 
mutants.  The pLLGL in the vector and PKC!-AIPA controls, were markedly reduced 
(Figure 5.9). 
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Figure 5.9 Effect on LLGL phosphorylation by PKC!  mutated at its putative PKN 
substrate motif.   
A, The human PKC! amino acid sequence and highlighted PKN substrate motifs (yellow).  B, Predicted 
phosphomimetic mutant (S477E) and phosphorylation deficient mutant (S477A) of PKC! were co-
expressed with LLGL in HEK293 cells and their effect on pLLGL elicited by Western blot. 
 
Chapter 5. Results 
 150 
5.2.6 The RIPR region is required for normal lumen formation in MDCK 
cysts 
Parental MDCK cells grown in Matrigel form a hollow sphere with an apical lumen that 
may be characterised by F-actin staining (see section 3.2.4).  In MDCK cells stably 
transfected with PKC!-AIPA they developed a multi-cystic appearance (figure 5.10A) 
and there was a 58% reduction in the number of spheroids with normal apical lumens 
compared to the PKC! -WT (figure 5.10B) despite similar protein expression levels 
(figure 5.10C). 
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Figure 5.10 The physiological relevance of the RIPR motif.   
A, MDCK cells were stably transfected with empty vector, PKC! or PKC!-AIPA and cultured in Matrigel 
for 6 days.  Representative single confocal images of actin staining (white) are presented.  Scale bars 
represent 50µm. B, Western blot showing the exogenous PKC! expression in the mutant cells lines.  C, 
Quantification of number of normal apical lumens.  At least 100 spheroids were counted per condition for 
each experiment and the mean ± SEM of 3 separate experiments are presented.  One way ANOVA was 
used to determine statistical significance of difference; *, p<0.05; **, p<0.01. 
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5.3 Discussion 
Collaboration with the SBL and with Cancer Research Technology, who provided 
selective PKC! ligands, presented a unique opportunity to explore the structure-function 
relationships of PKC!.  Predictions from the crystal structure directed initial investigation 
towards testing whether the RIPR motif was involved in allosteric transactivation of 
PKC!.  Enthusiasm for this line of investigation was fuelled by the finding that in a cell 
based pLLGL assay, previously shown to correlate with PKC! activity, mutation at the 
RIPR motif dramatically impaired substrate phosphorylation. 
There are significant parallels with this observation and the allosteric activation of the 
EGFR family of receptors proposed by the Kuryian Laboratory (also see section 1.2.6).  
From the crystal structure of inactive EGFR kinase domain they were able to identify an 
intermolecular interaction site and defined donor and acceptor regions.  A mutant form of 
the EGFR kinase domain that was donor deficient (V924R mutant) was mixed with the 
HER3 kinase, a pseudokinase that lacks catalytic activity, on lipid vesicles and in vitro 
kinase assays were performed.  Both the EGFR-V924R and HER3 lacked appreciable 
activity when assayed alone but when mixed the kinase inactive HER3, with an intact 
donor region, was able to rescue the activity of EGFR-V924R (Jura et al., 2009). 
For studies on PKC! a putative donor mutant (PKC!-AIPA) and acceptor mutant (the 
kinase dead PKC!-D368N) were fashioned.  Co-expression of PKC! mutants and LLGL 
were performed to test whether there was an in vivo rescue of PKC!-by PKC!-D368N.  
Considerable effort was spent optimizing the assay to enable quantification of the co-
expressed exogenous proteins and to concentrate the PKC! at the membrane in a fashion 
analogous to the in vitro lipid vesicles used by Kuryian’s group for EGFR.  Despite this 
no rescue of PKC!-AIPA was achieved with PKC!-D368N.  We concluded that activation 
of PKC! does not occur by transactivation in a RIPR dependent fashion.  However while 
testing this first hypothesis several notable observations came to light. 
Firstly, the co-expression studies of different PKC! mutants were technically challenging.  
In order to measure the relative expression of the mutants, different vectors (pcDNA3.1 
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or pEGFP-C1) were used as a means to differentially introduce GFP tags.  While both 
vectors efficiently expressed protein individually, in co-expression experiments the 
protein expression from pcDNA3 was markedly suppressed.  Following the introduction 
of a potent transcriptional activator into eukaryotic cells this paradoxical suppression of a 
co-introduced gene target is a recognised phenomenon and is termed “Squelching”.  It is 
thought that Squelching may be a result of competition for general transcription factors 
(GTFs) and seems to affect transient vector expression more than chromatin-integrated 
promoters.  It is speculated that this discrepancy between integrated and non-integrated 
promoters may be as a result of separate pools of GTFs for these compartments or 
possibly the presence of high affinity binding sites for GTFs within the chromatin 
(Natesan et al., 1997).  When pcDNA3 and pEGFP are co-transfected competition takes 
place between their respective episomal target genes with those derived from pEGFP 
winning.  Both constructs contain a human cytomegalovirus immediate early promoter 
and contain enhancer regions.  It is possible that differences seen are due to variable 
affinities of GTF binding sites in the two constructs.  Such difficulties could be overcome 
by use of a multicistronic vector where proteins are encoded by a single messenger RNA.  
When aiming for similar expression of two proteins, use of a 2A peptide might be 
appropriate.  Using this strategy the mRNA transcript contains 2 gene transcripts 
separated by a 2A-coding region.  The 2A-coding region leads to the co-translational 
production of an abnormal peptide bond between a glycine and proline resulting in 
cleavage of the nascent peptide at this site and therefore the two gene products in equal 
ratio (Trichas et al., 2008). 
Secondly, as predicted, myristolation of PKC! resulted in membrane targeting as 
determined by confocal microscopy.  This led to increased phosphorylation of LLGL2 
compared to non-myristolated proteins.  This provides evidence that its activity is 
enhanced at the membrane, at least for the LLGL2 substrate. 
Thirdly, while testing whether any requirement for the RIPR motif was concentration 
dependent, using a modified kinase assay that permitted high protein concentrations, a 
quite unexpected observation was made. This was that increased concentration of PKC! 
kinase domain lead to an increase in measured specific activity and that this was 
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independent of the RIPR motif.  This trend in specific activity was seen in at least five 
separate experiments derived from two different protein preparations.  The data presented 
in figure 5.3E are two separate experiments from a single protein preparation. From this 
experiment the specific activity is actually higher for the AIPA compared to the WT at all 
concentrations but the rate of change is the same.  Although the protein preparations were 
prepared using the same protocol, they were not generated synchronously and previous 
experiments conducted at single protein concentrations (5 !g/ml) actually showed a 
lower specific activity for PKC!-AIPA compared to PKC!.  It is likely, therefore, that the 
varying relative specific activities represent differences in protein preparations and 
further experiments with new protein preparations would be required to confirm this.   
The rate of phosphorylation per unit of kinase (specific activity) of PKC! kinase domain 
went up significantly with increasing kinase concentration. For an increase to this extent 
it is likely to require increasing efficiency of catalysis.  This could be mediated by a 
protein-protein allosteric activation or increased autophosphorylation. 
When autophosphorylation was looked at, in the modified kinase assay without the 
optimal peptide substrate, the specific activity remained low and constant over a broad 
range of concentrations.  This zero-order kinetic would be expected for cis-
autophosphorylation, as previously demonstrated for purified recombinant PKC"%II that 
will autophosphorylate on the C-terminal hydrophobic motif (Behn-Krappa and Newton, 
1999).  However the modified kinase assay, by virtue of the low reaction volume, would 
not be expected to be sensitive enough to reliably detect the low levels of 
phosphorylation associated with stoichiometric reactions of cis- or trans-
autophosphorylation.  It cannot be ruled out therefore that there is autophosphorylation 
(particularly in trans) that changes the activity state of the protein.  The protein 
preparations used in this experiment had been co-incubated with PDK1, shown to induce 
phosphorylation of aPKC at the activation loop (Le Good et al., 1998), and purified by 
ion exchange to enrich for the phosphorylated form.  There are further sites that may be 
autophosphoylated such at the turn motif (Thr555) and other sites that could be 
phosphorylated by contaminating tyrosine kinases such as Tyr256, a site thought to be 
involved in nuclear import (White et al., 2002).  One approach to address whether 
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autophosphorylation is involved in concentration dependent activation would be to carry 
out the modified kinase assay on a high and low concentration preparations and perform 
quantitative phosphoproteomics. 
As an additional control a low concentration PKC!-kinase domain kinase assay was 
carried out with incremental concentrations of bovine serum albumin.  Adsorption of 
kinase to the Eppendorf tube can prevent its involvement in catalysis, but above a 
threshold the surface becomes saturated with protein and this may be perceived as a 
concentration dependent gain in activity.  In this experiment there was no detected 
increase in activity ruling out significant adsorption and non-specific protein effects.  The 
experiment, however, does not control for differences in substrate binding to 
phosphocellulose paper (p81) under acidic conditions.  The p81 paper is an ion exchange 
matrix with a net negative charge at low pHs.  A phosphorylated peptide will bind if it 
has a net positive charge.  For PKCePS this is achieved by multiple arginines 
(RPRKRQGAVRRR) that are positively charged at most pHs (pI=10.8).  Unlike the 
classical kinase assay, the modified assay is terminated by mixing with glacial acetic acid 
before binding to the p81 paper.  There is a theoretical situation where this acid treatment 
prevents peptide adsorption to p81 and this effect is reduced by higher PKC! 
concentrations.  To carry out this control neutral termination solutions could be used, for 
example EDTA in HEPES. 
The preferred explanation for the protein concentration dependent activity is that there is 
an intra-molecular or homotypic protein interaction that results in an activating 
conformational change.  If proven, this could have significant implications for 
understanding PKC! function and on the development of potential specific allosteric 
inhibitors.  Initial experiments using a PKC! protein overlay on a PKC! peptide array 
suggested that there was a number of homotypic PKC! interaction sites.  Ongoing work in 
the Protein Phosphorylation Laboratory will aim to repeat this experiment to confirm the 
regions of interaction and test whether there is protein-concentration dependence.  
The second structure-derived hypothesis tested was that the RIPR motif could be 
involved in protein-protein interactions. Indeed, through an immunocomplex and whole 
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lane mass spectrometry screen, proteins that bound to PKC!-WT in preference to the 
PKC!-AIPA mutant and the GFP PKC!-WT were identified, one of which was LLGL2.  
In the mass spectrometry there were a large number of proteins that bound to the GFP 
control in addition to the experimental conditions and were therefore excluded.  These 
excluded proteins may have contained true PKC!-WT/ PKC!-AIPA interacting proteins 
that happened to also stick to the GFP.  An attempt to minimise such false negatives was 
made by using the GFP-TrapM system, a 13kD protein based on a single domain 
antibody from Lama Alpaca that has a high affinity, instead of conventional GFP 
monoclonal antibodies.  However a large number of non-GFP binding proteins (388) 
were identified in the screen.  To select hits the protein lists were filtered based on the 
abundance of unique peptide sequences for each protein and reproducibility.  
Identification of a unique peptide is more likely if the parent protein occurs at a high 
concentration in the sample but is not a quantitative measure of abundance.  There are a 
number of caveats to the use of this index.  Firstly, abundant peptides ions can be missed 
if they co elute on the reverse phase front end with other more abundant peptide ions as 
only the more abundant one is selected for analysis.  Secondly, a unique peptide sequence 
may be detected multiple times if prevalent but this is only recorded as a single unique 
peptide.  Thirdly, the ability for proteins to be detected depends upon the position of 
tryptic cleavage sites (carboxyl side of lysine and arginine) within the protein and 
fragment charges and thus the ability of the peptide ions to pass through the spectrometer 
(‘to fly’).  Reproducibility for the predominantly PKC!-WT interacting proteins was 
assessed by cross-reference to another PKC! based whole lane mass spec screen 
performed concomitantly in the Lab.  The methodology was similar with the exception of 
high salt IP washes and an additional 2 short IP washes.  Surprisingly, there was only a 
12% overlap between the proteins identified in the two studies after the GFP-control 
interacting proteins were subtracted.  The Human Proteome Organization (HUPO) 
conducted an audit of accurate identification of a protein test set and showed markedly 
varying results despite the same or similar instrumentation (Bell et al., 2009).  
LLGL was selected from the hit list to validate the mass spectrometry screen for several 
reasons.  Firstly, it is a well-established interaction partner with PKC! albeit one whose 
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site of interaction has not been described.  Secondly, the reagents for this target had been 
validated.  Analytical immunoprecipitations and immunoblots clearly demonstrated that 
the PKC!-AIPA mutant is a non-LLGL binding mutant.  By an astonishing coincidence, 
therefore, the very substrate chosen to interrogate the cell-based activity of the PKC!-
AIPA mutant was a protein for which the mutant was unable to bind.  It is worth noting 
here that based on the crystal structure, that reveals that the RIPR region is remote from 
the active site, it would not have been predicted to directly affect substrate binding.   
In the knowledge that the RIPR motif was required for LLGL2 binding the initial kinase 
assay was re-examined, this time also using recombinant LLGL as a substrate for the 
reaction.  Phosphorylation of LLGL2, but not PKCePS, was significantly reduced 
compared to PKC!-WT.  As the protein is capable of phosphorylating the short PKCePS 
in the absence of RIPR this would suggest that the RIPR site functions as a docking site 
rather than an allosteric regulator of catalysis.  Such a docking site is reminiscent of the 
Arg-X-Leu motif (RXL) used by cyclin partners of cyclin-dependent kinases (CDKs) to 
engage substrates.  In this case the RXL motif is within the substrate, however the RIPR 
motif is within the aPKC kinase and we speculate below where the RIPR motif may bind 
on the LLGL substrate.  For CDKs the local sequence motif that is phosphorylated is Ser-
Pro-X-Lys.  The RXL motif therefore acts as a recruitment site in addition to the 
phospho-motif of these proline-directed kinases (Jeffrey et al., 1995).  Parallels with 
MAPK substrates and regulators are also known (Tanoue and Nishida, 2003).  It is likely 
therefore that the RIPR motif plays an analogous role in helping to recruit highly 
selective aPKC substrates.   
LLGL is known to be phosphorylated in a low complexity region (LCR) or hinge region 
that lies within the WD40 %-propellers.  In light of the discovery that LLGL binds to 
PKC! via the RIPR motif an initial attempt has been made to model potential sites of 
interaction on LLGL.  The crystal structure of LLGL has not been solved but the yeast 
homologue provides a scaffold upon which the human LLGL sequence can be overlaid.  
From this structural overlay, surface acidic patches that were phylogenetically conserved 
were identified and considered possible sites of interaction.  From this preliminary model 
it appears plausible that PKC! could bind to LLGL at the interface between the two %-
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propellers as four conserved acidic pathches are found at this location.  The multiple 
WD40 regions and the hinge regions of LLGL would provide the length and flexibility to 
wrap around the PKC! kinase domain and position the LLGL hinge for optimal 
phosphorylation by PKC! (Figure 5.11). 
 
 
 
Figure 5.11 Model of LLGL interaction sites with PKC!  
A, LLGL2 model with a semi-transparent surface of a view looking into the two WD40 propellers.  
Conserved acidics (D/E) in red and basics (R/H/K) in cyan.  Acidics that co-evolved with a corresponding 
basic reside in the near vicinity have not been included in the model. B, side on view of LLGL2 model 
showing the low complexity region (LCR) with multiple phosphorylation sites. 
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The immunoblots provided further validation for the mass spectrometry screen.  Par3, a 
known binding partner of PKC! was complexed to both PKC!-WT and PKC!-AIPA as 
supported by the mass spectrometry and number of unique peptides.  Par6, that is 
reported to bind to PKC! via their respective PB1 domains, was also complexed to both 
PKC!-WT and PKC!-AIPA but was enriched in the PKC!-WT condition.  This was also 
the case in the mass spectrometry results where the ratio of number of unique peptides 
was 2:1 in favour of PKC!-WT. However, using my hit selection criteria this was 
considered equal abundance.  Endogenous Par6B was able to bind to exogenous LLGL2 
in the absence of detectable levels of PKC!.  This may be a direct or indirect association - 
murine Par6 isoforms have previously been shown to bind to murine Lgl (Mlgl).  
Immunoprecipitation experiments in Cos cells and recombinant murine proteins has 
suggested that the interaction is mediated via the first PDZ domain of Par6C and the N-
terminus of Mlgl (Plant et al., 2003).  A further interesting but provisional observation 
(only 2 separate experiments performed) is that there is greater Par6 interaction with 
PKC!-WT following LLGL2 knockdown with siRNA.  This would imply a degree of 
competition for binding to the PKC!-complexes. 
Having identified a novel protein-binding site in PKC!, excitement was roused by the 
potential convergence of 2 separate projects in the lab.  Dr Alejandra Collazos had 
identified a PKN consensus substrate motif that overlapped the RIPR motif in PKC! 
making PKN an ideal candidate as a RIPR binding regulating kinase; independently Dr 
Collazos had also identified the related PKC" as a PKN substrate in a screen of over 4000 
protein substrates.  Phosphorylation of this proposed PKC! phosphorylation site (S477) 
has previously been noted in mass spectrometry analysis of recombinant PKC! from 
insect cells (Neil McDonald, unpublished results).  While this may not represent the 
phosphorylation events in mammalian cells, it supported the basis for the subsequent 
mutagenesis experiments.  Attempted phosphomimetic and phosphorylation deficient 
mutants of S477 were generated but did not effect LLGL phosphorylation, a combined 
readout of LLGL binding to RIPR and catalytic activity.  This suggests that the S477 
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does not in fact regulate binding to the RIPR binding motif.  The ability of S477A and 
S477E to act as phosphorylation deficient and phosphomimetic mutants has not been 
formally tested.  The S477A hydrophobic substitution will not be able to become 
phosphorylated but the negatively charged glutamate is often not sufficient to mimic for 
phosphorylation dependent binding.  From this experiment alone therefore, it cannot be 
ruled out that for example phosphorylation at S477 leads to the binding of an adaptor that 
is required for binding to PKC!.   
In conclusion, the LLGL2 binding site of PKC! has been identified and functional 
analysis using mutants of this binding site show a disruption in normal polarity in an ex-
vivo MDCK cyst polarity assay. 
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Chapter 6. Development of a drug insensitive PKC!  
mutant and its utilisation for biomarker identification 
 
6.1 Introduction 
The interpretation of many studies ascribing PKC! function should be viewed with 
caution as the tools and reagents to study PKC! specifically have been of poor quality 
(Garcia-Paramio et al., 1998).  Commercial atypical PKC antibodies tested against 
recombinant atypical PKC isoforms were not specific for PKC! or PKC" (See Appendix 
1).  RNAi strategies have been fraught with off-target effects and need corroboration 
using mechanistically distinct rescue paradigms.   Other commonly employed tools 
include the use of chemical inhibitors.  Protein kinase inhibitors fall into 2 main classes, 
namely competitive and non-competitive.  Competitive inhibitors may be type I (DFG-
in), where the inhibitor competes with ATP for access to the nucleotide-binding pocket 
and the conserved Asp-Phe-Gly motif is locked in, or type II (DFG-out) where the Asp-
Phe-Gly motif is “flipped out” and the inhibitor binds to an inactive kinase 
conformation (Knight and Shokat, 2005).  The human genome encodes more than 518 
kinases with many shared structural and functional features, in particular, the highly 
homologous ATP binding pocket.  Therefore chemical inhibitors specific to a kinase are 
unusual and multiple off-target effects are reported.  Sorafenib (BAY-43-9006), for 
example, was originally designed as a Raf kinase inhibitor (Lyons et al., 2001) but its 
subsequent success in clinical trials was probably due to the inhibition of VEGFR and 
PDGFR, two tyrosine kinases. 
One way to circumvent the kinase promiscuity of inhibitors is the use of analogue 
sensitive kinases modified at their “gatekeeper” residue, an approach pioneered by the 
Shokat Laboratory (Bishop and Shokat, 1999).  The gatekeeper residue is located at the 
back of the nucleotide-binding pocket and controls access to an enlarged hydrophobic 
cavity, also known as the selectivity pocket.  In nature, secondary resistance to ATP 
competitive inhibitors is often as a result of a mutation of this gatekeeper residue.  For 
example, the small threonine gatekeeper in EGFR is mutated to a bulky residue, 
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preventing access to the selectivity pocket, in some tyrosine kinase inhibitor resistant 
forms of lung cancer (T790M).  The same pattern is true for Abl in Chronic 
Myelogenous Leukaemia (T315I) (Azam et al., 2008, Tamborini et al., 2006, Tamborini 
et al., 2004).  Conversely, the Shokat approach is to exploit the frequently bulky 
gatekeeper residues in kinases, mutating it to a small residue that enables back-pocket 
access to a specified chemical ligand.  For example, the mutant v-Src kinase (I388G) 
was exquisitely sensitive to inhibition by 1-NaPP1, a synthesized ligand that has little 
effect on wild type cells (Bishop and Shokat, 1999). 
A second technique of chemical-genetic intervention is to develop a drug-insensitive 
mutant form of the kinase of interest once a potent compound has been identified.  The 
mutant kinase is altered at the site of interaction between the kinase and an inhibitor 
while leaving its ATP binding site intact.  This approach was first described, for 
kinases, by the Cohen Laboratory.  Overexpression of a drug insensitive Stress 
Activated Protein Kinase 2a (SAPK2a) prevented reduced phosphorylation by the 
SB203580 inhibitor of some, but not all of, the previously cited downstream substrates.  
As such they were able to validate SAPK2a as a target of SB203580 and bona fide 
SAPK2a substrates (Eyers et al., 1999).  
The aim of the work described in this chapter was to apply chemical-genetic techniques 
to help validate PKC! as a druggable target and develop a platform to facilitate new 
biomarker discovery. 
 
6.2 Results 
6.2.1 PKC!  and ligand interaction sites observed in a crystal structure 
During the course of this thesis, the crystal structure of human PKC! kinase domain (di-
phospho-form phosphorylated at T403 and T555) was determined bound to the 
CRT66854 ligand.  The structure provided a basis for understanding critical drug 
interaction sites and therefore inhibitor specificity.  The CRT66854 ligand has several 
important features: (1) it has a thieno[2,3-d]pyrimidine scaffold that mimics the adenine 
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portion of ATP; (2) it has a benzyl moiety that displaces F543 from the nucleotide 
pocket disordering the loop containing F543; (3) a primary amine adjacent to the benzyl 
group directly contacts aspartic acid D330 and the main chain carbonyl of  D373 close 
to the ATP pocket and near the PKC substrate binding site (a pyridine substituted 
hydrogen bonds directly to the PKC! hinge main chain amide of V326 connecting the 
N- and C-lobes of the kinase).  The planar shape of the CRT66854 ligand ensures that 
no direct contacts are made to the conserved PKC! gatekeeper residue I323 leaving 
considerable space for chemical elaboration of the small molecule ligand.  Each of the 
above features is likely to contribute towards the selectivity of the CRT66854 ligand for 
the atypical PKCs. 
 
Figure 6.1 Schematic of CRT66854 ligand interactions 
PKC! drawn using LIGPLOT software, see http://www.ebi.ac.uk/thornton-srv/software/LIGPLOT/]. 
CRT66854 is abbreviated to 854. 
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6.2.2 PKC!  mutagenesis of ligand interaction sites results in drug 
insensitivity 
In order to validate the interactions observed within the crystal structure described 
above, a number of PKC! mutations were generated.  The first approach was to use the 
Shokat system (Figure 6.2A) and create an additional hydrophobic pocket by 
substituting the relatively bulky gatekeeper isoleucine for a small, hydrophobic alanine 
(I323A).  PP1, an ATP analogue found to inhibit Src kinase, and two derivatives (PP2 
and 1-NaPP1) were assessed to see if they could selectively inhibit PKC!-I323A activity 
in a pLLGL cell based assay.  HEK293 cells transfected with PKC!-I323A were treated 
with the ATP analogues over a range of concentrations (0.001-1µM) for 30mins or with 
17.5µM CRT66854, a PKC! selective inhibitor, for 1 hour.  Phosphorylation of LLGL 
was assessed by Western blot but was unaffected by the ATP analogues even up to the 
highest concentration.  As expected the PKC! inhibitor diminished the pLLGL signal 
for both PKC!-WT and the PKC!-I323A mutant (Figure 6.2B).  
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Figure 6.2 Attempted genetic sensitisation of PKC!  to ATP analogues 
A, schematic representing the ‘Shokat’ mutant principal.  The nucleotide binding pocket of wild type 
(WT) kinase binds to ATP, and is inhibited by the ATP analogue, Bis-indolylmaleimide (BIM) but not 
the modified inhibitor 1-NaPP1.  The gatekeeper mutant (GM, see text) can still bind ATP and BIM but is 
exquisitely sensitive to 1-NaPP1.  B, HEK293 cells were co-transfected with PKC! gatekeeper mutant 
(I323A) and LLGL.  The cells were treated with different ATP analogues over a range of concentrations 
(0.001, 0.01, 0.1 and 1µM).  pLLGL was used to assess PKC! activity and treatment with CRT66854, a 
specific PKC! inhibitor was used as the positive control.  The Western blot is representative of 3 separate 
experiments.  
 
As the gatekeeper mutant of PKC! did not allow selective inhibition of the kinase 
(Shokat system), a second chemical genetic approach was adopted.  Point mutants of 
the two predicted key interaction sites between the active site and the CRT66854 ligand 
were made.  HEK293 cells transfected with PKC!-WT, PKC!-D330A or PKC!-D373A 
were treated with CRT66854 or DMSO for 1h.  At this time point there was no 
evidence of cytotoxicity from phase microscopy.  PKC!-WT cells treated with 3.5µM or 
17.5µM of CRT66854 had a decrease in pLLGL of 48% and 80% respectively (Figure 
6.3A).  Both the point mutants had much less inhibitor induced reductions in pLLGL 
and at the high inhibitor dose, the level of phosphorylation suppression was 2 fold 
greater for PKC!-WT. 
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In an attempt to enhance the drug insensitivity a double substitution mutant was 
fashioned by sequential mutagenesis.  3.5µM CRT68854 caused minimal suppression 
of pLLGL in the HEK293 cells over-expressing PKC!-D330A/D373A and at 17.5µM 
the suppression of pLLGL was 3.4 fold greater for the PKC!-WT (Figure 6.3B).  The 
PKC! western blots reveal a slight band shift between different constructs (Figure 6.3A 
& B).  The constructs that ran fractionally higher contained both GFP and Myc tags 
whereas those that ran lower did not contain the Myc tag. 
To test that the intrinsic catalytic activity was not compromised by the mutations the 
GFP-tagged constructs were expressed in HEK293 cells and GFP pull-downs of total 
cell lysates were performed.  The immune complex kinase assay demonstrated 
comparable specific activities for PKC!-WT and the single and double substitution 
mutants (Figure 6.3C).  Importantly there was also no difference in activity between 
GFP-Myc-PKC! wild type and GFP-PKC!. 
In order to demonstrate that the diminished pLLGL signal in the cell based assay was a 
consequence of a PKC! (or PKC! complex) inhibitory effect, rather than a potential 
inhibitor ‘off target’ effect, a dose response curve was generated for one of the mutants.  
PKC!-D330A, was pulled down and immunocomplexes were added to the reaction mix 
containing PKC' pseudosubstrate, magnesium and ATP.  At low CRT66854 inhibitor 
concentration (0.1µM) PKC!-WT kinase and PKC!-D330A induced phosphorylation of 
LLGL was similarly suppressed but at higher inhibitor concentrations (0.1 and 1µM) 
the PKC!-WT kinase activity, as measured by pLLGL, was inhibited more than PKC!-
D330A kinase (Figure 6.3D).  The 50% reduction of the relative kinase activity was 
attained at 0.5µM for PKC!-WT and 1.8µM for PKC!-D330A. 
Predicted point mutations of the PKC! kinase domain resulted therefore, in decreased 
sensitivity to CRT66854 in both in vivo and in vitro phosphorylation studies.  In view 
of the greater level of insensitivity of the double point mutant (PKC!-D330A/D373A), 
over the single point mutants, this was taken forward for further studies and will be 
referred to hereafter as the drug insensitive mutant (PKC!-DIM). 
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Figure 6.3 Development of a drug insensitive mutant of PKC!  
A & B, HEK293 cells were transiently co-transfected with LLGL and PKC! containing point mutations 
of the ligand-kinase interaction sites.  Each PKC! mutant expressing cell line was treated with 3.5µM or 
17.5µM of CRT66854.  Drug insensitivity is demonstrated by failure to suppress the pLLGL signal.  The 
western blot is representative of 3 separate experiments.  C, An immunocomplex kinase assay normalised 
to the median of all values.  Error bars indicate the SEM from 3 separate experiments.  D, PKC! or PKC!-
D330A immunocomplexes were tested for activity in a kinase assay in the presence of a range of 
CRT66854 concentrations.  Error bars indicate the range from 2 separate experiments.   
 
6.2.3 Drug insensitive mutant is resistant to drug induced cellular 
phenotype 
To further characterize the PKC!-DIM it was incorporated into the MDCK cyst assay, 
previously defined as a PKC! dependent model (see chapter 3).  Inhibition of MDCK 
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cells, using PKC! siRNA, had resulted in a reduced proportion of MDCK cysts with a 
normal lumen as defined by apical actin staining.  Stable polyclonal cell lines were 
made expressing GFP-Empty Vector (EV), GFP-PKC!-WT or GFP-PKC!-DIM.  The 
cells were selected by FACS using the same GFP intensity gating for each cell line prior 
to seeding in Matrigel.  The MDCK cultures were treated with inhibitor, at a range of 
doses between 0 and 3µM, on the day of seeding and then on alternate days for 6 days.  
Inhibitor treatment diminished the percentage of cysts with a normal lumen for EV and 
PKC!-WT but had little effect on PKC!-DIM cysts (Figure 6.4A & B).  At 3µM 
CRT66854 there was extensive cytotoxicity precluding any quantification of normal 
lumens.  The basal level of normal lumens was 53% for EV and PKC!-DIM but over 
74% for PKC! cysts.  In light of the discrepancy between basal expression, particularly 
between the PKC! and PKC!-DIM, the total cell lysates from the experiment were 
immunoblotted and a marked difference in PKC! protein expression was seen (Figure 
6.4C).  The normalised PKC! expression was 2.2 times higher in the PKC!-MDCK cells 
compared to the PKC!-DIM-MDCK cells.  In light of these results, the data is also 
presented normalised to the basal level of normal lumens for each condition (figure 
6.4D).  This shows that the rate of drug induced polarity defects is lowest for the PKC!-
DIM suggesting that it is indeed relatively drug insensitive. 
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Figure 6.4 The drug insensitive mutant resists drug induced phenotypic change 
MDCK cells stably transfected with PKC!-WT, PKC!-DIM or empty vector were cultured in Matrigel for 
6 days.  The cultures were treated with a range of inhibitor concentrations (0-1µM) which were 
replenished, along with growth media, on alternate days.  Quantification of the number of predominantly 
single apical lumens (PSALs) was made.  At least 100 spheroids were counted per condition in each 
experiment and the results of at least 3 separate experiments are presented. A, the absolute percentage of 
single apical lumens. B, Single confocal images of actin staining (white).  Scale bars represent 50µM.  C, 
Western blot representing the exogenous PKC! expression in the stable cell lines.  The Western blot is 
representative of duplicate immunoblots.  D, the change in single apical lumen formation relative to 
exogenous PKC! expression and error bars represent the SEM. 
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6.2.4 PKC!  Drug Insensitive Mutant can be applied to biomarker 
discovery 
With a platform for specific PKC! intervention in place, the chemical-genetic strategy 
was applied to the identification of PKC! substrates. This work was carried out in 
collaboration with Dr Philippe Riou in the Protein Phosphorylation Laboratory. 
HCT 116 cells were transiently transfected with PKC! or PKC!-DIM.  36 hours post 
transfection the cells were treated with 10 !M CRT66854 for 1 hour followed by 
immunoprecipitation of the total cell lysates.  The colloidal Coomassie stain of the 
resulting SDS PAGE gel (see figure 6.5A) demonstrated equal protein loading between 
the four conditions and no obvious differential bands. 
The gel was immunoblotted with a phospho-serine-PKC (pPKC) substrate antibody 
(figure 6.5B).  Both the PKC! and PKC!-DIM transfected cells treated with vehicle 
control showed multiple immunoreactive bands.  Treatment of the PKC! transfected 
cells with CRT66854 led to almost complete loss of pPKC substrate signal whereas the 
PKC!-DIM transfected cells only had a partial reduction in pPKC signal.  To determine 
whether this PKC! specific effect of CRT66854 was a disruption in complex formation, 
substrate phosphorylation or both, an in vitro kinase assay was performed on the 
immunocomplexes extracted from the drug treated, PKC! transfected HCT116 cells. 
This demonstrated full reversibility of the phosphorylation signal indicating loss of 
phosphorylation and not loss of associated substrate (see figure 6.5C). 
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Figure 6.5 Chemical-genetic approach for substrate identification 
HCT116 cells were transiently transfected with GFP tagged PKC!-WT or PKC-DIM, treated with 
CRT66854 for 1 hour, lysed and immunoprecipitated.  A, colloidal Coomassie showing protein loading.  
B, Western blot for pPKC.  C, Cell transfected with PKC!-WT cells treated with CRT66854 and then an 
immunocomplex kinase assay performed.  The kinase assay mix was run on an SDS page gel and 
immunoblotted for pPKC.  The western blots shown are representative of at least 3 separate experiments.   
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6.3 Discussion 
In this chapter it was shown that a combined approach of structural biology, cell 
biology and medicinal chemistry has enabled new strategies to test the specific function 
of PKC! and potentially identify new clinically relevant biomarkers. 
The first strategy attempted however was unsuccessful as the mutated kinase made did 
not demonstrate any specific sensitivity to the ligands tested.  In this experiment the 
bulky isoleucine gatekeeper residue was substituted for a small hydrophobic alanine.  
This is in contrast to Bishop et al who mutated the isoleucine of the Src ATP pocket for 
a glycine.  The alanine substitution was chosen over the glycine as this had previously 
been demonstrated to be highly effective at sensitising other PKC family members 
(PKC' and PKC#) to 1-NaPP1 inhibition (Saurin et al., 2008, Cameron et al., 2009).  
The range of doses and treatment duration of PP1 and its analogues were selected based 
on the previously published results of the 1-NaPP1 and GFP-PKC'-M486A Shokat pair 
(Cameron et al., 2009).  It is possible that higher doses might be required or that a 
different bulky derivative of another core structure might have worked.  While there 
were no internal positive controls for the PP1 analogue batches, a synchronous 
experiment in the Parker Laboratory demonstrated the expected 1-NaPP1 induced 
PKC'-M486A inhibition in HeLa cells, as manifest by cytokinesis failure (personal 
communication with Dr Nicola Brownlow).  For further attempts to establish this model 
a larger panel of potential ligands should be considered, and in addition, alternative 
gatekeeper residues utilised.  This course of action was not pursued as the Drug 
Insensitivity mutant strategy, conducted in parallel, showed more promise.  Having said 
this, the Shokat system is particularly elegant for functional studies, as the ligand can be 
engineered to have virtually no cellular off target effects and therefore a clear 
background for subsequent studies. 
LLGL is a known substrate of PKC! and its phosphorylation was shown in chapter 3, in 
an exogenous co-expression assay, to be correlated with PKC! activity.  In this chapter 
suppression of pLLGL was achieved in a dose-dependent manner for drug treated PKC! 
wild type.  Doses were chosen as one times and five times the established cellular EC 
50 (Barton et al., 2009b).  Two main kinase-inhibitor interaction sites were identified 
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and upon mutation each resulted in drug insensitivity.  Unlike Eyers et al, when no 
additional effect was seen between a single mutation and quadruple mutations of the 
ATP site (Eyers et al., 1999), a clear additive insensitivity was seen for a double point 
mutant compared to the single mutants of PKC!.  This suggests that both aspartic acids 
make important charged interactions with the small molecule ligand.  
In view of the 3.5 fold difference in phosphorylation inhibition between the wild type 
and drug insensitive PKC!, a measured difference in a cell phenotypic assay could be 
anticipated.  Consistent with the previously demonstrated siRNA-PKC! results, 
inhibition with CRT66854 disrupted normal apical lumen formation in control MDCK 
cysts grown in Matrigel.  Kim et al have previously demonstrated abnormal lumen 
formation, increased apoptosis and proliferation, in parental MDCK cells grown for 6 
days in a collagen, in response to a myristolated aPKC pseudosubstrate inhibitor (Kim 
et al., 2007).  They did not include an apical marker in this assessment and so it is not 
clear whether there is a multi-lumen phenotype, delayed lumen formation or permanent 
apical-basal disruption.  
The sensitivity to CRT66854 induced polarity defects was highest for EV-MDCK, 
followed by PKC!-MDCK and was lowest for PKC!-DIM-MDCK.  This suggests that 
the exogenous PKC! affords the cell protection against aberrant lumen formation, 
because cellular substrates are in excess and the increased enzyme concentration leads 
to more catalytic product despite the presence of a competitive inhibitor.  In the drug 
insensitive mutant, the competition for catalysis by the inhibitor is negated and the rate 
of catalytic product is likely to be further increased.  It is noteworthy that this 
incremental rate of catalysis for the PKC!-DIM-MDCK cells over the PKC!-MDCK is 
despite considerably lower expression of the drug resistant protein and the observed 
effect may be much greater if equal expression could be achieved.   
In order to try and attain equal protein expression between PKC!-DIM-MDCK PKC!-
MDCK (both expressed in the pEGFP-C1 vector) the populations were FACS sorted 
using equivalent GFP intensity gating.  The polyclonal cell population was expanded 
over 1 week and then immediately used in the 3D Matrigel assay. The subsequent 
Western Blot for PKC!, however showed much lower PKC! expression in the PKC!-
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DIM-MDCK cells.  This could be due to a rapid drift of the polyclonal cell population 
indicating a potential detrimental effect of the drug insensitive protein or a selective 
survival advantage of the wild-type protein in MDCK cells.  In provisional experiments 
using the same constructs, no drift was observed in Normal Rat Kidney cells and in 
experiments by Dr Philippe Riou in the Parker Laboratory there was evidence in 
HCT116 cells of a rapid drift favouring high expression of PKC!-DIM over PKC!.  A 
further explanation is that within the defined range of GFP-intensity used for sorting the 
cells they happened to be predominantly at the low end of the range for PKC!-DIM but 
at the upper end of the range for PKC!. 
It is becoming evident that target inhibition as opposed to knock-down is more effective 
in determining the biological outputs of a target (Weiss et al., 2007).  Kinases often 
have both catalytic and scaffold functions.  Inhibition with small molecules will block 
the catalytic function but will not necessarily affect protein-protein interactions.  
Knockdown by allelic deletion or RNAi will affect both enzymatic and scaffold 
functions and remaining proteins from the now redundant complex may impact on other 
signalling pathways.  One example of this anomalous behaviour is the inhibition of 
p110%, one isoform of the catalytic subunit of PI3 Kinase.  In glioma cells siRNA 
directed against p110% decreased both proliferation and phosphorylation of PKB.  A 
panel of selective inhibitors, however, blocked only PKB phosphorylation.  The 
catalytic PI3 kinase subunits (p110#, % and *) form a stable heteromer with the 
regulatory subunit (p85# and %).  p110# inhibitors do block proliferation.  It has been 
proposed therefore that siRNA-p110% not only prevents phosphorylation of its 
downstream targets (PKB), but by virtue of the resulting free p85 sequestering proteins 
required for p110# complex activation, proliferation signalling is abrogated (Fan et al., 
2006).  In situations such as these, knockdown would not be helpful for the 
identification of physiological substrates that may be used as biomarkers for an 
upstream kinase.  As RNAi is commonly used to aid inhibitor target validation it is 
likely that inhibitor and RNAi incongruence is under-reported in the scientific literature. 
The potentially limited specificity of action of inhibitors precludes a simple drug versus 
no drug analysis.  However the use of a modified insensitive target circumvents this 
issue permitting comparative studies potentially leading to a robust biomarker.  
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CRT66854 induced loss of phosphorylation of multiple bands of PKC! 
immunocomplexes compared to the drug insensitive PKC! (PKC!-DIM) 
immunocomplexes.  The magnitude of this difference seen with the HCT116 
immunocomplexes was considerably greater than the 3.4 fold difference observed with 
pLLGL in total HEK293 cell lysates.  The differences could relate to cell type 
specificity, differences in transfection efficiency between the two studies or reduction of 
background substrate phosphorylation for immunocomplexes compared to total cell 
lysates.  For example, LLGL2 may be phosphorylated by other kinases in the cell and 
not be part of PKC! complexes.  This proportion of LLGL would be unaffected by 
PKC! inhibitors in a total cell lysate but would not be present in PKC! complexes.  The 
ability to take the PKC!-immunocomplexes of CRT66854 treated cells and then rescue 
the substrate phosphorylation in an in vitro kinase assay, demonstrates that the small 
molecule inhibitor is affecting catalytic function, and not complex formation.  A 
concern about protein over-expression studies is that they can result in saturation of the 
cells translation, sorting and protein modifications, artificially modifying normal 
signalling cascades.  Candidate biomarkers identified using over-expression systems 
must therefore undergo further validation in control matched disease tissue. 
In this study the drug insensitivity strategy worked well and there is the promise of the 
discovery of clinically relevant PKC! biomarkers.  Having established the principle, the 
mass spectrometry results, for identification of the substrate bands revealed in this 
study, are eagerly awaited.
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Chapter 7. Discussion 
7.1 Overview 
Protein Kinase C iota (PKC!) is a serine-threonine protein kinase that is a human 
oncogene, aberrantly expressed in cancer and is a prognostic indicator (Fields and 
Regala, 2007, Eder et al., 2005).  Consequently PKC! is considered a desirable target 
for drug development.  The work performed in this thesis was motivated by the desire to 
understand mammalian PKC! biology with a view to assisting in rational therapeutic 
design.  On commencing this work, little was known about robust inputs into the PKC! 
signalling cascade and less still was known about the downstream effectors.  PKC! 
function is essential in normal development as the knock out mouse is embryonic lethal 
(Soloff et al., 2004).  In non-transformed cells PKC! had been demonstrated to play a 
role in apical-basal polarity (Izumi et al., 1998, Aranda et al., 2006), growth (Grzeschik 
et al., 2010a) and asymmetric cell division (Atwood and Prehoda, 2009).  Additionally, 
during the period of this thesis, a role in migration and spindle orientation in mitosis 
were also firmly established (Durgan et al., 2011, Qin et al., 2010).  
Initial investigations in this thesis set out to identify a reproducible PKC! dependent 
phenotype in the context of mammalian oncogenic signalling.  In keeping with 
phenotypes described in non-transformed cells, the data in this thesis shows that PKC! 
only demonstrated a reliable phenotype following chemical or genetic perturbation in 
cells grown in 3D cultures.  This finding is in keeping with work from the Fields 
Laboratory that showed that treatment of a lung adenocarcinoma cell line, A549, with 
dominant negative PKC! mutant had no effect on the adherent cell growth or survival 
but caused a dramatic decrease in 3D colony formation (Regala et al., 2005a).  The 
differences in phenotypic response between 2D adherent cell growth and growth in 3D 
matrices is well described (Janda et al., 2002, Weigelt et al., 2010) and is perhaps 
unsurprising, given the known differential protein expression seen in proteomic studies 
of transformed cells between the two culture conditions (Toyli et al., 2010).  
Based on the well-established ability to form rapid polarised cysts in 3D gels, Madin-
Darby canine kidney (MDCK) cells were selected to interrogate PKC! function.  Single 
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apical lumen formation was disrupted by both high activity and dominant negative 
activity PKC! mutants, as well as siRNA against PKC!.  As normal levels of PKC! were 
required for single apical lumen formation it was hypothesised that PKC! may lie 
downstream of recognised human oncogenes.  Consequently MDCK cells lines 
transfected with single oncogenes, each one chosen due to their published interaction 
with PKC!/", were obtained or generated.  These cell lines were then screened for their 
lack of apical lumens in 3D culture and rescue of a predominant apical lumen upon 
treatment with 2 separate PKC! siRNA.  Activated Src- and Raf-MDCK had persistent 
apical lumens that were largely unaffected by siRNA against PKC!.  Activated ErbB2, 
H-Ras and p110# all had markedly abnormal morphology in 3D culture with large 
irregular structures often lacking a predominant apical lumen.  In structures that did 
maintain a lumen, the apical marker actin was frequently re-localised to sides facing the 
basal and lateral surface of the cells.  Upon PKC!-siRNA treatment, activated ErbB2- 
and Ras-MDCK developed a predominant lumen with prominent actin staining whereas 
activated p110#-MDCK did not.  The specificity of PKC! siRNA was demonstrated by 
overcoming the lumen and polarity induction using a siRNA resistant form of PKC! 
cDNA.  All oncogenic-MDCK spheroids appeared smaller in size following PKC! 
siRNA treatment but the size of parental MDCK cysts were not diminished.  Thus 
siRNA knockdown of PKC! had a range of effects depending on oncogenic contexts 
including decreased size alone, decreased size and rescue of apical lumen or unaffected 
size and disruption of apical lumen.  
From the crystal structure of PKC! bound to the CRT66854 ligand, a relatively specific 
ATP-competitive inhibitor of PKC!, a potential protein-protein interaction region was 
identified.  Mutagenesis of this region of PKC! (RIPR>AIPA) and subsequent mass 
spectrometry analysis identified a number of proteins that require this motif for binding.  
One of these hits, Lethal Giant Larvae 2 (LLGL2) was confirmed to require the RIPR 
motif by reciprocal immunoprecipitation and immunodetection, validating the mass 
spectrometry approach.  Stable transfection of MDCK cells with PKC!-AIPA disrupted 
normal polarity.  
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LLGL2, when co-transfected with PKC!, proved to be a useful system to assess the 
potency of PKC! inhibitors.  However, the expression of LLGL2 is variable in 
transformed cells and the current available antibodies are poor at detecting endogenous 
levels, limiting its potential application as a clinically relevant biomarker.  Low 
efficiency and off target effects of PKC! siRNA and lack of specific PKC! inhibitors 
and antibodies has made identification of PKC!-downstream effectors challenging.  To 
circumvent some of these issues a chemical genetic approach was adopted.  Based on 
predictions from the CRT66854 bound PKC! crystal structure a drug resistant mutant 
form of PKC! was generated.  PKC! inhibition with this drug was shown to decrease 
kinase activity in vitro, reduce LLGL phosphorylation in a cell based assay and lead to 
abnormal lumen formation in an MDCK cyst assay.  The PKC! drug insensitive mutant 
partially rescued each of these parameters, consistent with its reduced sensitivity.   
 
7.2 PKC!  as a downstream Ras effector in polarity signalling 
For the first time, the work in this thesis has demonstrated that PKC! may sit 
downstream of oncogenic Ras in a pathway responsible for regulating MDCK polarity.  
Over recent years a number of other groups have identified a role of PKC! downstream 
of oncogenic Ras in both tissue culture and murine models.  It has been suggested that 
PKC! plays a role in transformed growth and survival mediated by Rac1 and NF-+B 
signalling pathways respectively (see section 1.3.3.3).  It was also shown in this thesis 
that ErbB2 seems to act upstream of PKC! in MDCK polarity signalling.  This is in 
keeping with the findings of the Muthuswamy Laboratory which showed, in a MCF10a 
3D culture model, that activated ErbB2 induced a multicystic appearance, failed luminal 
clearance and relocalisation of apical markers to basal and lateral cell surfaces.  Genetic 
disruption of aPKC-Par6 binding partially rescued this activated ErbB2 induced 
phenotype.  It was also demonstrated, in both MDCK and MCF10a cells, that aPKC-
Par6 co-immunoprecipitated with ErbB2 although a direct interaction was not proven 
(Aranda et al., 2006).  It is well recognised that persistent ErbB2 signalling promotes 
oncogenic transformation that is mediated, at least in part, by activation of Ras (Satoh et 
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al., 1990, Eckert et al., 2004).  It is possible therefore that an ErbB2>Ras>PKC! polarity 
signalling axis exists.  
Activated Ras is now known to relay signals to multiple pathways including Raf, PI3-K, 
phospholipase C' and RalGEFs (Buday and Downward, 2008, Ferro et al., 2008) (see 
section 1.2.8).  The results from this screen of iota dependence, downstream of selected 
oncogenes, indicate that this polarity signalling is not via c-Raf or p110#.  Of course 
there are other isoforms of Raf (A-Raf and B-Raf) and PI3K (p110%, p110*, p110& 
catalytic subunits) that could mediate this response but it is intriguing to speculate about 
a third but less well recognized Ras signalling effector, Ral.  RalA, one of the two Ral 
isoforms, is a small GTPase that has been implicated as potentiating the interaction 
between par-3, aPKC, and the exocyst complex thus regulating neuronal polarity (Lalli, 
2009).  RalA has also been shown to be activated in human samples of Ras mutant 
colorectal cancer (Martin et al., 2011). 
A bioinformatics search for co-expressed gene products in epithelial cancers was 
performed using the oncomine database (www.oncomine.com).  Surprisingly, the gene 
mRNAs that were co-overexpressed with PKC! mRNA were the same genes identified 
as being upstream of PKC! in polarity signalling in this thesis, namely Ras and ErbB2 .  
In addition, RalA and its binding partner RalBP1, were also concomitantly 
overexpressed with PKC!.  V-Src, c-Raf and p110# are not concomitantly 
overexpressed and this is despite the fact that p110# is found within the same 
chromosomal band (3q26.3) as PKCi.  It should be noted that this result could be 
affected by a sampling bias as gene analysis studies that included PKC! were less likely 
to screen for Src, c-Raf and p110#.  Mechanistic studies into the potential role of RalA 
as a signalling intermediary between Ras and PKC! in epithelial polarity should be 
pursued.  The case to do so is further strengthened by the finding that Ral A co-
immunoprecipitated with exogenous PKC! in HCT116 cells (personal communication 
from Philippe Riou). 
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Figure 7.1 Oncomine analysis of selected gene expression in epithelial cancer 
The top 10% of epithelial cancer studies from the Oncomine database with at least a two-fold over-
expression of PKC! in cancer samples compared to normal controls were selected.  Concurrent expression 
of selected genes was analysed.  The heat map indicates the level of expression: over-expression (red), 
under-expression (blue), un-changed (white) and not measured (grey).  Tumour types: 1, Pancreatic; 2, 
Squamous cell carcinoma (SCC) of the lung; 3, Bladder; 4, SCC lung; 5, Ovarian; 6, Skin; 7, Pancreatic; 
8, Pancreatic; 9, Ovarian; 10, Ovarian. 
 
7.3 Polarised cysts 
Cell polarity is the restricted and organised localisation of cell components to distinct 
regions within the cell.  Loss of cell polarity is commonly observed in advanced 
tumours and correlates with their invasion into adjacent tissues and the formation of 
metastases (Wodarz and Nathke, 2007).  Polarity proteins may function within aberrant 
growth signalling pathways in cancer and intact global polarity may suppress signalling 
that is exploited by malignancy (Wodarz and Nathke, 2007, Lee and Vasioukhin, 2008).  
In a number of epithelial malignancies PKC! expression levels correlated to cancer 
stage and prognosis.  This clinical correlation suggests that PKC! is involved in cancer 
progression and metastasis rather than cancer initiation (Eder et al., 2005, Regala et al., 
2005b).  
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Cells lining ductal structures exhibit apical-basal polarity in which proteins 
asymmetrically distribute along the apical-basal axis (Huang and Muthuswamy, 2010).  
In order to study this process techniques have been devised to culture specialised 
epithelial cells in a 3D extracellular matrix (O'Brien et al., 2001, Debnath et al., 2003).  
The principle technique used in this thesis was MDCK cytogenesis in Matrigel.  From a 
single cyst of cells several parameters may be determined; proliferation, apoptosis, 
central luminal clearance and polarised protein distribution (Elia and Lippincott-
Schwartz, 2009). 
For the purposes of the screen undertaken in this work, looking into the role of PKC! 
downstream of selected oncogenes, a robust read-out was required.  The criteria chosen 
was the determination of predominantly single apical lumens (PSAL).  This was a 
composite end-point of lumen formation and polarity.  The apical polarity component 
was defined by the presence of more intense actin staining at the lumen than at basal 
and lateral cell aspects.  This assessment was deliberately simple and could be 
performed down the eye-piece of a confocal microscope which allowed for the 
inclusion of large, statistically relevant numbers of spheroids.  To take this assay further 
an automated determination of the centre of the spheroid, image capture and actin 
intensity would be desirable.  Aside from time, one of the excepted limitations of this 
assay was the difficulty in identifying normal apical polarity in the absence of a lumen. 
In this thesis manipulation of PKC! activity in parental MDCK cells led to irregular 
growth and multiple lumens.  In some cases, but not all, these multiple lumens 
continued to be have polarised actin at the apical interface.  Recently a number of other 
groups have identified that perturbation of ‘polarity proteins’ in epithelial cysts can, in 
some cases, lead to a multi-luminal phenotype that has normal apical protein 
localisation.  Potentially the multi-luminal phenotype is a more sensitive indicator of 
impending polarity failure.  Alternatively, the multi-luminal phenotype may be the 
result of aberration of a PKC! dependent signalling pathway that is distinct from or a 
different mechanism of polarity, for example mitotic spindle orientation (Durgan et al., 
2011, Qin et al., 2010, Jaffe et al., 2008).  At the current time therefore, the multi-lumen 
phenotype should not be considered a surrogate for polarity. 
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The MDCK assay was designed to identify differences in apical lumen polarity.  During 
the course of these investigations interesting preliminary observations were also made 
regarding the size of both parental MDCK cysts and the oncogenic-MDCK spheroids.  
The measurement of spheroid size is really a combination of two processes; 
proliferation and apoptosis (no evidence of larger cells).  In order to improve the 
understanding of the role of PKC! in cyst and spheroid growth, future studies would 
benefit from immunostaining with markers of proliferation and apoptosis such as Ki67 
and Caspase-3.  
 
7.4 Threshold effects of PKC!  signalling 
PKC! manipulation in MDCK cells appears to result in an all or nothing response with 
regard to normal lumen formation.  For example, over-expression of wild type PKC! 
had no detrimental effect on MDCK polarity but constitutively active PKC! expressed 
at a comparable level resulted in large, multi-cystic structures with poorly defined 
apical markers.  This observation suggests that above a particular activity level of PKC! 
a different signalling response is initiated.  Such a threshold effect is common in 
cellular signalling pathways and requires positive feedback mechanisms to achieve the 
binary response (see section 1.2.7).  
PKC! seems to exhibit multiple thresholding in MDCK cytogenesis.  Expression of 
activated PKC! or dominant negative PKC! both caused a decrease in normal 
cystogenesis, as does inhibition of PKC! with siRNA.  This strongly suggests that a 
normal activity of PKC! is tightly regulated.  It would be predicted that the 
improvement in polarity upon PKC! siRNA treatment of H-Ras-MDCK cells is derived 
from a reduction in activated PKC!.  By analogy to parental MDCK it would also be 
predicted that knockdown below a particular threshold would revert back to abnormal 
polarity.  With this in mind it is perhaps fortuitous that the siRNA knockdown in H-
Ras-MDCK only achieved a moderate knockdown, thus revealing the dramatic rescue 
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of a polarised lumen.  It would be interesting to test for the potential role of 
thresholding in Ras-MDCK but it may not be possible to achieve a good enough 
knockdown with siRNA.  Instead dominant negative PKC! constructs or titrated PKC! 
inhibitors could be used to test this hypothesis.     
While it has been inferred that the threshold behaviour described in this thesis is due to 
differing PKC! activity levels, the evidence to support this is lacking.  No increase in 
total PKC! or phosphorylated PKC! levels were detected in oncogenic-MDCK 
spheroids.  These findings may still be compatible with an activated PKC! state as PKC 
family members adopt an activated open configuration that is more sensitive to protease 
degradation (Gao et al., 2008).  Therefore, chronic activation of PKC could theoretically 
lead to decreased protein levels at steady state.  PKC! priming phosphorylation is only 
representative of activity levels in restricted cellular contexts as typically PKCs are 
constitutively primed.  PKC! protein turnover could be measured using a pulse-chase 
approach and may reveal increased turnover as a consequence of upstream oncogenic 
signalling.  In addition the identification of robust PKC! biomarker would be invaluable 
in this setting. 
 
7.5 Distinct PKC!  polarity and growth pathways 
In murine mammary cells the presence of endogenous PKC"II, a protein homologous to 
the PKC" regulatory domain that acts as a PKC" inhibitor, disrupted tight junction 
formation following calcium switch and caused cellular overgrowth (Parkinson et al., 
2004).  These findings led to the hypothesis that abnormal epithelial growth is a 
secondary effect of globally deregulated cell polarity.  In this thesis, knockdown of 
PKC! in 3D growth assays of oncogenic-MDCK cells revealed two features; decreased 
size and induction of a polarised apical lumen.  While all MDCK oncogenic spheroids 
(p110#-, c-Raf-, v-Src-, H-Ras- and ErbB2-MDCK) were diminished in size following 
PKC! siRNA only H-Ras- and ErbB2-MDCK cells demonstrated induction of a 
polarised apical lumen.  One explanation for this is that two distinct PKC! dependent 
pathways exist for growth and polarity and that the polarity pathway is only functional 
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in particular cellular contexts.  Similarly, the Hall Laboratory identified two separate 
functions of aPKC in Caco2 cystogenesis in 3D growth assays; multiple lumen 
formation and cell survival.  By titrating the siRNA concentration and thus the level of 
PKC! knockdown it was shown that the morphological changes were sensitive to partial 
PKC! knockdown whereas decreased cell survival only occurred with more robust 
knockdown (Durgan et al., 2011).  These data support the notion that PKC! is involved 
in distinct pathways. 
Three recent studies in D.melanogaster have all demonstrated that the polarity proteins 
Lgl, scrib and crb regulate tissue growth independently of cell polarity. (Ling et al., 
2010); (Robinson et al., 2010); (Grzeschik et al., 2010a).  In particular, control of 
growth (proliferation and apoptosis) was mediated by the Salvador/Warts/Hippo (SWH) 
pathway (see (Parsons et al., 2010) for review).  The SWH pathway is a kinase cascade 
where Hippo (Hpo) binds to its adapter protein Salvador (Sav) to enable 
phosphorylation of Warts (Wts) that phosphorylates and excludes from the nucleus the 
transcription factor Yorkie (Yki).  Among the transcriptional targets of Yki are cell 
cycle regulators E2F1 and CycE and the Drosophila inhibitor of apoptosis 1 (DIAP1).  
Upon knockdown of Lgl or over expression of aPKC or Crb the transcriptional targets 
of the SWH pathway were elevated suggesting that disruption of the polarity machinery 
leads to up regulation of this proliferation and anti-apoptotic pathway.   
Over-expression of a Crb,PDZ–transgene, that lacked polarity complex binding, (see 
section 1.2.5.3) up regulated the SWH pathway and was sufficient for wing tissue 
overgrowth.  Conversely, a Crb,FERM-transgene, that had intact polarity complex 
binding but was unable to bind FERM domain proteins did not affect the SWH 
transcription targets or result in tissue overgrowth (Grzeschik et al., 2010a).  
Surprisingly, knockdown of Crb led to overgrowth but with preserved polarity 
(Robinson et al., 2010, Richardson and Pichaud, 2010).  A possible explanation for this 
is that expanded (Ex), a FERM domain binding protein that negatively regulates the 
transcription activity of Yki, is reduced as a result of Crb over-expression and is 
increased but mislocalised in response to Crb knockout (Ling et al., 2010).  It has been 
proposed that the Ex protein is unable to inhibit Yki, as it is either absent or in a 
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location distinct from Yki, thereby resulting in increased SWH target transcription and 
growth. 
In larval eye disks Lgl knockout or aPKC overexpression, in addition to upregulation of 
the SWH pathway, caused co-mislocalisation of Hpo and RASSF (Grzeschik et al., 
2010b).  The Tapon Laboratory demonstrated that RASSF competes with Sal for Hpo 
binding and therefore inhibits Hpo (Polesello et al., 2006).  Expression of a membrane 
targeted dominant negative aPKC construct in an Lgl knockout clone rescued both the 
tissue overgrowth and the RASSF/Hpo mislocalisation.  Taken together, these data 
suggest that a disrupted balance between aPKC and Lgl leads to mislocalisation of 
RASSF and Hpo, suppression of Hpo catalytic activity and resulting Yki induced 
transcription and proliferation.  Eliciting the mechanism by which the aPKC-Lgl 
balance impacts on RASSF-Hpo localization is undoubtedly a hotly pursued area of 
biological research at the current time. 
Based on the current understanding, it seems likely that global polarity aberration can 
contribute to deregulated growth but is neither necessary nor sufficient.  The growth 
signalling resulting from neoplastic gene products is regulated by feedback mechanisms 
and cellular localisation and is interwoven with recognised hypertrophic growth 
pathways.  In addition these pathways may be cell type and species specific. 
 
7.6 RIPR protein binding region of PKC!   
During the work undertaken in this thesis a novel protein-binding region of PKC! was 
identified between residues 471 and 474 (RIPR).  Using stringent stratification criteria 5 
protein hits that require the RIPR motif for immunocomplex formation were identified 
from a mass spectrometry screen.  One of the hits was lethal giant larvae 2.   
The finding that this double arginine motif is conserved in a number of protein kinases 
including PKC", PKB and EGFR suggests that it is likely to be a functional motif.  This 
led to question of whether the RIPR binding domain has any physiological relevance.  
LLGL was identified as a tumour suppressor gene in D.melanogaster where its deletion 
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leads to a neoplastic phenotype (Gateff and Schneiderman, 1969).  LLGL plays an 
important role in epithelial polarity.  While genetic experiments have demonstrated 
LLGL to be a tumour suppressor gene in D.melanogaster the understanding of its role 
in mammalian tissue is less well understood (see section 1.3.5.4).  Both knockdown and 
over expression of LLGL has been shown to disrupt apical lumen formation in 3D-
MDCK cysts (Horikoshi et al., 2009, Yamanaka et al., 2006, Yamanaka et al., 2003).  In 
the studies presented in this thesis it was shown that expression of the AIPA mutant, 
that is unable to bind and unable to phosphorylate LLGL, caused MDCK cysts to be 
overgrown, poorly circumscribed and with multi-luminal cysts.  This would be 
consistent with the notion that LLGL displays polarity threshold behaviour, as described 
for PKC!, wherein either knockout or over expression results in a loss of polarity.  
While often referred to as “the best studied tumour suppressor gene in Drosophila” 
(Merz et al., 1990) this label does not necessarily relate to expression array data 
available in human cancer.  From two separate analyses of the Oncomine gene 
expression array and the EBI array, LLGL2 is significantly over-expressed in a number 
of human malignancies especially in breast, ovarian, pancreatic and bladder cancer.  
LLGL2 is under-expressed predominantly in non-epithelial malignancies such as 
leukaemia, renal cancer, melanoma and sarcoma.   
From searching the COSMIC database for somatic mutations in cancer, 3 mutations of 
PKC! have been identified in human samples.  One of those mutations was a 
substitution of R471C, the first arginine of the RIPR motif, and occurred in a patient 
with ovarian carcinoma (1 out of 24 samples).  Thus the RIPR motif is an LLGL2 
binding region, that when mutated disrupts polarity in MDCK cells and may be 
associated with human epithelial cancer.  This intriguing finding should be followed up, 
firstly by determining whether the R471C mutation is sufficient to affect protein 
binding to the RIPR region.  This could be tested by measuring the phosphorylation of 
LLGL2 in a cell-based assay.  If R471C is confirmed as a functional binding mutant, 
then there is a strong case to sequence the PKC! gene (or specifically this exon) in 
human ovarian cancer samples as this could represent a new mechanism-based cancer 
driver-mutation. 
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It would be of considerable interest to further interrogate the molecular basis behind the 
PKC!-RIPR protein-binding site.  The recently defined PKN consensus substrate motif 
(Collazos et al., 2011) overlaps with the RIPR binding motif.  Provisional mutagenesis 
experiments of the proposed phosphorylated serine (S477) has not demonstrated a role 
of this residue in LLGL binding and phosphorylation.  However, it was recently shown 
that the recombinant PKC! protein generated from insect cells was phosphorylated at 
stoichiometric levels at S475 and not S477, (R-I-P-R-S-L-S-V-K) (personal 
communication Neil McDonald).  It would be interesting to test whether this second 
serine site is phosphorylated by an as yet unidentified kinase at S475 and whether this 
contributes to binding of protein interaction modules at this site.  These interaction 
modules potentially include the WD40 domains within LLGL2 although the RIPR 
region would be an unusual consensus motif for WD40 binding.  Identification of 
putative upstream kinases could be screened for using a kinase panel and a peptide 
substrate incorporating the RIPR motif.  The role of S475 in LLGL interaction could 
easily be tested by the generation of phosphorylation deficient and phosphomimetic 
mutants at this site.  
The 5 hits from the mass spectrometry screen included a diverse array of proteins.  
While searching for any commonality between these proteins that might point to a 
binding mechanism, it was identified that 4 out of 5 proteins (MTA2, MAGI1, FARP2, 
PDIA3 with LLGL2 being the exception) contained a strong predicted mode II 14.3.3 
binding site.  14.3.3 are a family of adapter proteins that have two modes of binding 
(mode I and II) and can greatly impact on protein-protein interactions (see section 
1.2.5).  PKC! itself contains a suboptimal Mode I 14.3.3 binding site that also overlaps 
the RIPR motif.  To determine the likelihood that this enrichment for strong 14.3.3 
binding motifs was by chance, a bioinformatics screen was performed on 71809 human 
protein sequences.  Strong type I 14.3.3 binding motifs were identified in 2.6% of 
sequences and strong type II 14.3.3 binding motifs were present in 17.4% of sequences.  
It is highly unlikely therefore that this enrichment for Type II 14.3.3 binding in the 
protein hits was by chance suggesting that their interaction with PKC! is stabilised by 
14.3.3. 
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7.7 Downstream effectors 
Guided by the crystal structure of PKC! bound to CRT66854, a relatively potent 
inhibitor, a drug insensitive PKC! mutant was designed, PKC!-D330A/D373A (PKC!-
DIM).  PKC!-DIM and CRT66854 have been validated as a resistant protein-inhibitor 
pairing both in vitro and in vivo and provide a platform for specifically interrogating 
PKC! biology. 
This chemical genetic system, which has the advantage of minimising ‘off target 
effects’ commonly seen with RNAi and inhibitors alone, could be exploited in a number 
of ways.  Using cells expressing exogenous PKC!-WT or PKC!-DIM, cells may be 
subjected to PKC! inhibition (PKC!-WT and CRT66854) or not (PKC!-DIM and 
CRT66854).  Analysis of modified patterns of transcription expression between the two 
conditions could be performed using micro-array technology.  Alternatively, using 
stable isotope labelling with amino acids in cell culture (SILAC) and mass spectrometry 
the (phospho) proteome as a function of specific PKC! inhibition may be assessed.  
Both of these techniques would ideally be carried out in 2 separate cell lines and any 
hits individually validated.  The transcriptional and proteomic data could potentially 
provide a marker or signature for PKC! activation/inhibition.  A biomarker of this type 
could be used to drive forward clinical PKC! drug development and in particular enable 
dose determination, patient selection and monitoring of response to potential anti-PKC! 
therapies. 
7.8 Concluding Remarks 
During the course of the work in this thesis, a role of PKC! in regulation of polarity 
downstream of oncogenic Ras has been identified, a new PKC! protein-protein binding 
domain has been described and a platform for biomarker discovery has been 
established.  Hopefully, a measure of the success of this work can be summed up by the 
seemingly paradoxical statement that there are more unanswered questions at the end 
than there were at the beginning.
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Appendicies 
 
Appendix 1 Western blot of aPKC antibodies against recombinant aPKC proteins.  
Different concentrations of recombinant aPKC" or aPKC! protein kinase domains were probed with the 
different antisera overnight at a dilution of 1/1000.  Molecular weights markers are shown on the left and 
the stated antibody and catalogue number is on the right.  The blots are representative of 2 separate 
experiments. 
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Appendix 2. Abundant Hits from the Immunocomplex-mass spectrometry screen.                                                                 
Abundant proteins were defined as 3 or more unique peptides or 3 times or more unique peptides than observed in the GFP control.  Coloured boxes refer to the 
relative abunance of unique peptides between PKC!-WT and PKC!-AIPA mutant.  Yellow, WT" 3x AIPA; Red, AIPA" 3x WT; Blue, WT#AIPA 
 
Protein 
Mass Abundance of unique peptides 
Entry Name & Accession 
No. 
Protein ID 
 GFP PKC!-WT PKC!-AIPA 
PLCB3_HUMAN 
1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase beta-3 OS=Homo sapiens 
GN=PLCB3 PE=1 SV=2 139 kDa 0 2 3 
1433F_HUMAN (+10) 
14-3-3 protein eta OS=Homo sapiens 
GN=YWHAH PE=1 SV=4 28 kDa 0 2 1 
1433T_HUMAN (+13) 
14-3-3 protein theta OS=Homo sapiens 
GN=YWHAQ PE=1 SV=1 28 kDa 1 3 2 
KI67_HUMAN 
Antigen KI-67 OS=Homo sapiens GN=MKI67 
PE=1 SV=2 359 kDa 0 11 1 
API5_HUMAN (+7) 
Apoptosis inhibitor 5 OS=Homo sapiens 
GN=API5 PE=1 SV=2 58 kDa 1 6 0 
AATM_HUMAN (+3) 
Aspartate aminotransferase, mitochondrial 
OS=Homo sapiens GN=GOT2 PE=1 SV=3 48 kDa 1 5 1 
A8K092_HUMAN (+7) 
ATP synthase subunit alpha OS=Homo sapiens 
PE=2 SV=1 54 kDa 1 5 5 
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E41L5_HUMAN (+5) 
Band 4.1-like protein 5 OS=Homo sapiens 
GN=EPB41L5 PE=1 SV=3 82 kDa 0 5 0 
B4DR68_HUMAN 
(+5) 
cDNA FLJ58608, highly similar to Heat shock 
protein 75 kDa, mitochondrial OS=Homo 
sapiens PE=2 SV=1 74 kDa 0 4 0 
B4DLN1_HUMAN 
cDNA FLJ60124, highly similar to Mitochondrial 
dicarboxylate carrier OS=Homo sapiens PE=2 
SV=1 48 kDa 1 4 4 
A8K5H7_HUMAN 
(+5) 
cDNA FLJ77542, highly similar to Homo sapiens 
YME1-like 1 (S. cerevisiae) (YME1L1), transcript 
variant 3, mRNA OS=Homo sapiens PE=2 SV=1 80 kDa 0 4 1 
A8MPX7_HUMAN 
(+4) 
Chromosome X open reading frame 56, isoform 
CRA_b OS=Homo sapiens GN=CXorf56 PE=2 
SV=1 20 kDa 1 6 4 
COIL_HUMAN Coilin OS=Homo sapiens GN=COIL PE=1 SV=1 63 kDa 0 5 2 
HEM6_HUMAN 
Coproporphyrinogen-III oxidase, mitochondrial 
OS=Homo sapiens GN=CPOX PE=1 SV=3 50 kDa 1 4 2 
H2AY_HUMAN (+5) 
Core histone macro-H2A.1 OS=Homo sapiens 
GN=H2AFY PE=1 SV=4 40 kDa 1 4 1 
KCRB_HUMAN (+3) 
Creatine kinase B-type OS=Homo sapiens 
GN=CKB PE=1 SV=1 43 kDa 0 4 2 
CYFP1_HUMAN (+4) 
Cytoplasmic FMR1-interacting protein 1 
OS=Homo sapiens GN=CYFIP1 PE=1 SV=1 145 kDa 0 4 0 
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CKAP4_HUMAN (+3) 
Cytoskeleton-associated protein 4 OS=Homo 
sapiens GN=CKAP4 PE=1 SV=2 66 kDa 2 7 4 
Q86X36_HUMAN 
(+15) 
DEAH (Asp-Glu-Ala-His) box polypeptide 8 
OS=Homo sapiens GN=DHX8 PE=2 SV=2 139 kDa 0 4 2 
TFB1M_HUMAN (+2) 
Dimethyladenosine transferase 1, mitochondrial 
OS=Homo sapiens GN=TFB1M PE=1 SV=1 40 kDa 1 4 0 
MCM2_HUMAN (+3) 
DNA replication licensing factor MCM2 
OS=Homo sapiens GN=MCM2 PE=1 SV=4 102 kDa 1 5 0 
Q4G0F4_HUMAN 
(+1) 
DNA-directed RNA polymerase OS=Homo 
sapiens GN=POLRMT PE=2 SV=1 139 kDa 1 6 1 
B7Z823_HUMAN (+1) 
DNA-directed RNA polymerase OS=Homo 
sapiens PE=2 SV=1 132 kDa 1 4 0 
RPAC1_HUMAN (+3) 
DNA-directed RNA polymerases I and III 
subunit RPAC1 OS=Homo sapiens GN=POLR1C 
PE=1 SV=1 39 kDa 0 4 2 
Q9NX84_HUMAN 
Erythrocyte membrane protein band 4.1 like 4B, 
isoform CRA_b OS=Homo sapiens 
GN=EPB41L4B PE=2 SV=1 51 kDa 1 7 2 
EIF2A_HUMAN (+2) 
Eukaryotic translation initiation factor 2A 
OS=Homo sapiens GN=EIF2A PE=1 SV=3 65 kDa 0 4 1 
SSRP1_HUMAN (+8) 
FACT complex subunit SSRP1 OS=Homo 
sapiens GN=SSRP1 PE=1 SV=1 81 kDa 0 4 2 
FARP2_HUMAN FERM, RhoGEF and pleckstrin domain- 120 kDa 0 5 0 
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containing protein 2 OS=Homo sapiens 
GN=FARP2 PE=1 SV=3 
B2ZZ83_HUMAN 
(+4) 
Filamin B OS=Homo sapiens GN=FLNB PE=2 
SV=1 282 kDa 0 4 1 
B4DE36_HUMAN 
(+3) 
Glucose-6-phosphate isomerase OS=Homo 
sapiens PE=2 SV=1 60 kDa 1 4 3 
KT33B_HUMAN 
Keratin, type I cuticular Ha3-II OS=Homo 
sapiens GN=KRT33B PE=1 SV=3 46 kDa 0 6 0 
O60382_HUMAN 
(+1) 
KIAA0324 (Fragment) OS=Homo sapiens 
GN=KIAA0324 PE=2 SV=1 191 kDa 0 6 0 
L2GL1_HUMAN 
Lethal(2) giant larvae protein homolog 1 
OS=Homo sapiens GN=LLGL1 PE=1 SV=3 115 kDa 0 5 3 
L2GL2_HUMAN 
Lethal(2) giant larvae protein homolog 2 
OS=Homo sapiens GN=LLGL2 PE=1 SV=2 113 kDa 1 16 5 
SYLC_HUMAN (+3) 
Leucyl-tRNA synthetase, cytoplasmic OS=Homo 
sapiens GN=LARS PE=1 SV=2 134 kDa 1 5 0 
MAGI1_HUMAN (+8) 
Membrane-associated guanylate kinase, WW 
and PDZ domain-containing protein 1 
OS=Homo sapiens GN=MAGI1 PE=1 SV=3 165 kDa 0 5 1 
MTA2_HUMAN (+6) 
Metastasis-associated protein MTA2 OS=Homo 
sapiens GN=MTA2 PE=1 SV=1 75 kDa 0 4 0 
E5KSU5_HUMAN 
(+8) 
Mitochondrial transcription factor A OS=Homo 
sapiens PE=4 SV=1 29 kDa 0 3 4 
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E5KSY5_HUMAN (+1) 
Mitochondrial twinkle protein OS=Homo sapiens 
PE=4 SV=1 77 kDa 0 5 0 
PLPL6_HUMAN (+3) 
Neuropathy target esterase OS=Homo sapiens 
GN=PNPLA6 PE=1 SV=2 150 kDa 0 5 3 
NOG1_HUMAN (+5) 
Nucleolar GTP-binding protein 1 OS=Homo 
sapiens GN=GTPBP4 PE=1 SV=3 74 kDa 1 7 0 
PARD3_HUMAN (+2) 
Partitioning defective 3 homolog OS=Homo 
sapiens GN=PARD3 PE=1 SV=2 151 kDa 0 19 17 
PAR6B_HUMAN (+3) 
Partitioning defective 6 homolog beta 
OS=Homo sapiens GN=PARD6B PE=1 SV=1 41 kDa 0 6 3 
PCID2_HUMAN (+2) 
PCI domain-containing protein 2 OS=Homo 
sapiens GN=PCID2 PE=1 SV=2 46 kDa 1 4 4 
A8K401_HUMAN (+7) 
Prohibitin, isoform CRA_a OS=Homo sapiens 
GN=PHB PE=2 SV=1 30 kDa 1 4 5 
A8K3Z3_HUMAN 
(+21) 
Proteasome (Prosome, macropain) 26S subunit, 
ATPase, 5, isoform CRA_b OS=Homo sapiens 
GN=PSMC5 PE=2 SV=1 45 kDa 0 4 1 
DEK_HUMAN 
Protein DEK OS=Homo sapiens GN=DEK PE=1 
SV=1 43 kDa 1 5 0 
PDIA3_HUMAN (+5) 
Protein disulfide-isomerase A3 OS=Homo 
sapiens GN=PDIA3 PE=1 SV=4 57 kDa 2 8 2 
FA32A_HUMAN (+6) 
Protein FAM32A OS=Homo sapiens GN=FAM32A 
PE=1 SV=2 13 kDa 0 8 2 
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KPCI_HUMAN 
Protein kinase C iota type OS=Homo sapiens 
GN=PRKCI PE=1 SV=2 68 kDa 0 46 33 
POP1_HUMAN (+1) 
Ribonucleases P/MRP protein subunit POP1 
OS=Homo sapiens GN=POP1 PE=1 SV=2 115 kDa 0 4 1 
Q53EP4_HUMAN 
(+5) 
Ribophorin I variant (Fragment) OS=Homo 
sapiens PE=2 SV=1 69 kDa 0 4 2 
RBM27_HUMAN 
RNA-binding protein 27 OS=Homo sapiens 
GN=RBM27 PE=1 SV=2 119 kDa 1 7 2 
Q9Y6G0_HUMAN 
(+1) 
RNA-binding protein OS=Homo sapiens PE=2 
SV=1 32 kDa 1 4 3 
RUVB1_HUMAN (+8) 
RuvB-like 1 OS=Homo sapiens GN=RUVBL1 
PE=1 SV=1 50 kDa 1 7 2 
SQSTM_HUMAN 
Sequestosome-1 OS=Homo sapiens 
GN=SQSTM1 PE=1 SV=1 48 kDa 0 10 11 
SPS2L_HUMAN (+2) 
SPATS2-like protein OS=Homo sapiens 
GN=SPATS2L PE=1 SV=2 62 kDa 1 6 1 
SMC1A_HUMAN 
(+10) 
Structural maintenance of chromosomes protein 
1A OS=Homo sapiens GN=SMC1A PE=1 SV=2 143 kDa 0 4 1 
SQRD_HUMAN (+3) 
Sulfide:quinone oxidoreductase, mitochondrial 
OS=Homo sapiens GN=SQRDL PE=1 SV=1 50 kDa 0 5 2 
THSD4_HUMAN 
Thrombospondin type-1 domain-containing 
protein 4 OS=Homo sapiens GN=THSD4 PE=2 
SV=2 112 kDa 0 5 0 
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TAF2_HUMAN (+4) 
Transcription initiation factor TFIID subunit 2 
OS=Homo sapiens GN=TAF2 PE=1 SV=3 137 kDa 0 4 1 
TBL2_HUMAN (+4) 
Transducin beta-like protein 2 OS=Homo 
sapiens GN=TBL2 PE=1 SV=1 50 kDa 1 4 3 
Q53G69_HUMAN 
(+2) 
Translocase of inner mitochondrial membrane 
44 homolog (Fragment) OS=Homo sapiens 
PE=2 SV=1 51 kDa 0 4 0 
TPP2_HUMAN (+4) 
Tripeptidyl-peptidase 2 OS=Homo sapiens 
GN=TPP2 PE=1 SV=4 138 kDa 0 2 5 
TRM1L_HUMAN (+2) 
TRMT1-like protein OS=Homo sapiens 
GN=TRMT1L PE=1 SV=2 82 kDa 0 4 3 
NSUN2_HUMAN (+2) 
tRNA (cytosine-5-)-methyltransferase NSUN2 
OS=Homo sapiens GN=NSUN2 PE=1 SV=2 86 kDa 1 5 1 
CJ018_HUMAN 
Uncharacterized protein C10orf18 OS=Homo 
sapiens GN=C10orf18 PE=1 SV=1 269 kDa 0 4 2 
E7ENH9_HUMAN 
(+6) 
Uncharacterized protein OS=Homo sapiens 
GN=ACLY PE=4 SV=1 125 kDa 1 5 0 
A6NDY9_HUMAN 
(+5) 
Uncharacterized protein OS=Homo sapiens 
GN=FLNA PE=4 SV=3 246 kDa 2 7 0 
WDR61_HUMAN 
WD repeat-containing protein 61 OS=Homo 
sapiens GN=WDR61 PE=1 SV=1 34 kDa 1 5 2 
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Appendix 3 PKC!  protein overlay 
PKC! peptide array membrane was incubated with A, GST-C3 fusion protein or B, No protein or C, GST-
PKC! (kinase domain) for 20minutes.  The protein was cross-linked to the membrane, washed and then 
incubated with anti-GST antibody and species specific secondary-HRP antibody.  There were three areas of 
enhanced binding of GST-PKC! as compared to the control (red boxes numbered 1-3).  The yellow box 
highlights a region of unexpected binding of the GST antibody in the control despite no GST tagged protein 
being present.  D, when the 3 regions of putative homotypic interaction were overlayed on the PKC!-
inhibitor bound crystal structure of two interacting PKC! kinase domains (kinase 1 = green and kinase 2 
=brown), 2 of the regions formed a contiguous region (red) on the surface of the peptide at the interface 
between the two kinases.  Sites of bound inhibitor (cyan).  This experiment has only been performed under 
these conditions on a single occasion. 
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